Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof

ABSTRACT

Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

RELATED APPLICATIONS

This application is a Continuation of U.S. patent application Ser. No.16/138,680, filed Sep. 21, 2018, which is a Divisional Application ofU.S. application Ser. No. 15/695,911, filed on Sep. 5, 2017, which is aContinuation of International Patent Application No. PCT/US2016/020732entitled “FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF”filed on Mar. 3, 2016, which claims the benefit of U.S. ProvisionalPatent Application No. 62/129,543 filed on Mar. 6, 2015, each of whichis herein incorporated by reference in its entirety.

FIELD OF THE INVENTION

Described herein are compounds that are fluorinated lysyl oxidase-like 2(LOXL2) inhibitors, methods of making such compounds, pharmaceuticalcompositions and medicaments comprising such compounds, and methods ofusing such compounds in the treatment of conditions, diseases, ordisorders associated with LOXL2 activity.

BACKGROUND OF THE INVENTION

Lysyl oxidase like-2 (LOXL2) is an amine oxidase enzyme that catalyzescrosslinking of extracellular matrix proteins. LOXL2 is also involved inintracellular processes such as mediating epithelial-to-mesenchymaltransition of cells. LOXL2 signaling is implicated in, for example, infibrotic diseases and cancer.

SUMMARY OF THE INVENTION

In one aspect, described herein are LOXL2 inhibitors and uses thereof.In some embodiments, the LOXL2 inhibitors described herein have thestructure of Formula (I), or a pharmaceutically acceptable salt thereof.

In one aspect, described herein is a compound of Formula (I), or apharmaceutically acceptable salt thereof:

wherein,

-   -   each R¹ is independently H, D, or F;    -   L¹ is absent, X¹, X¹—C₁-C₆alkylene, or C₁-C₆alkylene;        -   X¹ is —O—, —S—, —S(═O)—, —S(═O)₂—, —C(═O)—, —C(═O)O—,            —C(═O)NR²—, —NR²C(═O)—, or —NR²—;        -   R² is H, substituted or unsubstituted C₁-C₆alkyl,            C₁-C₆fluoroalkyl, or C₁-C₆deuteroalkyl;    -   each R³ is independently H, D, halogen, —CN, —OR⁵, —SR⁵,        —S(═O)R⁴, —S(═O)₂R⁴, —S(═O)₂N(R⁵)₂, —NR²S(═O)₂R⁴, —C(═O)R⁴,        —OC(═O)R⁴, —CO₂R⁵, —OCO₂R⁴, —N(R⁵)₂, —OC(═O)N(R⁵)₂, —NR²C(═O)R⁴,        —NR²C(═O)OR⁴, C₁-C₆alkyl, C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl,        C₁-C₆heteroalkyl, substituted or unsubstituted C₃-C₁₀cycloalkyl,        substituted or unsubstituted C₂-C₁₀heterocycloalkyl, substituted        or unsubstituted aryl, or substituted or unsubstituted        heteroaryl;        -   m is 0, 1, or 2;    -   each R⁴ is independently selected from C₁-C₆alkyl,        C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl, C₁-C₆heteroalkyl,        substituted or unsubstituted C₃-C₁₀cycloalkyl, substituted or        unsubstituted C₂-C₁₀heterocycloalkyl, substituted or        unsubstituted aryl, and substituted or unsubstituted heteroaryl;    -   each R⁵ is independently selected from H, C₁-C₆alkyl,        C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl, C₁-C₆heteroalkyl,        substituted or unsubstituted C₃-C₁₀cycloalkyl, substituted or        unsubstituted C₂-C₁₀heterocycloalkyl, substituted or        unsubstituted aryl, and substituted or unsubstituted heteroaryl;        or two R⁵ on the same N atom are taken together with the N atom        to which they are attached to a substituted or unsubstituted        N-containing heterocycle;    -   Ring A is monocyclic carbocycle, bicyclic carbocycle, monocyclic        heterocycle, or bicyclic heterocycle;    -   L² is absent, —X²—, or —C₁-C₆alkylene-X²—;        -   X² is —O—, —S—, —S(═O)—, —S(═O)₂—, —S(═O)₂NR⁶—, —C(═O)—,            —C(═O)O—, —C(═O)NR⁶—, —C(═O)NR⁶O—, —NR⁶C(═O)—, —NR⁶S(═O)₂—,            or —NR⁶—;        -   R⁶ is H, C₁-C₆alkyl, C₁-C₆fluoroalkyl, or C₁-C₆deuteroalkyl;    -   Q is H, substituted or unsubstituted C₁-C₆alkyl, substituted or        unsubstituted C₁-C₆fluoroalkyl, substituted or unsubstituted        C₁-C₆heteroalkyl, substituted or unsubstituted C₃-C₈cycloalkyl,        —C₁-C₄alkylene-(substituted or unsubstituted C₃-C₈cycloalkyl),        substituted or unsubstituted C₂-C₈heterocycloalkyl,        —C₁-C₄alkylene-(substituted or unsubstituted        C₂-C₈heterocycloalkyl), substituted or unsubstituted aryl,        —C₁-C₄alkylene-(substituted or unsubstituted aryl), substituted        or unsubstituted heteroaryl, or —C₁-C₄alkylene-(substituted or        unsubstituted heteroaryl); wherein if Q is substituted then Q is        substituted with one or more R⁸;    -   or Q and R⁶ are taken together with the N atom to which they are        attached to form ring B, wherein ring B is a substituted or        unsubstituted N-containing heterocycle, wherein if ring B is        substituted then ring B is substituted with 1-3 R⁸;    -   each R⁸ is independently D, halogen, CN, —OR⁵, —SR⁵, —S(═O)R⁴,        —S(═O)₂R⁴, —S(═O)₂N(R⁵)₂, NR⁵S(═O)₂R⁴, C(═O)R⁴, OC(═O)R⁴, CO₂R⁵,        OCO₂R⁴, N(R⁴)₂, OC(═O)N(R⁵)₂, —NHC(═O)R⁴, —NHC(═O)OR⁴,        C₁-C₆alkyl, C₁-C₆alkenyl, C₁-C₆alkynyl, C₁-C₆fluoroalkyl,        C₁-C₆deuteroalkyl, C₁-C₆heteroalkyl, substituted or        unsubstituted C₃-C₁₀cycloalkyl, substituted or unsubstituted        C₂-C₁₀heterocycloalkyl, substituted or unsubstituted aryl, or        substituted or unsubstituted heteroaryl;    -   or two R⁸ groups attached to the same carbon atom are taken        together with carbon atom to which they are attached to form        either a substituted or unsubstituted carbocycle or substituted        or unsubstituted heterocycle.

For any and all of the embodiments, substituents are selected from amonga subset of the listed alternatives. For example, in some embodiments,each R¹ is independently H, D, or F. In some other embodiments, each R¹is independently H, or F. In other embodiments, each R¹ is H. In someembodiments, each R¹ is D. In some embodiments, each R¹ is F.

In some embodiments, each R¹ is H; L¹ is absent, X¹, orX¹—C₁-C₆alkylene.

In some embodiments, X¹ is —O—.

In some embodiments, L¹ is absent, —O—, or —O—CH₂—.

In some embodiments, the compound of Formula (I) has the structure ofFormula (II), or a pharmaceutically acceptable salt thereof:

In some embodiments, L¹ is —O—, or —O—CH₂—.

In some embodiments, the compound of Formula (I) has the structure ofFormula (III), or a pharmaceutically acceptable salt thereof:

In some embodiments, Ring A is monocyclic C₃-C₆carbocycle, bicyclicC₅-C₁₂carbocycle, monocyclic C₁-C₅heterocycle, bicyclicC₅-C₁₀heterocycle.

In some embodiments, Ring A is monocyclic C₃-C₆carbocycle, bicyclicC₉-C₁₀carbocycle, monocyclic C₁-C₅heterocycle, bicyclicC₆-C₉heterocycle.

In some embodiments, Ring A is monocyclic C₃-C₆carbocycle.

In some embodiments, Ring A is phenyl, cyclopropyl, cyclobutyl,cyclopentyl, or cyclohexyl.

In some embodiments, Ring A is phenyl.

In some embodiments, Ring A is

In some embodiments, Ring A is

In some embodiments, Ring A is a bicyclic C₅-C₁₂carbocycle. In someembodiments, Ring A is a bicyclic C₅-C₁₂carbocycle that is a fusedC₅-C₁₂carbocycle, bridged C₅-C₁₂carbocycle, or spirocyclicC₅-C₁₂carbocycle.

In some embodiments, Ring A is bicyclic C₉-C₁₀carbocycle.

In some embodiments, Ring A is naphthyl, indanyl, indenyl, ortetrahyodronaphthyl.

In some embodiments, Ring A is a monocyclic heterocycle containing 1-4 Natoms and 0 or 1 O or S atom, monocyclic heterocycle containing 0-4 Natoms and 1 O or S atoms, bicyclic heterocycle containing 1-4 N atomsand 0 or 1 O or S atoms, or bicyclic heterocycle containing 0-4 N atomsand 1 O or S atoms.

In some embodiments, Ring A is pyrrolidinyl, pyrrolidinonyl,tetrahydrofuranyl, tetrahydrofuranonyl, dihydrofuranonyl,dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl,dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl,thiomorpholinyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl,thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl,thiazepinyl, 1,2,3,6-tetrahydropyridinyl, indolinyl, indolinonyl,1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl,3,4-dihydro-2(1H)-quinolinonyl, furanyl, pyrrolyl, oxazolyl, thiazolyl,imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl,oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinazolinyl,quinoxalinyl, naphthyridinyl, indolyl, indazolyl, benzoxazolyl,benzisoxazolyl, benzofuranyl, benzothienyl, benzothiazolyl,benzimidazolyl, purinyl, cinnolinyl, phthalazinyl, pteridinyl,pyridopyrimidinyl, pyrazolopyrimidinyl, or azaindolyl.

In some embodiments, Ring A is pyrrolidinyl, pyrrolidinonyl,piperidinyl, piperazinyl, indolinyl, indolinonyl,1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl,3,4-dihydro-2(1H)-quinolinonyl, pyrrolyl, imidazolyl, pyrazolyl,pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, orbenzimidazolyl.

In some embodiments, Ring A is

In some embodiments, Ring A is a bicyclic C₅-C₁₀heterocycle containing1-4 N atoms and 0 or 1 O or S atoms, or bicyclic heterocycle containing0-4 N atoms and 1 O or S atoms that is a fused bicyclicC₅-C₁₀heterocycle, bridged bicyclic C₅-C₁₀ heterocycle, or spirobicyclic C₅-C₁₀heterocycle.

In some embodiments, Ring A is

In some embodiments, L² is absent, —O—, —CH₂—O—, —C(═O)—, —C(═O)NR⁶—,—NR⁶C(═O)—, —NR⁶—, or —CH₂—C(═O)NR⁶—. In some embodiments, L² is absent,—O—, —CH₂—O—, —C(═O)—, —C(═O)NR⁶—, —NR⁶—, or —CH₂—C(═O)NR⁶—.

In some embodiments, Q is H, substituted or unsubstituted C₁-C₆alkyl,substituted or unsubstituted C₁-C₆fluoroalkyl, substituted orunsubstituted C₁-C₆heteroalkyl, substituted or unsubstitutedC₃-C₆cycloalkyl, —C₁-C₂alkylene-(substituted or unsubstitutedC₃-C₆cycloalkyl), substituted or unsubstituted C₂-C₈heterocycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₂-C₈heterocycloalkyl),substituted or unsubstituted phenyl, —C₁-C₂alkylene-(substituted orunsubstituted phenyl), substituted or unsubstituted heteroaryl, or—C₁-C₂alkylene-(substituted or unsubstituted heteroaryl); wherein if Qis substituted then Q is substituted with one or more R⁸; or Q and R⁶are taken together with the N atom to which they are attached to formring B, wherein ring B is a substituted or unsubstituted monocyclicN-containing heterocycle, or a substituted or unsubstituted bicyclicN-containing heterocycle, wherein if ring B is substituted then ring Bis substituted with 1-3 R⁸.

In some embodiments, Q is substituted or unsubstituted C₃-C₆cycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₃-C₆cycloalkyl),substituted or unsubstituted C₂-C₈heterocycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₂-C₈heterocycloalkyl),substituted or unsubstituted phenyl, —C₁-C₂alkylene-(substituted orunsubstituted phenyl), substituted or unsubstituted heteroaryl, or—C₁-C₂alkylene-(substituted or unsubstituted heteroaryl); wherein if Qis substituted then Q is substituted with one or more R⁸; or Q and R⁶are taken together with the N atom to which they are attached to formring B, wherein ring B is a substituted or unsubstituted monocyclicN-containing heterocycle, or a substituted or unsubstituted bicyclicN-containing heterocycle, wherein if ring B is substituted then ring Bis substituted with 1-3 R⁸.

In some embodiments, L² is —C(═O)NR⁶—, or —CH₂—C(═O)NR⁶—; Q is H,substituted or unsubstituted C₁-C₆alkyl, substituted or unsubstitutedC₁-C₆fluoroalkyl, substituted or unsubstituted C₁-C₆heteroalkyl,substituted or unsubstituted C₃-C₆cycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₃-C₆cycloalkyl),substituted or unsubstituted C₂-C₈heterocycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₂-C₈heterocycloalkyl),substituted or unsubstituted phenyl, —C₁-C₂alkylene-(substituted orunsubstituted phenyl), substituted or unsubstituted heteroaryl, or—C₁-C₂alkylene-(substituted or unsubstituted heteroaryl); wherein if Qis substituted then Q is substituted with one or more R⁸; or Q and R⁶are taken together with the N atom to which they are attached to formring B, wherein ring B is a substituted or unsubstituted monocyclicN-containing heterocycle, or a substituted or unsubstituted bicyclicN-containing heterocycle, wherein if ring B is substituted then ring Bis substituted with 1-3 R⁸.

In some embodiments, the compound of Formula (I) has the structure ofFormula (IV), or a pharmaceutically acceptable salt thereof:

In some embodiments, -L²-Q is —C(═O)NR⁶-Q; Q and R⁶ are taken togetherwith the N atom to which they are attached to form a ring B, whereinring B is a substituted or unsubstituted monocyclic N-containingheterocycle, or a substituted or unsubstituted bicyclic N-containingheterocycle, wherein if ring B is substituted then ring B is substitutedwith 1-3 R⁸.

In some embodiments, Q and R⁶ are taken together with the N atom towhich they are attached to form a ring B, wherein ring B is asubstituted or unsubstituted aziridinyl, substituted or unsubstitutedazetidinyl, substituted or unsubstituted pyrrolidinyl, substituted orunsubstituted pyrrolidinonyl, substituted or unsubstituted piperidinyl,substituted or unsubstituted piperidinonyl, substituted or unsubstitutedmorpholinyl, substituted or unsubstituted thiomorpholinyl, substitutedor unsubstituted piperazinyl, substituted or unsubstitutedpiperazinonyl, substituted or unsubstituted indolinyl, substituted orunsubstituted indolinonyl, substituted or unsubstituted1,2,3,4-tetrahydroquinolinyl, substituted or unsubstituted1,2,3,4-tetrahydroisoquinolinyl, substituted or unsubstituted3,4-dihydro-2(1H)-quinolinonyl, wherein if ring B is substituted thenring B is substituted with 1-3 R⁸.

In some embodiments, the compound of Formula (I) has the structure ofFormula (V), or a pharmaceutically acceptable salt thereof:

wherein,ring B is a monocyclic N-containing heterocycle or a bicyclicN-containing heterocycle;n is 0, 1, 2, or 3.

In some embodiments,

and n is 0, 1, or 2.

In some embodiments,

In some embodiments, the compound of Formula (I) has the structure ofFormula (VI), or a pharmaceutically acceptable salt thereof:

wherein,L¹ is absent, —O— or —O—CH₂—;L² is absent, —O—, —CH₂—O—, —C(═O)—, —C(═O)NR⁶—, —NR⁶—, or—CH₂—C(═O)NR⁶—.

In some embodiments, the compound of Formula (I) has the structure ofFormula (VII), or a pharmaceutically acceptable salt thereof:

In some embodiments, L² is absent, —O—, —C(═O)NR⁶—, or —CH₂—C(═O)NR⁶—.

In some embodiments, the compound of Formula (I) has the structure ofFormula (VIII), or a pharmaceutically acceptable salt thereof:

In some embodiments, the compound of Formula (I) has the structure ofFormula (IX), or a pharmaceutically acceptable salt thereof:

In some embodiments, L² is absent, —O—, —C(═O)NR⁶—, or —CH₂—C(═O)NR⁶—.

In some embodiments, the compound of Formula (I) has the structure ofFormula (X), or a pharmaceutically acceptable salt thereof:

Any combination of the groups described above for the various variablesis contemplated herein. Throughout the specification, groups andsubstituents thereof are chosen by one skilled in the field to providestable moieties and compounds.

In one aspect, described herein is a pharmaceutical compositioncomprising a compound described herein, or a pharmaceutically acceptablesalt, or solvate thereof, and at least one pharmaceutically acceptableexcipient. In some embodiments, the pharmaceutical composition isformulated for administration to a mammal by intravenous administration,subcutaneous administration, oral administration, inhalation, nasaladministration, dermal administration, or ophthalmic administration. Insome embodiments, the pharmaceutical composition is formulated foradministration to a mammal by intravenous administration, subcutaneousadministration, or oral administration. In some embodiments, thepharmaceutical composition is formulated for administration to a mammalby oral administration. In some embodiments, the pharmaceuticalcomposition is in the form of a tablet, a pill, a capsule, a liquid, asuspension, a gel, a dispersion, a solution, an emulsion, an ointment,or a lotion. In some embodiments, the pharmaceutical composition is inthe form of a tablet, a pill, or a capsule.

In one aspect, described herein is a method of treating a disease orcondition in a mammal that would benefit from the inhibition orreduction of Lysyl oxidase like-2 (LOXL2) activity comprisingadministering a substituted trifluoromethylpyridinylmethylaminecompound, or pharmaceutically acceptable salt, or solvate thereof, tothe mammal in need thereof. In some embodiments, the disease orcondition is fibrosis or cancer. In some embodiments, the fibrosiscomprises lung fibrosis, liver fibrosis, kidney fibrosis, cardiacfibrosis, peritoneal fibrosis, ocular fibrosis or cutaneous fibrosis. Insome embodiments, the fibrosis is myelofibrosis. In some embodiments,the substituted trifluoromethylpyridinylmethylamine compound, orpharmaceutically acceptable salt, or solvate thereof, is a Lysyl oxidaselike-2 (LOXL2) inhibitor. In some embodiments, the substituted2-(trifluoromethyl)pyridin-4-ylmethylamine compound

In one aspect, described herein is a method of treating or preventingany one of the diseases or conditions described herein comprisingadministering a therapeutically effective amount of a compound describedherein, or a pharmaceutically acceptable salt, or solvate thereof, to amammal in need thereof.

In one aspect, described herein is a method for the treatment orprevention of fibrosis in a mammal comprising administering atherapeutically effective amount of a compound described herein, or apharmaceutically acceptable salt, or solvate thereof, to the mammal inneed thereof. In other embodiments, the fibrosis is amenable totreatment with a LOXL2 inhibitor. In some embodiments, the fibrosis islung fibrosis. In some embodiments, the method further comprisesadministering a second therapeutic agent to the mammal in addition tothe compound described herein, or a pharmaceutically acceptable salt, orsolvate thereof.

In any of the aforementioned aspects are further embodiments in whichthe effective amount of the compound described herein, or apharmaceutically acceptable salt thereof, is: (a) systemicallyadministered to the mammal; and/or (b) administered orally to themammal; and/or (c) intravenously administered to the mammal; and/or (d)administered by inhalation; and/or (e) t administered by nasaladministration; or and/or (f) administered by injection to the mammal;and/or (g) administered topically to the mammal; and/or (h) administeredby ophthalmic administration; and/or (i) administered rectally to themammal; and/or (j) adminstered non-systemically or locally to themammal.

In any of the aforementioned aspects are further embodiments comprisingsingle administrations of the effective amount of the compound,including further embodiments in which the compound is administered oncea day to the mammal or the compound is administered to the mammalmultiple times over the span of one day. In some embodiments, thecompound is administered on a continuous dosing schedule. In someembodiments, the compound is administered on a continuous daily dosingschedule.

In any of the aforementioned aspects involving the treatment of adisease or condition are further embodiments comprising administering atleast one additional agent in addition to the administration of acompound of Formula (I) described herein, or a pharmaceuticallyacceptable salt thereof. In various embodiments, each agent isadministered in any order, including simultaneously.

In any of the embodiments disclosed herein, the mammal is a human.

In some embodiments, compounds provided herein are administered to ahuman.

In some embodiments, compounds provided herein are orally administered.

Articles of manufacture, which include packaging material, a compounddescribed herein, or a pharmaceutically acceptable salt thereof, withinthe packaging material, and a label that indicates that the compound orcomposition, or pharmaceutically acceptable salt, pharmaceuticallyactive metabolite, pharmaceutically acceptable prodrug, orpharmaceutically acceptable solvate thereof, is used for inhibiting theactivity of LOXL2, or for the treatment, prevention or amelioration ofone or more symptoms of a disease or condition that would benefit frominhibition or reduction of the LOXL2 activity, are provided.

Other objects, features and advantages of the compounds, methods andcompositions described herein will become apparent from the followingdetailed description. It should be understood, however, that thedetailed description and the specific examples, while indicatingspecific embodiments, are given by way of illustration only, sincevarious changes and modifications within the spirit and scope of theinstant disclosure will become apparent to those skilled in the art fromthis detailed description.

DETAILED DESCRIPTION OF THE INVENTION

Lysyl oxidase like-2 (LOXL2) is a member of the lysyl oxidase (LOX)family, which comprises Cu²⁺ and lysine tyrosylquinone (LTQ)-dependentamine oxidases. The family comprises five genes: lox (LOX), loxl1 (lysyloxidase like-1, LOXL1), loxl2 (LOXL2), loxl3 (lysyl oxidase like-3,LOXL3), and loxl4 (lysyl oxidase like-4, LOXL4). The LOX family is knownfor catalyzing the oxidative deamination of the e-amino group of lysinesand hydroxylysines in collagen and elastin to promote crosslinking ofthese molecules. Crosslinking of collagen and elastin is essential formaintaining tensile strength of the extracellular matrix.

LOXL2 has been demonstrated to have intracellular functions aside fromits role in remodeling of the extracellular matrix. LOXL2 positivelyregulates the epithelial-to-mesenchymal transition (EMT) transducer,Snail1, by promoting Snail1 stability and functional activity. LOXL2contributes positively to the activation of the focal adhesion kinase(FAK) signaling pathway and participates in the organization of focaladhesion complexes. Silencing of LOXL2 gene leads to reacquisition ofepithelial cell polarity and decreases the migratory and invasiveability of mammary cell lines. The modulation of cell adhesion and cellpolarity has been reported to be mediated by intracellular LOXL2. LOXL2transcriptionally represses E-cadherin as well as tight junction andcell polarity genes by Snail1-dependent and Snail1-independentmechanisms. LOXL2 has been more recently described to be associated withchromatin and reported to be involved in histone H2 deamination, afunction that is dependent on the LOXL2 catalytic domain.

In some embodiments, the methods disclosed herein are methods forinhibiting intracellular LOXL2. In some embodiments, the methodsdisclosed herein are methods for inhibiting extracellular (secreted)LOXL2. In some embodiments, the methods disclosed herein are methods forinhibiting extracellular and intracellular LOXL2.

Fibrosis

LOXL2 has been shown to be involved in fibrotic processes. Fibroticprocesses include an excessive deposition of extracellular matrixcomponents, such as collagen, which alters the physical, biochemical andbiomechanical matrix properties leading to defective organ function andorgan failure. Tissue fibrosis is also associated with cancerprogression by direct promotion of cellular transformation andmetastasis. Tumors are typically stiffer than normal tissue and tumorrigidity influences tumor metastasis.

Excessive LOXL2 enzyme activity has been implicated in the increasedstiffness of tumors. Elevated LOXL2 is also associated with fibroticlesions from livers of patients suffering from Wilson disease andprimary biliary cirrhosis. Additionally, the administration of aLOXL2-specific monoclonal antibody AB0023 was efficacious in reducingdisease in a model of fibrosis. AB0023 was shown to inhibit theproduction of growth factors and of crosslinked collagenous matrix andTGF-beta signaling.

In some embodiments, disclosed herein are methods of treating fibrosiswith a compound disclosed herein.

“Fibrosis,” as used herein, refers to the accumulation of extracellularmatrix constituents that occurs following trauma, inflammation, tissuerepair, immunological reactions, cellular hyperplasia, and neoplasia.

In some embodiments, disclosed herein is a method of reducing fibrosisin a tissue comprising contacting a fibrotic cell or tissue with acompound disclosed herein, in an amount sufficient to decrease orinhibit the fibrosis. In some embodiments, the fibrosis includes afibrotic condition.

In some embodiments, the fibrosis comprises lung fibrosis, liverfibrosis, kidney fibrosis, cardiac fibrosis, peritoneal fibrosis, ocularfibrosis or cutaneous fibrosis. In some embodiments, the fibrosiscomprises lung fibrosis. In some embodiments, the fibrosis comprisesliver fibrosis. In some embodiments, the fibrosis comprises kidneyfibrosis. In some embodiments, the fibrosis comprises cardiac fibrosis.In some embodiments, the fibrosis comprises peritoneal fibrosis. In someembodiments, the fibrosis comprises ocular fibrosis. In someembodiments, the fibrosis comprises cutaneous fibrosis.

In some embodiments, reducing fibrosis, or treatment of a fibroticcondition, includes reducing or inhibiting one or more of: formation ordeposition of extracellular matrix proteins; the number of pro-fibroticcell types (e.g., fibroblast or immune cell numbers); cellular collagenor hydroxyproline content within a fibrotic lesion; expression oractivity of a fibrogenic protein; or reducing fibrosis associated withan inflammatory response.

In some embodiments, the fibrotic condition is a fibrotic condition ofthe lung.

In some embodiments, the fibrotic condition is a fibrotic condition ofthe liver.

In some embodiments, the fibrotic condition is a fibrotic condition ofthe heart.

In some embodiments, the fibrotic condition is a fibrotic condition ofthe kidney.

In some embodiments, the fibrotic condition is a fibrotic condition ofthe skin.

In some embodiments, the fibrotic condition is a fibrotic condition ofthe eye.

In some embodiments, the fibrotic condition is a fibrotic condition ofthe gastrointestinal tract.

In some embodiments, the fibrotic condition is a fibrotic condition ofthe bone marrow.

In some embodiments, the fibrotic condition is idiopathic. In someembodiments, the fibrotic condition is associated with (e.g., issecondary to) a disease (e.g., an infectious disease, an inflammatorydisease, an autoimmune disease, a malignant or cancerous disease, and/ora connective disease); a toxin; an insult (e.g., an environmental hazard(e.g., asbestos, coal dust, polycyclic aromatic hydrocarbons), cigarettesmoking, a wound); a medical treatment (e.g., surgical incision,chemotherapy or radiation), or a combination thereof.

In some embodiments, disclosed herein is a method for the treatment orprevention of fibrosis in a mammal comprising administering a LOXL2inhibitor described herein, or a pharmaceutically acceptable saltthereof, to the mammal in need thereof.

In some embodiments, disclosed herein is a method of improving lungfunction in a mammal comprising administering a LOXL2 inhibitordescribed herein, or a pharmaceutically acceptable salt thereof, to themammal in need thereof. In some embodiments, the mammal has beendiagnosed as having lung fibrosis.

In some embodiments, disclosed herein is a method of treating idopathicpulmonary fibrosis in a mammal comprising administering a LOXL2inhibitor described herein, or a pharmaceutically acceptable saltthereof, to the mammal in need thereof.

In some embodiments, disclosed herein is a method of controlling anabnormal accumulation or activation of cells, fibronectin, collagen orincreased fibroblast recruitment in a tissue of a mammal comprisingadministering a LOXL2 inhibitor described herein, or a pharmaceuticallyacceptable salt thereof, to the mammal in need thereof. In someembodiments, the abnormal accumulation or activation of cells,fibronectin, collagen or increased fibroblast recruitment in the tissueresults in fibrosis.

In some embodiments, disclosed herein is a method for the treatment orprevention of scleroderma in a mammal comprising administering a LOXL2inhibitor described herein, or a pharmaceutically acceptable saltthereof, to the mammal in need thereof.

In some embodiments, disclosed herein is a method for reducing undesiredor abnormal dermal thickening in a mammal comprising administering tomammal in need thereof a LOXL2 inhibitor described herein, or apharmaceutically acceptable salt thereof. In some embodiments, thedermal thickening is associated with scleroderma.

In some embodiments, described herein is a method of controlling anabnormal accumulation or activation of cells, fibronectin, collagen orincreased fibroblast recruitment in tissues of a mammal comprisingadministering to mammal in need thereof a LOXL2 inhibitor describedherein, or a pharmaceutically acceptable salt thereof. In someembodiments, the abnormal accumulation or activation of cells,fibronectin, collagen or increased fibroblast recruitment in the dermaltissues results in fibrosis. In some embodiments, described herein is amethod of reducing hydroxyproline content in tissues of a mammal withfibrosis comprising administering to mammal in need thereof a LOXL2inhibitor described herein, or a pharmaceutically acceptable saltthereof.

Cancer

LOXL2 has been shown to be involved in signaling related to cancer cellgrowth, adhesion, motility and invasion. Specifically, LOXL2 inducesepithelial-to-mesenchymal transition (EMT) of cells to promote tumorinvasion. LOXL2 is also upregulated in hypoxic tumor environments whichleads to enhanced invasion of tumor cells. LOXL2 has also been shown topromote angiogenesis in hypoxic tumor environments.

Increased LOXL2 expression is associated with poor prognosis in patientswith colon, esophageal tumors, oral squamous cell carcinomas, laryngealsquamous cell carcinomas, and head and neck squamous cell carcinomas.LOXL2 has been proposed to participate in cancers of the breast, colon,gastric, head and neck, lung, and melanoma.

In some embodiments, disclosed herein are methods of treating cancerwith a compound disclosed herein.

The term “cancer” as used herein, refers to an abnormal growth of cellsthat tend to proliferate in an uncontrolled way and, in some cases, tometastasize (spread). Types of cancer include, but are not limited to,solid tumors (such as those of the bladder, bowel, brain, breast,endometrium, heart, kidney, lung, liver, uterus, lymphatic tissue(lymphoma), ovary, pancreas or other endocrine organ (thyroid),prostate, skin (melanoma or basal cell cancer) or hematological tumors(such as the leukemias and lymphomas) at any stage of the disease withor without metastases.

Compounds

Compounds described herein, including pharmaceutically acceptable salts,prodrugs, active metabolites and pharmaceutically acceptable solvatesthereof, are LOXL2 inhibitors.

In one aspect, described herein is a compound of Formula (I), or apharmaceutically acceptable salt thereof:

wherein,

-   -   each R¹ is independently H, D, or F;    -   L¹ is absent, X¹, X¹—C₁-C₆alkylene, or C₁-C₆alkylene;        -   X¹ is —O—, —S—, —S(═O)—, —S(═O)₂—, —C(═O)—, —C(═O)O—,            —C(═O)NR²—, —NR²C(═O)—, or —NR²—;        -   R² is H, substituted or unsubstituted C₁-C₆alkyl,            C₁-C₆fluoroalkyl, or C₁-C₆deuteroalkyl;    -   each R³ is independently H, D, halogen, —CN, —OR⁵, —SR⁵,        —S(═O)R⁴, —S(═O)₂R⁴, —S(═O)₂N(R⁵)₂, —NR²S(═O)₂R⁴, —C(═O)R⁴,        —OC(═O)R⁴, —CO₂R⁵, —OCO₂R⁴, —N(R⁵)₂, —OC(═O)N(R⁵)₂, —NR²C(═O)R⁴,        —NR²C(═O)OR⁴, C₁-C₆alkyl, C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl,        C₁-C₆heteroalkyl, substituted or unsubstituted C₃-C₁₀cycloalkyl,        substituted or unsubstituted C₂-C₁₀heterocycloalkyl, substituted        or unsubstituted aryl, or substituted or unsubstituted        heteroaryl;        -   m is 0, 1, or 2;    -   each R⁴ is independently selected from C₁-C₆alkyl,        C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl, C₁-C₆heteroalkyl,        substituted or unsubstituted C₃-C₁₀cycloalkyl, substituted or        unsubstituted C₂-C₁₀heterocycloalkyl, substituted or        unsubstituted aryl, and substituted or unsubstituted heteroaryl;    -   each R⁵ is independently selected from H, C₁-C₆alkyl,        C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl, C₁-C₆heteroalkyl,        substituted or unsubstituted C₃-C₁₀cycloalkyl, substituted or        unsubstituted C₂-C₁₀heterocycloalkyl, substituted or        unsubstituted aryl, and substituted or unsubstituted heteroaryl;        or two R⁵ on the same N atom are taken together with the N atom        to which they are attached to a substituted or unsubstituted        N-containing heterocycle;    -   Ring A is monocyclic carbocycle, bicyclic carbocycle, monocyclic        heterocycle, or bicyclic heterocycle;    -   L² is absent, —X²—, or —C₁-C₆alkylene-X²—;        -   X² is —O—, —S—, —S(═O)—, —S(═O)₂—, —S(═O)₂NR⁶—, —C(═O)—,            —C(═O)O—, —C(═O)NR⁶—, —C(═O)NR⁶—, —NR⁶C(═O)—, —NR⁶S(═O)₂—,            or —NR⁶—;        -   R⁶ is H, C₁-C₆alkyl, C₁-C₆fluoroalkyl, or C₁-C₆deuteroalkyl;    -   Q is H, substituted or unsubstituted C₁-C₆alkyl, substituted or        unsubstituted C₁-C₆fluoroalkyl, substituted or unsubstituted        C₁-C₆heteroalkyl, substituted or unsubstituted C₃-C₈cycloalkyl,        —C₁-C₄alkylene-(substituted or unsubstituted C₃-C₈cycloalkyl),        substituted or unsubstituted C₂-C₈heterocycloalkyl,        —C₁-C₄alkylene-(substituted or unsubstituted        C₂-C₈heterocycloalkyl), substituted or unsubstituted aryl,        —C₁-C₄alkylene-(substituted or unsubstituted aryl), substituted        or unsubstituted heteroaryl, or —C₁-C₄alkylene-(substituted or        unsubstituted heteroaryl); wherein if Q is substituted then Q is        substituted with one or more R⁸;    -   or Q and R⁶ are taken together with the N atom to which they are        attached to form ring B, wherein ring B is a substituted or        unsubstituted N-containing heterocycle, wherein if ring B is        substituted then ring B is substituted with 1-3 R⁸;    -   each R⁸ is independently D, halogen, CN, —OR⁵, —SR⁵, —S(═O)R⁴,        —S(═O)₂R⁴, —S(═O)₂N(R⁵)₂, NR⁵S(═O)₂R⁴, C(═O)R⁴, OC(═O)R⁴, CO₂R⁵,        OCO₂R⁴, N(R⁴)₂, OC(═O)N(R⁵)₂, —NHC(═O)R⁴, —NHC(═O)OR⁴,        C₁-C₆alkyl, C₁-C₆alkenyl, C₁-C₆alkynyl, C₁-C₆fluoroalkyl,        C₁-C₆deuteroalkyl, C₁-C₆heteroalkyl, substituted or        unsubstituted C₃-C₁₀cycloalkyl, substituted or unsubstituted        C₂-C₁₀heterocycloalkyl, substituted or unsubstituted aryl, or        substituted or unsubstituted heteroaryl; or two R⁸ groups        attached to the same carbon atom are taken together with carbon        atom to which they are attached to form either a substituted or        unsubstituted carbocycle or substituted or unsubstituted        heterocycle.

For any and all of the embodiments, substituents are selected from amonga subset of the listed alternatives. For example, in some embodiments,each R¹ is independently H, D, or F. In some other embodiments, each R¹is independently H, or F. In other embodiments, each R¹ is H. In someembodiments, each R¹ is D. In some embodiments, each R¹ is F.

In some embodiments, each R¹ is H; L¹ is absent, X¹, orX¹—C₁-C₆alkylene.

In some embodiments, L¹ is absent, X¹, X¹—CH₂—, or —CH₂—;

In some embodiments, L¹ is absent, —O—, —S—, —S(═O)—, —S(═O)₂—, —C(═O)—,—C(═O)O—, —C(═O)NR²—, —NR²C(═O)—, —NR²—, —O—CH₂—, —S—CH₂—, —S(═O)—CH₂—,—S(═O)₂—CH₂—, —C(═O)—CH₂—, —C(═O)O—CH₂—, —C(═O)NR²—CH₂—, —NR²C(═O)—CH₂—,—NR²—CH₂—, or —CH₂—.

In some embodiments, L¹ is absent, —O—, —S—, —S(═O)₂—, —C(═O)—,—C(═O)O—, —C(═O)NR²—, —NR²C(═O)—, —NR²—, —O—CH₂—, —S—CH₂—, —NR²—CH₂—, or—CH₂—.

In some embodiments, X¹ is —O—.

In some embodiments, L¹ is absent, X¹, X¹—CH₂—, or —CH₂—;

In some embodiments, L¹ is absent, —O—, or —O—CH₂—.

In some embodiments, the compound of Formula (I) has the structure ofFormula (II), or a pharmaceutically acceptable salt thereof:

In some embodiments, L¹ is —O—, or —O—CH₂—.

In some embodiments, the compound of Formula (I) has the structure ofFormula (III), or a pharmaceutically acceptable salt thereof:

In some embodiments, Ring A is monocyclic C₃-C₆carbocycle, bicyclicC₅-C₁₂carbocycle, monocyclic C₁-C₅heterocycle, bicyclicC₅-C₁₀heterocycle.

In some embodiments, Ring A is monocyclic C₃-C₆carbocycle, bicyclicC₉-C₁₀carbocycle, monocyclic C₁-C₅heterocycle, bicyclicC₆-C₉heterocycle.

In some embodiments, Ring A is monocyclic C₃-C₆carbocycle.

In some embodiments, Ring A is phenyl, cyclopropyl, cyclobutyl,cyclopentyl, or cyclohexyl.

In some embodiments, Ring A is phenyl.

In some embodiments, Ring A is

In some embodiments, Ring A is

In some embodiments, Ring A is a bicyclic C₅-C₁₂carbocycle. In someembodiments, Ring A is a bicyclic C₅-C₁₂carbocycle that is a fusedC₅-C₁₂carbocycle, bridged C₅-C₁₂carbocycle, or spirocyclicC₅-C₁₂carbocycle.

In some embodiments, Ring A is bicyclic C₉-C₁₀carbocycle.

In some embodiments, Ring A is naphthyl, indanyl, indenyl, ortetrahyodronaphthyl.

In some embodiments, Ring A is a bridged bicyclic C₅-C₁₂carbocycle thatis

In some embodiments, Ring A is a monocyclic heterocycle containing 1-4 Natoms and 0 or 1 O or S atom, monocyclic heterocycle containing 0-4 Natoms and 1 O or S atoms, bicyclic heterocycle containing 1-4 N atomsand 0 or 1 O or S atoms, or bicyclic heterocycle containing 0-4 N atomsand 1 O or S atoms.

In some embodiments, Ring A is pyrrolidinyl, pyrrolidinonyl,tetrahydrofuranyl, tetrahydrofuranonyl, dihydrofuranonyl,dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl,dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl,thiomorpholinyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl,thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl,thiazepinyl, 1,2,3,6-tetrahydropyridinyl, indolinyl, indolinonyl,1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl,3,4-dihydro-2(1H)-quinolinonyl, furanyl, pyrrolyl, oxazolyl, thiazolyl,imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl,oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinazolinyl,quinoxalinyl, naphthyridinyl, indolyl, indazolyl, benzoxazolyl,benzisoxazolyl, benzofuranyl, benzothienyl, benzothiazolyl,benzimidazolyl, purinyl, cinnolinyl, phthalazinyl, pteridinyl,pyridopyrimidinyl, pyrazolopyrimidinyl, or azaindolyl.

In some embodiments, Ring A is pyrrolidinyl, pyrrolidinonyl,piperidinyl, piperazinyl, indolinyl, indolinonyl,1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl,3,4-dihydro-2(1H)-quinolinonyl, pyrrolyl, imidazolyl, pyrazolyl,pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, orbenzimidazolyl.

In some embodiments, Ring A

In some embodiments, Ring A is a bicyclic C₅-C₁₀heterocycle containing1-4 N atoms and 0 or 1 O or S atoms, or bicyclic heterocycle containing0-4 N atoms and 1 O or S atoms that is a fused bicyclicC₅-C₁₀heterocycle, bridged bicyclic C₅-C₁₀ heterocycle, or spirobicyclic C₅-C₁₀heterocycle.

In some embodiments, Ring A is a bicyclic heterocycle containing 1-4 Natoms and 0 or 1 O or S atoms, or bicyclic heterocycle containing 0-4 Natoms and 1 O or S atoms.

In some embodiments, Ring A is a bicyclic C₅-C₁₀heterocycloalkylcontaining 1-4 N atoms and 0 or 1 O or S atoms, or bicyclic heterocyclecontaining 0-4 N atoms and 1 O or S atoms that is a fused bicyclicC₅-C₁₀heterocycloalkyl, bridged bicyclic C₅-C₁₀heterocycloalkyl, orspiro bicyclic C₅-C₁₀heterocycloalkyl.

In some embodiments, Ring A is a bridged bicyclic C₅-C₁₀heterocycloalkylthat is

In some embodiments, Ring A is spiro bicyclic C₅-C₁₀heterocycloalkylthat is

In some embodiments, L² is absent, —O—, —CH₂—O—, —C(═O)—, —C(═O)NR⁶—,—NR⁶C(═O)—, —NR⁶—, or —CH₂—C(═O)NR⁶—. In some embodiments, L² is absent,—O—, —CH₂—O—, —C(═O)—, —C(═O)NR⁶—, —NR⁶—, or —CH₂—C(═O)NR⁶—.

In some embodiments, Q is H, substituted or unsubstituted C₁-C₆alkyl,substituted or unsubstituted C₁-C₆fluoroalkyl, substituted orunsubstituted C₁-C₆heteroalkyl, substituted or unsubstitutedC₃-C₆cycloalkyl, —C₁-C₂alkylene-(substituted or unsubstitutedC₃-C₆cycloalkyl), substituted or unsubstituted C₂-C₈heterocycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₂-C₈heterocycloalkyl),substituted or unsubstituted phenyl, —C₁-C₂alkylene-(substituted orunsubstituted phenyl), substituted or unsubstituted heteroaryl, or—C₁-C₂alkylene-(substituted or unsubstituted heteroaryl); wherein if Qis substituted then Q is substituted with one or more R⁸; or Q and R⁶are taken together with the N atom to which they are attached to formring B, wherein ring B is a substituted or unsubstituted monocyclicN-containing heterocycle, or a substituted or unsubstituted bicyclicN-containing heterocycle, wherein if ring B is substituted then ring Bis substituted with 1-3 R⁸.

In some embodiments, Q is substituted or unsubstituted C₃-C₆cycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₃-C₆cycloalkyl),substituted or unsubstituted C₂-C₈heterocycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₂-C₈heterocycloalkyl),substituted or unsubstituted phenyl, —C₁-C₂alkylene-(substituted orunsubstituted phenyl), substituted or unsubstituted heteroaryl, or—C₁-C₂alkylene-(substituted or unsubstituted heteroaryl); wherein if Qis substituted then Q is substituted with one or more R⁸; or Q and R⁶are taken together with the N atom to which they are attached to formring B, wherein ring B is a substituted or unsubstituted monocyclicN-containing heterocycle, or a substituted or unsubstituted bicyclicN-containing heterocycle, wherein if ring B is substituted then ring Bis substituted with 1-3 R⁸.

In some embodiments, L² is —C(═O)NR⁶—, or —CH₂—C(═O)NR⁶—; Q is H,substituted or unsubstituted C₁-C₆alkyl, substituted or unsubstitutedC₁-C₆fluoroalkyl, substituted or unsubstituted C₁-C₆heteroalkyl,substituted or unsubstituted C₃-C₆cycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₃-C₆cycloalkyl),substituted or unsubstituted C₂-C₈heterocycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₂-C₈heterocycloalkyl),substituted or unsubstituted phenyl, —C₁-C₂alkylene-(substituted orunsubstituted phenyl), substituted or unsubstituted heteroaryl, or—C₁-C₂alkylene-(substituted or unsubstituted heteroaryl); wherein if Qis substituted then Q is substituted with one or more R⁸; or Q and R⁶are taken together with the N atom to which they are attached to formring B, wherein ring B is a substituted or unsubstituted monocyclicN-containing heterocycle, or a substituted or unsubstituted bicyclicN-containing heterocycle, wherein if ring B is substituted then ring Bis substituted with 1-3 R⁸.

In some embodiments, the compound of Formula (I) has the structure ofFormula (IV), or a pharmaceutically acceptable salt thereof:

In some embodiments, -L²-Q is —C(═O)NR⁶-Q; Q and R⁶ are taken togetherwith the N atom to which they are attached to form a ring B, whereinring B is a substituted or unsubstituted monocyclic N-containingheterocycle, or a substituted or unsubstituted bicyclic N-containingheterocycle, wherein if ring B is substituted then ring B is substitutedwith 1-3 R⁸.

In some embodiments, —NR⁶Q is

In some embodiments, Q and R⁶ are taken together with the N atom towhich they are attached to form a ring B, wherein ring B is asubstituted or unsubstituted aziridinyl, substituted or unsubstitutedazetidinyl, substituted or unsubstituted pyrrolidinyl, substituted orunsubstituted pyrrolidinonyl, substituted or unsubstituted piperidinyl,substituted or unsubstituted piperidinonyl, substituted or unsubstitutedmorpholinyl, substituted or unsubstituted thiomorpholinyl, substitutedor unsubstituted piperazinyl, substituted or unsubstitutedpiperazinonyl, substituted or unsubstituted indolinyl, substituted orunsubstituted indolinonyl, substituted or unsubstituted1,2,3,4-tetrahydroquinolinyl, substituted or unsubstituted1,2,3,4-tetrahydroisoquinolinyl, substituted or unsubstituted3,4-dihydro-2(1H)-quinolinonyl, wherein if ring B is substituted thenring B is substituted with 1-3 R⁸.

In some embodiments, the compound of Formula (I) has the structure ofFormula (V), or a pharmaceutically acceptable salt thereof:

wherein,ring B is a monocyclic N-containing heterocycle or a bicyclicN-containing heterocycle;n is 0, 1, 2, or 3.

In some embodiments, —NR⁶Q is

In some embodiments,

and n is 0, 1, or 2. In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments,

In some embodiments, each R⁸ is independently D, F, Cl, CN, —OH, —OCH₃,—OCH₂CH₃, —S(═O)₂CH₃, —S(═O)₂NH₂, —S(═O)₂N(CH₃)₂, —C(═O)CH₃, OC(═O)CH₃,—CO₂H, —CO₂CH₃, —CO₂CH₂CH₃, —CO₂CH(CH₃)₂, —CO₂C(CH₃)₃, —NH₂, —N(CH₃)₂,—CH₃, —CH₂CH₃, —C≡CH, —CF₃, —CH₂CF₃, or —OCH₂OH.

In some embodiments, each R⁸ is independently D, F, Cl, CN, —OH, —OCH₃,—OCH₂CH₃, —NH₂, —N(CH₃)₂, —CH₃, —CH₂CH₃, —CF₃, —CH₂CF₃, or —OCH₂OH.

In some embodiments, two R⁸ groups attached to the same carbon atom aretaken together with carbon atom to which they are attached to formeither a substituted or unsubstituted monocyclic 3 to 6 memberedcarbocycle or substituted or unsubstituted monocyclic 3 to 6 memberedheterocycle.

In some embodiments, the compound of Formula (I) has the structure ofFormula (VI), or a pharmaceutically acceptable salt thereof:

wherein,L¹ is absent, —O— or —O—CH₂—;L² is absent, —O—, —CH₂—O—, —C(═O)—, —C(═O)NR⁶—, —NR⁶—, or—CH₂—C(═O)NR⁶—.

In some embodiments, the compound of Formula (I) has the structure ofFormula (VII), or a pharmaceutically acceptable salt thereof:

In some embodiments, L² is absent, —O—, —C(═O)NR⁶—, or —CH₂—C(═O)NR⁶—.

In some embodiments, the compound of Formula (I) has the structure ofFormula (VIII), or a pharmaceutically acceptable salt thereof:

In some embodiments, the compound of Formula (I) has the structure ofFormula (IX), or a pharmaceutically acceptable salt thereof:

In some embodiments, L² is absent, —O—, —C(═O)NR⁶—, or —CH₂—C(═O)NR⁶—.

In some embodiments, the compound of Formula (I) has the structure ofFormula (X), or a pharmaceutically acceptable salt thereof:

In some embodiments, the compound of Formula (I) has the followingstructure:

or a pharmaceutically acceptable salt thereof.

In some instances, R¹ is as described in Table 1. In some instances,-L¹- is as described in Table 1. In some instances,

is as described in Table 1. In some instances, -L²-Q is as described inTable 1. In some instances, R¹, -L¹-, and -L²-Q are as described inTable 1. In some instances, R¹, -L¹-,

and -L²-Q are as described in Table 1.

In some embodiments, compounds of Formula (I) include, but are notlimited to, those described in Table 1.

TABLE 1

Compound Number R¹ —L¹—

—L₂—Q 1-1 H —

— 1-2 H —O—

1-3 H —O—

1-4 H —O—

1-5 H —O—

1-6 H —O—

1-7 H —O—

1-8 D —O—

1-9 H —O—

1-10 H —O—

1-11 H —O—

1-12 H —O—

1-13 H —O—

1-14 H —O—

1-15 H —O—

1-16 H —O—

1-17 H —O—

1-18 H —O—

1-19 (racemic trans) H —O—

1-20 H —O—

1-21 H —O—

1-22 H —O—

1-23 (racemic trans) H —O—

1-24 H —O—

1-25 H —O—

1-26 H —O—

1-27 H —O—

1-28 H —O—

1-29 (racemic) H —O—

1-30 H —O—

1-31 H —O—

1-32 H —O—

1-33 H —O—

1-34 H —O—

1-35 H —O—

1-36 (racemic trans) H —OCH₂—

1-37 H —O—

1-38 H —O—

1-39 H —O—

1-40 H —O—

1-41 H —O—

1-42 H —OCH₂—

1-43 H —O—

1-44 H —O—

1-45 H —OCH₂—

1-46 H —O—

1-47 H —O—

1-48 H —O—

1-49 H —O—

1-50 H —O—

1-51 H —O—

1-52 H —O—

1-53 H —O—

1-54 H —O—

1-55 (racemic trans) H —O—

1-56 H —O—

1-57 H —O—

1-58 H —O—

— 1-59 H —O—

— 1-60 H —O—

1-61 H —O—

1-62 H —O—

1-63 H —O—

1-64 H —O—

1-65 H —O—

1-66 H —O—

1-67 H —O—

1-68 H —S—

1-69 H —S—

1-70 H —S—

1-71 H —S—

1-72 H —S—

1-73 H —S—

1-74 H —S—

1-75 H —S—

1-76 H —S—

1-77 H —S—

1-78 H —S—

1-79 H —S—

1-80 H —S—

1-81 H —SCH₂—

1-82 H —SCH₂—

1-83 H —SCH₂—

1-84 H —SCH₂—

1-85 H —SCH₂—

1-86 H —SCH₂—

1-87 H —SCH₂—

1-88 H —SCH₂—

1-89 H —SCH₂—

1-90 H —SCH₂—

1-91 H —SCH₂—

1-92 H —NH—

1-93 H —NH—

1-94 H —NH—

1-95 H —NH—

1-96 H —NH—

1-97 H —NH—

1-98 H —NH—

1-99 H —NH—

1-100 H —NH—

1-101 H —NH—

1-102 H —NH—

1-103 H —NH—

1-104 H —NH—

1-105 H —NHCH₂—

1-106 H —NHCH₂—

1-107 H —NHCH₂—

1-108 H —NHCH₂—

1-109 H —NHCH₂—

1-110 H —NHCH₂—

1-111 H —NHCH₂—

1-112 H —NHCH₂—

1-113 H —NHCH₂—

1-114 H —NHCH₂—

1-115 H —NHCH₂—

1-116 H —NHCH₂—

1-117 H —NHCH₂—

1-118 H

1-119 H

1-120 H

1-121 H

1-122 H

1-123 H —CH₂—

1-124 H —CH₂—

1-125 H —CH₂—

1-126 H —CH₂—

1-127 H —CH₂—

1-128 H —CH₂—

1-129 H —CH₂—

1-130 H —CH₂—

1-131 H —CH₂—

1-132 H —CH₂—

1-133 H —CH₂—

1-134 H —CH₂—

1-135 H —CH₂—

1-136 H —SO₂—

1-137 H —SO₂—

1-138 H —SO₂—

1-139 H —SO₂—

1-140 H —SO₂—

1-141 H —SO₂—

1-142 H —SO₂—

1-143 H —SO₂—

1-144 H —SO₂—

1-145 H —SO₂—

1-146 H —SO₂—

1-147 H —SO₂—

1-148 H —C(═O)NH—

1-149 H C(═O)NH

1-150 H —C(═O)NH—

1-151 H —C(═O)NH—

1-152 H —C(═O)NH—

1-153 H —C(═O)NH—

1-154 H —C(═O)NH—

1-155 H —C(═O)NH—

1-156 H —C(═O)NH—

1-157 H —C(═O)NH

1-158 H —C(═O)NH—

1-159 H —C(═O)NH—

1-160 H —C(═O)NH—

1-161 H —

— 1-162 H —

— 1-163 H —

— 1-164 H —

— 1-165 H —

— 1-166 H O

Me 1-167 H —O—

1-168 H —O—

1-169 H —O—

1-170 H —O—

1-171 H —O—

1-172 H —O—

1-173 H —O—

1-174 H —O—

1-175 H —O—

1-176 H —O—

1-177 H —O—

1-178 H —O—

1-179 H —O—

1-180 H —O—

1-181 H —O—

1-182 H —O—

1-183 H —O—

1-184 H —O—

1-185 H —O—

1-186 H —O—

1-187 H —O—

1-188 H —O—

1-189 H —O—

1-190 H —O—

1-191 H —O—

1-192 H —Ov

1-193 H —O—

1-194 H —O—

1-195 H —O—

1-196 H —O—

1-197 H —O—

1-198 H —O—

1-199 H —O—

1-200 H —O—

1-201 H —O—

1-202 H —O—

1-203 H —O—

1-204 H —O—

1-205 H —O—

1-206 H —O—

1-207 H —O—

1-208 H —O—

1-209 H —O—

1-210 H —O—

1-211 (racemic cis) H —O—

1-212 H —O—

1-213 H —O—

1-214 H —O—

1-215 H —O—

1-216 H —O—

1-217 H —O—

1-218 H —O—

1-219 H —O—

1-220 H —O—

1-221 H —O—

1-222 H —O—

1-223 H —O—

1-224 H —O—

1-225 H —O—

1-226 H —O—

1-227 H —O—

1-228 H —O

1-229 (racemic- trans) H —O—

1-230 (racemic- trans) H —O—

1-231 (racemic- trans) H —O—

1-232 (racemic- trans) H —O—

1-233 H —O—

1-234 H —O—

1-235 H —O—

1-236 H —O—

1-237 H —NHCH₂—

1-238 H —NHC(═O)—

1-239 H —NHC(═O)—

1-240 H —NHC(═O)—

1-241 H —NHC(═O)—

1-242 H —NHC(═O)—

1-243 H —CH₂—

1-244 H —O—

1-245 H —O—

1-246 H —O—

1-247 H —O—

1-248 H —O—

1-249 H —O—

1-250 (cis Enant-1) H —O—

1-251 (cis Enant-2) H —O—

1-252 H —O—

In some embodiments, compounds of Formula (I) include, but are notlimited to:

-   (6-(Trifluoromethyl)-[2,3′-bipyridin]-4-yl)methanamine (Compound    1-1);-   (2-([1,1′-Biphenyl]-3-yloxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine    (Compound 1-2);-   (2-(3-Phenoxyphenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine    (Compound 1-3);-   (2-(3-(Phenoxymethyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine    (Compound 1-4);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylaniline    (Compound 1-5);-   (2-(3-(1H-Pyrazol-4-yl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine    (Compound 1-6);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylbenzamide    (Compound 1-7);-   3-((4-(Aminomethyl-d₂)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylbenzamide    (Compound 1-8);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-fluorobenzyl)benzamide    (Compound 1-9);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(benzo[b]thiophen-2-ylmethyl)benzamide    (Compound 1-10);-   (3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3,4-dihydroisoquinolin-2(1H)-yl)methanone    (Compound 1-11);-   (3-(1H-Pyrazol-1-yl)azetidin-1-yl)(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)methanone    (Compound 1-12);-   N-((2H-Tetrazol-5-yl)methyl)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamide    (Compound 1-13);-   N-(2-(1H-1,2,4-Triazol-1-yl)ethyl)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamide    (Compound 1-14);-   N-(2-(1H-Tetrazol-1-yl)ethyl)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamide    (Compound 1-15);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-hydroxyethyl)benzamide    (Compound 1-16);-   (S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-hydroxypyrrolidin-1-yl)methanone    (Compound 1-17);-   (R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-hydroxypyrrolidin-1-yl)methanone    (Compound 1-18);-   Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-19);-   (S,S)-trans-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-20);-   (R,R)-trans-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-21);-   (R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-aminopyrrolidin-1-yl)methanone    (Compound 1-22);-   Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(-3-(dimethylamino)-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-23);-   (S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)pyrrolidine-2-carboxylic    acid (Compound 1-24);-   (R)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)pyrrolidine-2-carboxylic    acid (Compound 1-25);-   (R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-(hydroxymethyl)pyrrolidin-1-yl)methanone    (Compound 1-26);-   8-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one    (Compound 1-27);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(2-oxooxazolidin-3-yl)ethyl)benzamide    (Compound 1-28);-   Racemic-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((5-oxopyrrolidin-2-yl)methyl)benzamide    (Compound 1-29);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(methylsulfonyl)ethyl)benzamide    (Compound 1-30);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(1-(hydroxymethyl)cyclopropyl)benzamide    (Compound 1-31);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-hydroxy-2-methylpropyl)benzamide    (Compound 1-32);-   (R)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2,3-dihydroxypropyl)benzamide    (Compound 1-33);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-sulfamoylethyl)benzamide    (Compound 1-34);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(dimethylamino)ethyl)benzamide    (Compound 1-35);-   Racemic-trans-(3-(((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-36);-   (2-((1-(1-Methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)oxy)-6-(trifluoromethyl)pyridin-4-yl)    methanamine (Compound 1-37);-   2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-N-methyl-N-phenylacetamide    (Compound 1-38);-   (R)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpyrrolidine-1-carboxamide    (Compound 1-39);-   (S)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpyrrolidine-1-carboxamide    (Compound 1-40);-   4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpiperidine-1-carboxamide    (Compound 1-41);-   4-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)-N-phenylpiperidine-1-carboxamide    (Compound 1-42);-   (R)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpiperidine-1-carboxamide    (Compound 1-43);-   (S)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpiperidine-1-carboxamide    (Compound 1-44);-   (S)-3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)-N-phenylpiperidine-1-carboxamide    (Compound 1-45);-   (5)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-phenylethanone    (Compound 1-46);-   (S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-(3,4-dichlorophenyl)ethanone    (Compound 1-47);-   (S)-2-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidine-1-carbonyl)-4H-chromen-4-one    (Compound 1-48);-   (S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)(pyridin-3-yl)methanone    (Compound 1-49);-   (S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)(pyrimidin-5-yl)methanone    (Compound 1-50);-   (S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanone    (Compound 1-51);-   (S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-methylpropan-1-one    (Compound 1-52);-   5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(methylsulfonyl)ethyl)nicotinamide    (Compound 1-53);-   (R)-(5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)pyridin-3-yl)(3-aminopyrrolidin-1-yl)methanone    (Compound 1-54);-   Racemic-trans-(5-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)pyridin-3-yl)(-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-55);-   2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-1-(piperidin-1-yl)ethanone    (Compound 1-56);-   tert-Butyl    4-(2-(4-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)acetyl)piperazine-1-carboxylate    (Compound 1-57);-   (2-((1H-Indol-4-yl)oxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine    (Compound 1-58);-   5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-3,4-dihydroquinolin-2(1H)-one    (Compound 1-59);-   5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1-(2-hydroxyethyl)-3,4-dihydroquinolin-2(1H)-one    (Compound 1-60);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)thio)-N-phenylbenzamide    (Compound 1-68);-   3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)-N-phenylbenzamide    (Compound 1-105);-   3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)-N-(2-(methylsulfonyl)ethyl)benzamide    (Compound 1-106);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-1-benzyl-6-methylpyrimidine-2,4(1H,3H)-dione    (Compound 1-134);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-1-(2-hydroxyethyl)-6-methylpyrimidine-2,4(1H,3H)-dione    (Compound 1-135);-   4′-(Aminomethyl)-6′-(trifluoromethyl)-2H-[1,2′-bipyridin]-2-one    (Compound 1-161);-   1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)pyridin-2(1H)-one-   (Compound 1-169);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-cyanoethyl)benzamide    (Compound 1-198);-   1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)azetidine-3-carbonitrile    (Compound 1-199);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(oxetan-3-yl)benzamide    (Compound 1-200);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((1-hydroxycyclobutyl)methyl)benzamide    (Compound 1-201);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-hydroxyethyl)-N-methylbenzamide    (Compound 1-202);-   (S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-(hydroxymethyl)piperidin-1-yl)methanone    (Compound 1-203);-   (3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(4-(hydroxymethyl)piperidin-1-yl)methanone    (Compound 1-204);-   (3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(4-hydroxy-4-methylpiperidin-1-yl)methanone    (Compound 1-205);-   (3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-(methoxymethyl)azetidin-1-yl)methanone    (Compound 1-206);-   (3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(7-oxa-2-azaspiro[3.5]nonan-2-yl)methanone    (Compound 1-207);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)benzamide    (Compound 1-208);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((1R,2S)-2-hydroxycyclopentyl)benzamide    (Compound 1-209);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((1S,2R)-2-hydroxycyclopentyl)benzamide    (Compound 1-210);-   Racemic-cis-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-211);-   (R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoropyrrolidin-1-yl)methanone    (Compound 1-212);-   (S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoropyrrolidin-1-yl)methanone    (Compound 1-213);-   (3R,4R)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)-4-fluoropyrrolidin-3-yl-methanesulfonate    (Compound 1-214);-   (3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(2,5-dihydro-1H-pyrrol-1-yl)methanone    (Compound 1-215);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(hex-5-yn-1-yl)benzamide    (Compound 1-216);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-(1-phenyl-1H-1,2,3-triazol-4-yl)butyl)benzamide    (Compound 1-217);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-hydroxybenzamide    (Compound 1-218);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-methoxybenzamide    (Compound 1-219);-   Methyl    (S)-3-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoate    (Compound 1-220);-   (S)-3-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoic    acid (Compound 1-221);-   Methyl    (R)-3-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoate    (Compound 1-222);-   (R)-3-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoic    acid (Compound 1-223);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid    (Compound 1-224);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-aminophenyl)benzamide    (Compound 1-225);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(pyrimidin-5-yl)benzamide    (Compound 1-226);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(oxazol-2-yl)benzamide    (Compound 1-227);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(1,3,4-oxadiazol-2-yl)benzamide    (Compound 1-228);-   Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-4-hydroxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-229);-   Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-hydroxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-230);-   Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-4-(benzyloxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-231);-   Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-methoxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-232);-   2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-1-(piperazin-1-yl)ethan-1-one    (Compound 1-233);-   2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-N-carbamimidoylacetamide    (Compound 1-234);-   Ethyl    2-(5-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate    (Compound 1-235);-   2-(5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetic    acid (Compound 1-236);-   (S)-(3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)phenyl)(3-hydroxypyrrolidin-1-yl)methanone    (Compound 1-237);-   Methyl    3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)carbamoyl)benzoate    (Compound 1-238);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)carbamoyl)benzoic    acid (Compound 1-239);-   Ni-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-N³-phenylisophthalamide    (Compound 1-240);-   (S)—N-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-3-(3-hydroxypyrrolidine-1-carbonyl)benzamide    (Compound 1-241);-   N′-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-N³-(2-(methylsulfonyl)ethyl)isophthalamide    (Compound 1-242);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-6-methyl-1-(pyrimidin-4-ylmethyl)pyrimidine-2,4(1H,3H)-dione    (Compound 1-243);-   1-(2-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-6-azaspiro[3.4]octan-6-yl)ethanone    (Compound 1-244);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(3-ethylphenyl)benzamide    (Compound 1-245);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-ethylphenyl)benzamide    (Compound 1-246);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(3-ethynylphenyl)benzamide    (Compound 1-247);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(prop-2-yn-1-yl)benzamide    (Compound 1-248);-   3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-methyl-2-oxo-2H-chromen-7-yl)benzamide    (Compound 1-249);-   (R,S) or    (S,R)-cis-(3-((4-(Aminomethyl)-6-(trifluoromethyl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-250);-   (R,S) or    (S,R)-cis-(3-((4-(Aminomethyl)-6-(trifluoromethyl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone    (Compound 1-251);-   4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpicolinamide    (Compound 1-252);    or a pharmaceutically acceptable salt thereof.

Any combination of the groups described above for the various variablesis contemplated herein. Throughout the specification, groups andsubstituents thereof are chosen by one skilled in the field to providestable moieties and compounds.

In one aspect, compounds described herein are in the form ofpharmaceutically acceptable salts. As well, active metabolites of thesecompounds having the same type of activity are included in the scope ofthe present disclosure. In addition, the compounds described herein canexist in unsolvated as well as solvated forms with pharmaceuticallyacceptable solvents such as water, ethanol, and the like. The solvatedforms of the compounds presented herein are also considered to bedisclosed herein.

“Pharmaceutically acceptable,” as used herein, refers a material, suchas a carrier or diluent, which does not abrogate the biological activityor properties of the compound, and is relatively nontoxic, i.e., thematerial is administered to an individual without causing undesirablebiological effects or interacting in a deleterious manner with any ofthe components of the composition in which it is contained.

The term “pharmaceutically acceptable salt” refers to a form of atherapeutically active agent that consists of a cationic form of thetherapeutically active agent in combination with a suitable anion, or inalternative embodiments, an anionic form of the therapeutically activeagent in combination with a suitable cation. Handbook of PharmaceuticalSalts: Properties, Selection and Use. International Union of Pure andApplied Chemistry, Wiley-VCH 2002. S. M. Berge, L. D. Bighley, D. C.Monkhouse, J. Pharm. Sci. 1977, 66, 1-19. P. H. Stahl and C. G. Wermuth,editors, Handbook of Pharmaceutical Salts: Properties, Selection andUse, Weinheim/Zurich: Wiley-VCH/VHCA, 2002. Pharmaceutical saltstypically are more soluble and more rapidly soluble in stomach andintestinal juices than non-ionic species and so are useful in soliddosage forms. Furthermore, because their solubility often is a functionof pH, selective dissolution in one or another part of the digestivetract is possible and this capability can be manipulated as one aspectof delayed and sustained release behaviours. Also, because thesalt-forming molecule can be in equilibrium with a neutral form, passagethrough biological membranes can be adjusted.

In some embodiments, pharmaceutically acceptable salts are obtained byreacting a compound described herein with an acid. In some embodiments,the compound described herein (i.e. free base form) is basic and isreacted with an organic acid or an inorganic acid. Inorganic acidsinclude, but are not limited to, hydrochloric acid, hydrobromic acid,sulfuric acid, phosphoric acid, nitric acid, and metaphosphoric acid.Organic acids include, but are not limited to, 1-hydroxy-2-naphthoicacid; 2,2-dichloroacetic acid; 2-hydroxyethanesulfonic acid;2-oxoglutaric acid; 4-acetamidobenzoic acid; 4-aminosalicylic acid;acetic acid; adipic acid; ascorbic acid (L); aspartic acid (L);benzenesulfonic acid; benzoic acid; camphoric acid (+);camphor-10-sulfonic acid (+); capric acid (decanoic acid); caproic acid(hexanoic acid); caprylic acid (octanoic acid); carbonic acid; cinnamicacid; citric acid; cyclamic acid; dodecylsulfuric acid;ethane-1,2-disulfonic acid; ethanesulfonic acid; formic acid; fumaricacid; galactaric acid; gentisic acid; glucoheptonic acid (D); gluconicacid (D); glucuronic acid (D); glutamic acid; glutaric acid;glycerophosphoric acid; glycolic acid; hippuric acid; isobutyric acid;lactic acid (DL); lactobionic acid; lauric acid; maleic acid; malic acid(-L); malonic acid; mandelic acid (DL); methanesulfonic acid; monomethylfumarate, naphthalene-1,5-disulfonic acid; naphthalene-2-sulfonic acid;nicotinic acid; oleic acid; oxalic acid; palmitic acid; pamoic acid;phosphoric acid; proprionic acid; pyroglutamic acid (-L); salicylicacid; sebacic acid; stearic acid; succinic acid; sulfuric acid; tartaricacid (+L); thiocyanic acid; toluenesulfonic acid (p); and undecylenicacid.

In some embodiments, a compound described herein is prepared as achloride salt, sulfate salt, bromide salt, mesylate salt, maleate salt,citrate salt or phosphate salt. In some embodiments, a compounddescribed herein is prepared as a hydrochloride salt.

In some embodiments, pharmaceutically acceptable salts are obtained byreacting a compound described herein with a base. In some embodiments,the compound described herein is acidic and is reacted with a base. Insuch situations, an acidic proton of the compound described herein isreplaced by a metal ion, e.g., lithium, sodium, potassium, magnesium,calcium, or an aluminum ion. In some cases, compounds described hereincoordinate with an organic base, such as, but not limited to,ethanolamine, diethanolamine, triethanolamine, tromethamine, meglumine,N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine. Inother cases, compounds described herein form salts with amino acids suchas, but not limited to, arginine, lysine, and the like. Acceptableinorganic bases used to form salts with compounds that include an acidicproton, include, but are not limited to, aluminum hydroxide, calciumhydroxide, potassium hydroxide, sodium carbonate, potassium carbonate,sodium hydroxide, lithium hydroxide, and the like. In some embodiments,the compounds provided herein are prepared as a sodium salt, calciumsalt, potassium salt, magnesium salt, meglumine salt, N-methylglucaminesalt or ammonium salt. In some embodiments, the compounds providedherein are prepared as a sodium salt.

It should be understood that a reference to a pharmaceuticallyacceptable salt includes the solvent addition forms. In someembodiments, solvates contain either stoichiometric ornon-stoichiometric amounts of a solvent, and are formed during theprocess of crystallization with pharmaceutically acceptable solventssuch as water, ethanol, and the like. Hydrates are formed when thesolvent is water, or alcoholates are formed when the solvent is alcohol.Solvates of compounds described herein are conveniently prepared orformed during the processes described herein. In addition, the compoundsprovided herein optionally exist in unsolvated as well as solvatedforms.

The methods and formulations described herein include the use ofN-oxides (if appropriate), crystalline forms (also known as polymorphs),or pharmaceutically acceptable salts of compounds described herein, aswell as active metabolites of these compounds having the same type ofactivity.

In some embodiments, sites on the organic radicals (e.g. alkyl groups,aromatic rings) of compounds described herein are susceptible to variousmetabolic reactions. Incorporation of appropriate substituents on theorganic radicals will reduce, minimize or eliminate this metabolicpathway. In specific embodiments, the appropriate substituent todecrease or eliminate the susceptibility of the aromatic ring tometabolic reactions is, by way of example only, a halogen, deuterium, analkyl group, a haloalkyl group, or a deuteroalkyl group.

In another embodiment, the compounds described herein are labeledisotopically (e.g. with a radioisotope) or by another other means,including, but not limited to, the use of chromophores or fluorescentmoieties, bioluminescent labels, or chemiluminescent labels.

Compounds described herein include isotopically-labeled compounds, whichare identical to those recited in the various formulae and structurespresented herein, but for the fact that one or more atoms are replacedby an atom having an atomic mass or mass number different from theatomic mass or mass number usually found in nature. Examples of isotopesthat can be incorporated into the present compounds include isotopes ofhydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, such as, forexample, ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³⁵S, ¹⁸F, ³⁶Cl. In one aspect,isotopically-labeled compounds described herein, for example those intowhich radioactive isotopes such as ³H and ¹⁴C are incorporated, areuseful in drug and/or substrate tissue distribution assays. In oneaspect, substitution with isotopes such as deuterium affords certaintherapeutic advantages resulting from greater metabolic stability, suchas, for example, increased in vivo half-life or reduced dosagerequirements.

In some embodiments, the compounds described herein possess one or morestereocenters and each stereocenter exists independently in either the Ror S configuration. The compounds presented herein include alldiastereomeric, enantiomeric, atropisomers, and epimeric forms as wellas the appropriate mixtures thereof. The compounds and methods providedherein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z)isomers as well as the appropriate mixtures thereof.

Individual stereoisomers are obtained, if desired, by methods such as,stereoselective synthesis and/or the separation of stereoisomers bychiral chromatographic columns. In certain embodiments, compoundsdescribed herein are prepared as their individual stereoisomers byreacting a racemic mixture of the compound with an optically activeresolving agent to form a pair of diastereoisomeric compounds/salts,separating the diastereomers and recovering the optically pureenantiomers. In some embodiments, resolution of enantiomers is carriedout using covalent diastereomeric derivatives of the compounds describedherein. In another embodiment, diastereomers are separated byseparation/resolution techniques based upon differences in solubility.In other embodiments, separation of steroisomers is performed bychromatography or by the forming diastereomeric salts and separation byrecrystallization, or chromatography, or any combination thereof. JeanJacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates andResolutions”, John Wiley And Sons, Inc., 1981. In some embodiments,stereoisomers are obtained by stereoselective synthesis.

In some embodiments, compounds described herein are prepared asprodrugs. A “prodrug” refers to an agent that is converted into theparent drug in vivo. Prodrugs are often useful because, in somesituations, they are easier to administer than the parent drug. Theyare, for instance, bioavailable by oral administration whereas theparent is not. The prodrug may be a substrate for a transporter. Furtheror alternatively, the prodrug also has improved solubility inpharmaceutical compositions over the parent drug. In some embodiments,the design of a prodrug increases the effective water solubility. Anexample, without limitation, of a prodrug is a compound describedherein, which is administered as an ester (the “prodrug”) but then ismetabolically hydrolyzed to provide the active entity. A further exampleof a prodrug is a short peptide (polyaminoacid) bonded to an acid groupwhere the peptide is metabolized to reveal the active moiety. In certainembodiments, upon in vivo administration, a prodrug is chemicallyconverted to the biologically, pharmaceutically or therapeuticallyactive form of the compound. In certain embodiments, a prodrug isenzymatically metabolized by one or more steps or processes to thebiologically, pharmaceutically or therapeutically active form of thecompound.

Prodrugs of the compounds described herein include, but are not limitedto, esters, ethers, carbonates, thiocarbonates, N-acyl derivatives,N-acyloxyalkyl derivatives, quaternary derivatives of tertiary amines,N-Mannich bases, Schiff bases, amino acid conjugates, phosphate esters,and sulfonate esters. See for example Design of Prodrugs, Bundgaard, A.Ed., Elseview, 1985 and Method in Enzymology, Widder, K. et al., Ed.;Academic, 1985, vol. 42, p. 309-396; Bundgaard, H. “Design andApplication of Prodrugs” in A Textbook of Drug Design and Development,Krosgaard-Larsen and H. Bundgaard, Ed., 1991, Chapter 5, p. 113-191; andBundgaard, H., Advanced Drug Delivery Review, 1992, 8, 1-38, each ofwhich is incorporated herein by reference. In some embodiments, ahydroxyl group in the compounds disclosed herein is used to form aprodrug, wherein the hydroxyl group is incorporated into an acyloxyalkylester, alkoxycarbonyloxyalkyl ester, alkyl ester, aryl ester, phosphateester, sugar ester, ether, and the like. In some embodiments, a hydroxylgroup in the compounds disclosed herein is a prodrug wherein thehydroxyl is then metabolized in vivo to provide a carboxylic acid group.In some embodiments, a carboxyl group is used to provide an ester oramide (i.e. the prodrug), which is then metabolized in vivo to provide acarboxylic acid group. In some embodiments, compounds described hereinare prepared as alkyl ester prodrugs.

Prodrug forms of the herein described compounds, wherein the prodrug ismetabolized in vivo to produce a compound described herein as set forthherein are included within the scope of the claims. In some cases, someof the herein-described compounds is a prodrug for another derivative oractive compound.

In additional or further embodiments, the compounds described herein aremetabolized upon administration to an organism in need to produce ametabolite that is then used to produce a desired effect, including adesired therapeutic effect.

A “metabolite” of a compound disclosed herein is a derivative of thatcompound that is formed when the compound is metabolized. The term“active metabolite” refers to a biologically active derivative of acompound that is formed when the compound is metabolized. The term“metabolized,” as used herein, refers to the sum of the processes(including, but not limited to, hydrolysis reactions and reactionscatalyzed by enzymes) by which a particular substance is changed by anorganism. Thus, enzymes may produce specific structural alterations to acompound. For example, cytochrome P450 catalyzes a variety of oxidativeand reductive reactions while uridine diphosphate glucuronyltransferasescatalyze the transfer of an activated glucuronic-acid molecule toaromatic alcohols, aliphatic alcohols, carboxylic acids, amines and freesulphydryl groups. Metabolites of the compounds disclosed herein areoptionally identified either by administration of compounds to a hostand analysis of tissue samples from the host, or by incubation ofcompounds with hepatic cells in vitro and analysis of the resultingcompounds.

Synthesis of Compounds

Compounds of Formula (I) described herein are synthesized using standardsynthetic techniques or using methods known in the art in combinationwith methods described herein.

Unless otherwise indicated, conventional methods of mass spectroscopy,NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniquesand pharmacology are employed.

Compounds are prepared using standard organic chemistry techniques suchas those described in, for example, March's Advanced Organic Chemistry,6^(th) Edition, John Wiley and Sons, Inc. Alternative reactionconditions for the synthetic transformations described herein may beemployed such as variation of solvent, reaction temperature, reactiontime, as well as different chemical reagents and other reactionconditions. The starting materials are available from commercial sourcesor are readily prepared.

Pyridines are prepared using well known synthetic routes (see Allais etal Chem. Rev., 2014, 114, p 10829-10868 and references cited) and theseare further functionalized to provide 2-substituted pyridines using avariety of methods. In some embodiments, 2-chloropyridines are obtainedfrom direct chlorination of a pyridine using a suitable chlorinationreagent. In some embodiments, the chlorination reagent is Cl₂. In someembodiments, 2-chloropyridines are prepared from the treatment of2-hydroxypyridines with POCl₃. In other embodiments, 2-chloropyridinesare prepared by the chlorination of a pyridine-N-oxide with a suitablechlorination reagent. In some embodiments, the chorination reagent isPOCl₃, phosgene or triphosgene. 2-Aminopyridines are prepared by avariety of methods. In some embodiments, 2-aminopyridines are convertedto 2-halopyridines using the Sandmeyer reaction. In other embodiments,2-aminopyridines are prepared from the reaction of the correspondingN-oxide via treatment with t-butyl amine/Ts₂O followed by in situdeprotection (see Yin et al, J. Org. Chem., 2007, 72, p 4554-4557 andreferences cited). 2-Trifluoromethyl substituted pyridines are preparedby a variety of routes. In some embodiments, 2-iodopyridine is reactedwith (trifluoromethyl)copper to afford 2-trifluoromethylpyridine (seeCottet and Schlosser Eur. J. Org. Chem., 2002, 2, p 327-330).

In some embodiments, the O-linked compounds of Formula (I) having thegeneral structure 1-2 are prepared as shown in Scheme 1.

In some embodiments, 4-substituted-2-halo pyridine 1-1 is treated withan appropriately substituted alcohol R²OH in the presence of a strongbase using a suitable polar solvent to provide 1-2. In some embodiments,the strong base is KO^(t)Bu. In some embodiments, the polar solvent isDMF. In some embodiments, if R² is aryl or heteroaryl, a suitable milderbase may be employed. In some embodiments, the milder base is Cs₂CO₃. Inother embodiments, 1-2 is prepared from 2-hydroxypyridine (2-pyridone)1-3. In some embodiments, o-alkylation is performed with suitable baseand an alkylating agent in an appropriate organic solvent provides 1-2.In some embodiments, the suitable base is Ag₂CO₃. In other embodiments,the suitable alkylating agent is R²—Br or R²—I. In other embodiments,Mitsunobu conditions are used to achieve the same transformation.

In some embodiments, 2-thioalkylpyridines/2-thioarylpyridines 2-2(compounds of Formula (I) containing a sulfur linkage), are prepared bytreatment of the corresponding 2-halopyridine 2-1 with the appropriatethiol R²SH and a suitable base in a suitable solvent (Scheme 2). In someembodiments, the suitable base is Cs₂CO₃. In some embodiments, thesuitable solvent is DMF.

In some embodiments, compounds of Formula (I) in which there is an aminelinking group (Y═NR²R^(2′)) are synthesized according to Scheme 3.

In some embodiments, nucleophilic displacement of a 2-halopyridine 3-1using an amine NHR²R^(2′) and a suitable base in a suitable organicsolvent provides 3-2. In some embodiments, heat and pressure facilitatethe reaction. In some embodiments, the suitable base is KO^(t)Bu. Insome embodiments, the suitable organic solvent is DMF. In someembodiments, a palladium or a copper catalyst is also used. In someembodiments, pyridines of general structure 3-3 are oxidized to theN-oxide (3-4) using a suitable oxidant. In some embodiments, thesuitable oxidant is mCPBA. In some embodiments, treatment of the N-oxidewith an amine NHR²R^(2′) in the presence ofbromotripyrrolidinophosphonium hexafluorophosphate (PyBroP) and asuitable organic base in a solvent yields 3-2 (see Londregan Org. Lett.,2010, 12, p 5254-5257). In some embodiments, the suitable organic baseis ^(i)PrEt₂N. In some embodiments, the suitable solvent is CH₂Cl₂.

In some embodiments, the compounds of Formula (I) containing an amidelinkage (4-) are prepared as shown in Scheme 4.

In some embodiments, 2-halopyridine 4-1 may be treated with CO in thepresence of a suitable palladium catalyst, a suitable base in a suitableorganic solvent to afford the ester 4-2. In some embodiments, thepalladium catalyst is PdCl₂(PPh₃)₄. In some embodiments, the base isNaOAc. In some embodiments, the organic solvent is MeOH. In someembodiments, the ester is hydrolyzed using aqueous LiOH with a suitableorganic solvent to afford acid 4-3. In some embodiments, the organicsolvent is MeOH or THF. In some embodiments, standard peptide couplingreaction conditions with an appropriately substituted amine HNR′R″ areused to yield amide 4-4.

In some embodiments, the compounds of Formula (I) containing amethyleneoxy or a methylene linkage are prepared as shown in Scheme 5.

In some embodiments, ester 5-1 is reduced to the alcohol 5-2 using asuitable reducing agent in an appropriate solvent. In some embodiments,the suitable reducing agent is NaBH₄. In some embodiments, theappropriate solvent is MeOH. In some embodiments, alcohol 5-2 isconverted to ether 5-3 using the Mitsunobu reaction protocol. In otherembodiments, alcohol 5-2 is converted into halogenated 5-4 using anappropriate halogenating reagent. In some embodiments, Y═Br in 5-4. Insome embodiments the halogenating reagent is TPP or CBr₄. In someembodiments, displacement of the leaving group on 5-4 with an alcohol orphenol yields 5-3. In other embodiments compound 5-4 is reacted withother nucleophiles in the presence of a suitable base and suitablesolvent to provide the methylene linked compound 5-5. In someembodiments, the base is NaH. In some embodiments, the suitable solventis THF.

In some embodiments, the compounds of Formula (I) that contain a bond toan aryl (or heteroaryl) substituent are prepared as described in Scheme6.

In some embodiments, 2-halopyridine compound of general structure 6-1 isconverted to the corresponding 2-boronic acid or 2-boronate esterderivative 6-2 using standard methodologies, such as those described inLiu et al, ARKIVOC, 2013, (i) p 135-153. In some embodiments, a Suzukireaction employing 6-2 and an appropriately substituted aryl (orheteroaryl) bromide or iodide using a palladium catalyst in the presenceof a suitable base and a suitable solvent affords compound 6-3. In someembodiments, the palladium catalyst is Pd(OAc)₂ or Pd(PPh₃)₄. In otherembodiments, the suitable base is K₂CO₃. In other embodiments, thesolvent is DMF. In other embodiments, compound 6-1 is coupled with anaryl (or heteroaryl) boronic acid/ester using standard conditions forthe Suzuki reaction to afford 6-3 directly.

4-Aminomethylpyridines are prepared using a number of routes known toone skilled in the art. In some embodiments, 4-aminomethylpyridines areprepared as described in Scheme 7.

In some embodiments, 4-bromo-2-picolinic ester derivative 7-1 (Scheme 7)is converted into the 4-cyano analog 7-2 with Zn(CN)₂ in the presence ofa suitable palladium catalyst. In some embodiments, the suitablepalladium catalyst is Pd(PPh₃)₄. In some embodiments, reduction of thenitrile with a suitable reducing agent affords the methyl amine 7-3. Insome embodiments, the reducing agent is CoCl₂ and NaBH₄. In someembodiments, the use of NaBD₄ in place of NaBH₄ allows for thepreparation of the corresponding deuteromethyamine.

In some embodiments, pyridine compounds containing a 4-aminomethylsubstituent are prepared as shown in Scheme 8.

In some embodiments, the appropriately functionalized 4-aminomethylpyridine 8-1 is treated with Boc₂O to afford 8-2. In some embodiments,8-2 is transformed into 8-3 using the procedures described herein toinstall the appropriate substituent —ZR². In some embodiments,deprotection of the amine with TFA or HCl provides 8-4 as thecorresponding salt.

In some embodiments, the compounds of Formula (I) containing an amidelinkage (9-3) are prepared as shown in Scheme 9.

In some embodiments, 2-halopyridine 9-1 is treated with an amine NH₂R²in the presence of a suitable base and in an organic solvent to afford9-2. In some embodiments, the suitable base is KO^(t)Bu. In someembodiments, the suitable organic solvent is DMF. In some embodiments,standard peptide coupling reaction conditions with an appropriatelysubstituted carboxylic acid R³CO₂H affords amide 9-3.

In some embodiments, compounds are prepared as described in theExamples.

Certain Terminology

Unless otherwise stated, the following terms used in this applicationhave the definitions given below. The use of the term “including” aswell as other forms, such as “include”, “includes,” and “included,” isnot limiting. The section headings used herein are for organizationalpurposes only and are not to be construed as limiting the subject matterdescribed.

As used herein, C₁-C_(x) includes C₁-C₂, C₁-C₃ . . . C₁-C_(x). By way ofexample only, a group designated as “C₁-C₄” indicates that there are oneto four carbon atoms in the moiety, i.e. groups containing 1 carbonatom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms. Thus, by way ofexample only, “C₁-C₄ alkyl” indicates that there are one to four carbonatoms in the alkyl group, i.e., the alkyl group is selected from amongmethyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, andt-butyl.

An “alkyl” group refers to an aliphatic hydrocarbon group. The alkylgroup is branched or straight chain. In some embodiments, the “alkyl”group has 1 to 10 carbon atoms, i.e. a C₁-C₁₀alkyl. Whenever it appearsherein, a numerical range such as “1 to 10” refers to each integer inthe given range; e.g., “1 to 10 carbon atoms” means that the alkyl groupconsist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up toand including 10 carbon atoms, although the present definition alsocovers the occurrence of the term “alkyl” where no numerical range isdesignated. In some embodiments, an alkyl is a C₁-C₆alkyl. In one aspectthe alkyl is methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl,sec-butyl, or t-butyl. Typical alkyl groups include, but are in no waylimited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tertiary butyl, pentyl, neopentyl, or hexyl.

An “alkylene” group refers to a divalent alkyl radical. Any of the abovementioned monovalent alkyl groups may be an alkylene by abstraction of asecond hydrogen atom from the alkyl. In some embodiments, an alkelene isa C₁-C₆alkylene. In other embodiments, an alkylene is a C₁-C₄alkylene.Typical alkylene groups include, but are not limited to, —CH₂—,—CH(CH₃)—, —C(CH₃)₂—, —CH₂CH₂—, —CH₂CH(CH₃)—, —CH₂C(CH₃)₂—, —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, and the like.

“Deuteroalkyl” refers to an alkyl group where 1 or more hydrogen atomsof an alkyl are replaced with deuterium.

The term “alkenyl” refers to a type of alkyl group in which at least onecarbon-carbon double bond is present. In one embodiment, an alkenylgroup has the formula —C(R)═CR₂, wherein R refers to the remainingportions of the alkenyl group, which may be the same or different. Insome embodiments, R is H or an alkyl. Non-limiting examples of analkenyl group include —CH═CH₂, —C(CH₃)═CH₂, —CH═CHCH₃, —C(CH₃)═CHCH₃,and —CH₂CH═CH₂.

The term “alkynyl” refers to a type of alkyl group in which at least onecarbon-carbon triple bond is present. In one embodiment, an alkenylgroup has the formula —C═C—R, wherein R refers to the remaining portionsof the alkynyl group. In some embodiments, R is H or an alkyl.Non-limiting examples of an alkynyl group include —C≡CH,—C≡CCH₃—C≡CCH₂CH₃, —CH₂C≡CH.

An “alkoxy” group refers to a (alkyl)O— group, where alkyl is as definedherein.

The term “alkylamine” refers to the —N(alkyl)_(x)H_(y) group, where x is0 and y is 2, or where x is 1 and y is 1, or where x is 2 and y is 0.

The term “aromatic” refers to a planar ring having a delocalizedt-electron system containing 4n+2 it electrons, where n is an integer.The term “aromatic” includes both carbocyclic aryl (“aryl”, e.g.,phenyl) and heterocyclic aryl (or “heteroaryl” or “heteroaromatic”)groups (e.g., pyridine). The term includes monocyclic or fused-ringpolycyclic (i.e., rings which share adjacent pairs of carbon atoms)groups.

The term “carbocyclic” or “carbocycle” refers to a ring or ring systemwhere the atoms forming the backbone of the ring are all carbon atoms.The term thus distinguishes carbocyclic from “heterocyclic” rings or“heterocycles” in which the ring backbone contains at least one atomwhich is different from carbon. In some embodiments, at least one of thetwo rings of a bicyclic carbocycle is aromatic. In some embodiments,both rings of a bicyclic carbocycle are aromatic. In some embodiments,bicyclic carbocycles are fused, bridged or spirocyclic.

As used herein, the term “aryl” refers to an aromatic ring wherein eachof the atoms forming the ring is a carbon atom. In one aspect, aryl isphenyl or a naphthyl. In some embodiments, an aryl is a phenyl. In someembodiments, an aryl is a C₆-C₁₀aryl. Depending on the structure, anaryl group is a monoradical or a diradical (i.e., an arylene group).

The term “cycloalkyl” refers to a monocyclic or polycyclic aliphatic,non-aromatic radical, wherein each of the atoms forming the ring (i.e.skeletal atoms) is a carbon atom. In some embodiments, cycloalkyls arespirocyclic or bridged compounds. In some embodiments, cycloalkyls areoptionally fused with an aromatic ring, and the point of attachment isat a carbon that is not an aromatic ring carbon atom. Cycloalkyl groupsinclude groups having from 3 to 10 ring atoms. In some embodiments,cycloalkyl groups are selected from among cyclopropyl, cyclobutyl,cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl,cyclooctyl, spiro[2.2]pentyl, norbornyl and bicycle[1.1.1]pentyl. Insome embodiments, a cycloalkyl is a C₃-C₆cycloalkyl.

The term “halo” or, alternatively, “halogen” or “halide” means fluoro,chloro, bromo or iodo. In some embodiments, halo is fluoro, chloro, orbromo.

The term “fluoroalkyl” refers to an alkyl in which one or more hydrogenatoms are replaced by a fluorine atom. In one aspect, a fluoralkyl is aC₁-C₆fluoroalkyl.

The term “heteroalkyl” refers to an alkyl group in which one or moreskeletal atoms of the alkyl are selected from an atom other than carbon,e.g., oxygen, nitrogen (e.g. —NH—, —N(alkyl)-, sulfur, or combinationsthereof. A heteroalkyl is attached to the rest of the molecule at acarbon atom of the heteroalkyl. In one aspect, a heteroalkyl is aC₁-C₆heteroalkyl.

The term “heterocycle” or “heterocyclic” refers to heteroaromatic rings(also known as heteroaryls) and heterocycloalkyl rings (also known asheteroalicyclic groups) containing one to four heteroatoms in thering(s), where each heteroatom in the ring(s) is selected from O, S andN, wherein each heterocyclic group has from 3 to 10 atoms in its ringsystem, and with the proviso that any ring does not contain two adjacentO or S atoms. Non-aromatic heterocyclic groups (also known asheterocycloalkyls) include rings having 3 to 10 atoms in its ring systemand aromatic heterocyclic groups include rings having 5 to 10 atoms inits ring system. The heterocyclic groups include benzo-fused ringsystems. Examples of non-aromatic heterocyclic groups are pyrrolidinyl,tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl,tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl,morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, aziridinyl,azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl,oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl,pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl,dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl,dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl,imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl,3-azabicyclo[4.1.0]heptanyl, 3H-indolyl, indolin-2-onyl,isoindolin-1-onyl, isoindoline-1,3-dionyl,3,4-dihydroisoquinolin-1(2H)-onyl, 3,4-dihydroquinolin-2(1H)-onyl,isoindoline-1,3-dithionyl, benzo[d]oxazol-2(3H)-onyl,1H-benzo[d]imidazol-2(3H)-onyl, benzo[d]thiazol-2(3H)-onyl, andquinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl,imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl,furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl,quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl,cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl,triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl,furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl,benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, andfuropyridinyl. The foregoing groups are either C-attached (or C-linked)or N-attached where such is possible. For instance, a group derived frompyrrole includes both pyrrol-1-yl (N-attached) or pyrrol-3-yl(C-attached). Further, a group derived from imidazole includesimidazol-1-yl or imidazol-3-yl (both N-attached) or imidazol-2-yl,imidazol-4-yl or imidazol-5-yl (all C-attached). The heterocyclic groupsinclude benzo-fused ring systems. Non-aromatic heterocycles areoptionally substituted with one or two oxo (═O) moieties, such aspyrrolidin-2-one. In some embodiments, at least one of the two rings ofa bicyclic heterocycle is aromatic. In some embodiments, both rings of abicyclic heterocycle are aromatic. In some embodiments, bicyclicheterocycles are fused, bridged or spirocyclic.

The terms “heteroaryl” or, alternatively, “heteroaromatic” refers to anaryl group that includes one or more ring heteroatoms selected fromnitrogen, oxygen and sulfur. Illustrative examples of heteroaryl groupsinclude monocyclic heteroaryls and bicyclcic heteroaryls. Monocyclicheteroaryls include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl,triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl,oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl,thiadiazolyl, and furazanyl. Monocyclic heteroaryls include indolizine,indole, benzofuran, benzothiophene, indazole, benzimidazole, purine,quinolizine, quinoline, isoquinoline, cinnoline, phthalazine,quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine. In someembodiments, a heteroaryl contains 0-4 N atoms in the ring. In someembodiments, a heteroaryl contains 1-4 N atoms in the ring. In someembodiments, a heteroaryl contains 0-4 N atoms, 0-1 O atoms, and 0-1 Satoms in the ring. In some embodiments, a heteroaryl contains 1-4 Natoms, 0-1 O atoms, and 0-1 S atoms in the ring. In some embodiments,heteroaryl is a C₁-C₉heteroaryl. In some embodiments, monocyclicheteroaryl is a C₁-C₅heteroaryl. In some embodiments, monocyclicheteroaryl is a 5-membered or 6-membered heteroaryl. In someembodiments, bicyclic heteroaryl is a C₆-C₉heteroaryl.

A “heterocycloalkyl” or “heteroalicyclic” group refers to a cycloalkylgroup that includes at least one heteroatom selected from nitrogen,oxygen and sulfur. In some embodiments, a heterocycloalkyl is fused withan aryl or heteroaryl. In some embodiments, the heterocycloalkyl isoxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl,tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl,thiomorpholinyl, piperazinyl, piperidin-2-onyl,pyrrolidine-2,5-dithionyl, pyrrolidine-2,5-dionyl, pyrrolidinonyl,imidazolidinyl, imidazolidin-2-onyl, or thiazolidin-2-onyl. The termheteroalicyclic also includes all ring forms of the carbohydrates,including but not limited to the monosaccharides, the disaccharides andthe oligosaccharides. In one aspect, a heterocycloalkyl is aC₂-C₁₀heterocycloalkyl. In another aspect, a heterocycloalkyl is aC₄-C₁₀heterocycloalkyl. In some embodiments, a heterocycloalkyl contains0-2 N atoms in the ring. In some embodiments, a heterocycloalkylcontains 0-2 N atoms, 0-2 O atoms and 0-1 S atoms in the ring. In someembodiments, bicyclic heterocycloalkyls are fused, bridged orspirocyclic.

The term “bond” or “single bond” refers to a chemical bond between twoatoms, or two moieties when the atoms joined by the bond are consideredto be part of larger substructure. In one aspect, when a group describedherein is a bond, the referenced group is absent thereby allowing a bondto be formed between the remaining identified groups.

The term “moiety” refers to a specific segment or functional group of amolecule. Chemical moieties are often recognized chemical entitiesembedded in or appended to a molecule.

The term “optionally substituted” or “substituted” means that thereferenced group is optionally substituted with one or more additionalgroup(s) individually and independently selected from halogen, —CN,—NH₂, —NH(alkyl), —N(alkyl)₂, —OH, —CO₂H, —CO₂alkyl, —C(═O)NH₂,—C(═O)NH(alkyl), —C(═O)N(alkyl)₂, —S(═O)₂NH₂, —S(═O)₂NH(alkyl),—S(═O)₂N(alkyl)₂, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy,fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl, aryloxy, alkylthio,arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone.In some other embodiments, optional substituents are independentlyselected from halogen, —CN, —NH₂, —NH(CH₃), —N(CH₃)₂, —OH, —CO₂H,—CO₂(C₁-C₄alkyl), —C(═O)NH₂, —C(═O)NH(C₁-C₄alkyl), —C(═O)N(C₁-C₄alkyl)₂,—S(═O)₂NH₂, —S(═O)₂NH(C₁-C₄alkyl), —S(═O)₂N(C₁-C₄alkyl)₂, C₁-C₄alkyl,C₃-C₆cycloalkyl, C₁-C₄fluoroalkyl, C₁-C₄heteroalkyl, C₁-C₄alkoxy,C₁-C₄fluoroalkoxy, —SC₁-C₄alkyl, —S(═O)C₁-C₄alkyl, and—S(═O)₂C₁-C₄alkyl. In some embodiments, optional substituents areindependently selected from halogen, —CN, —NH₂, —OH, —NH(CH₃), —N(CH₃)₂,—CH₃, —CH₂CH₃, —CF₃, —OCH₃, and —OCF₃. In some embodiments, substitutedgroups are substituted with one or two of the preceding groups. In someembodiments, an optional substituent on an aliphatic carbon atom(acyclic or cyclic) includes oxo (═O).

The term “acceptable” with respect to a formulation, composition oringredient, as used herein, means having no persistent detrimentaleffect on the general health of the subject being treated.

The term “modulate” as used herein, means to interact with a targeteither directly or indirectly so as to alter the activity of the target,including, by way of example only, to enhance the activity of thetarget, to inhibit the activity of the target, to limit the activity ofthe target, or to extend the activity of the target.

The term “modulator” as used herein, refers to a molecule that interactswith a target either directly or indirectly. The interactions include,but are not limited to, the interactions of an agonist, partial agonist,an inverse agonist, antagonist, degrader, or combinations thereof. Insome embodiments, a modulator is an antagonist. In some embodiments, amodulator is a degrader.

The terms “administer,” “administering”, “administration,” and the like,as used herein, refer to the methods that may be used to enable deliveryof compounds or compositions to the desired site of biological action.These methods include, but are not limited to oral routes, intraduodenalroutes, parenteral injection (including intravenous, subcutaneous,intraperitoneal, intramuscular, intravascular or infusion), topical andrectal administration. Those of skill in the art are familiar withadministration techniques that can be employed with the compounds andmethods described herein. In some embodiments, the compounds andcompositions described herein are administered orally.

The terms “co-administration” or the like, as used herein, are meant toencompass administration of the selected therapeutic agents to a singlepatient, and are intended to include treatment regimens in which theagents are administered by the same or different route of administrationor at the same or different time.

The terms “effective amount” or “therapeutically effective amount,” asused herein, refer to a sufficient amount of an agent or a compoundbeing administered, which will relieve to some extent one or more of thesymptoms of the disease or condition being treated. The result includesreduction and/or alleviation of the signs, symptoms, or causes of adisease, or any other desired alteration of a biological system. Forexample, an “effective amount” for therapeutic uses is the amount of thecomposition comprising a compound as disclosed herein required toprovide a clinically significant decrease in disease symptoms. Anappropriate “effective” amount in any individual case is optionallydetermined using techniques, such as a dose escalation study.

The terms “enhance” or “enhancing,” as used herein, means to increase orprolong either in potency or duration a desired effect. Thus, in regardto enhancing the effect of therapeutic agents, the term “enhancing”refers to the ability to increase or prolong, either in potency orduration, the effect of other therapeutic agents on a system. An“enhancing-effective amount,” as used herein, refers to an amountadequate to enhance the effect of another therapeutic agent in a desiredsystem.

The term “pharmaceutical combination” as used herein, means a productthat results from the mixing or combining of more than one activeingredient and includes both fixed and non-fixed combinations of theactive ingredients. The term “fixed combination” means that the activeingredients, e.g. a compound described herein, or a pharmaceuticallyacceptable salt thereof, and a co-agent, are both administered to apatient simultaneously in the form of a single entity or dosage. Theterm “non-fixed combination” means that the active ingredients, e.g. acompound described herein, or a pharmaceutically acceptable saltthereof, and a co-agent, are administered to a patient as separateentities either simultaneously, concurrently or sequentially with nospecific intervening time limits, wherein such administration provideseffective levels of the two compounds in the body of the patient. Thelatter also applies to cocktail therapy, e.g. the administration ofthree or more active ingredients.

The terms “kit” and “article of manufacture” are used as synonyms.

The term “subject” or “patient” encompasses mammals. Examples of mammalsinclude, but are not limited to, any member of the Mammalian class:humans, non-human primates such as chimpanzees, and other apes andmonkey species; farm animals such as cattle, horses, sheep, goats,swine; domestic animals such as rabbits, dogs, and cats; laboratoryanimals including rodents, such as rats, mice and guinea pigs, and thelike. In one aspect, the mammal is a human.

The terms “treat,” “treating” or “treatment,” as used herein, includealleviating, abating or ameliorating at least one symptom of a diseaseor condition, preventing additional symptoms, inhibiting the disease orcondition, e.g., arresting the development of the disease or condition,relieving the disease or condition, causing regression of the disease orcondition, relieving a condition caused by the disease or condition, orstopping the symptoms of the disease or condition eitherprophylactically and/or therapeutically.

Pharmaceutical Compositions

In some embodiments, the compounds described herein are formulated intopharmaceutical compositions. Pharmaceutical compositions are formulatedin a conventional manner using one or more pharmaceutically acceptableinactive ingredients that facilitate processing of the active compoundsinto preparations that are used pharmaceutically. Proper formulation isdependent upon the route of administration chosen. A summary ofpharmaceutical compositions described herein is found, for example, inRemington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton,Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington'sPharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975;Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms,Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms andDrug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999),herein incorporated by reference for such disclosure.

In some embodiments, the compounds described herein are administeredeither alone or in combination with pharmaceutically acceptablecarriers, excipients or diluents, in a pharmaceutical composition.Administration of the compounds and compositions described herein can beeffected by any method that enables delivery of the compounds to thesite of action. These methods include, though are not limited todelivery via enteral routes (including oral, gastric or duodenal feedingtube, rectal suppository and rectal enema), parenteral routes (injectionor infusion, including intraarterial, intracardiac, intradermal,intraduodenal, intramedullary, intramuscular, intraosseous,intraperitoneal, intrathecal, intravascular, intravenous, intravitreal,epidural and subcutaneous), inhalational, transdermal, transmucosal,sublingual, buccal and topical (including epicutaneous, dermal, enema,eye drops, ear drops, intranasal, vaginal) administration, although themost suitable route may depend upon for example the condition anddisorder of the recipient. By way of example only, compounds describedherein can be administered locally to the area in need of treatment, byfor example, local infusion during surgery, topical application such ascreams or ointments, injection, catheter, or implant. The administrationcan also be by direct injection at the site of a diseased tissue ororgan.

In some embodiments, pharmaceutical compositions suitable for oraladministration are presented as discrete units such as capsules, cachetsor tablets each containing a predetermined amount of the activeingredient; as a powder or granules; as a solution or a suspension in anaqueous liquid or a non-aqueous liquid; or as an oil-in-water liquidemulsion or a water-in-oil liquid emulsion. In some embodiments, theactive ingredient is presented as a bolus, electuary or paste.

Pharmaceutical compositions which can be used orally include tablets,push-fit capsules made of gelatin, as well as soft, sealed capsules madeof gelatin and a plasticizer, such as glycerol or sorbitol. Tablets maybe made by compression or molding, optionally with one or more accessoryingredients. Compressed tablets may be prepared by compressing in asuitable machine the active ingredient in a free-flowing form such as apowder or granules, optionally mixed with binders, inert diluents, orlubricating, surface active or dispersing agents. Molded tablets may bemade by molding in a suitable machine a mixture of the powdered compoundmoistened with an inert liquid diluent. In some embodiments, the tabletsare coated or scored and are formulated so as to provide slow orcontrolled release of the active ingredient therein. All formulationsfor oral administration should be in dosages suitable for suchadministration. The push-fit capsules can contain the active ingredientsin admixture with filler such as lactose, binders such as starches,and/or lubricants such as talc or magnesium stearate and, optionally,stabilizers. In soft capsules, the active compounds may be dissolved orsuspended in suitable liquids, such as fatty oils, liquid paraffin, orliquid polyethylene glycols. In some embodiments, stabilizers are added.Dragee cores are provided with suitable coatings. For this purpose,concentrated sugar solutions may be used, which may optionally containgum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethyleneglycol, and/or titanium dioxide, lacquer solutions, and suitable organicsolvents or solvent mixtures. Dyestuffs or pigments may be added to thetablets or Dragee coatings for identification or to characterizedifferent combinations of active compound doses.

In some embodiments, pharmaceutical compositions are formulated forparenteral administration by injection, e.g., by bolus injection orcontinuous infusion. Formulations for injection may be presented in unitdosage form, e.g., in ampoules or in multi-dose containers, with anadded preservative. The compositions may take such forms as suspensions,solutions or emulsions in oily or aqueous vehicles, and may containformulatory agents such as suspending, stabilizing and/or dispersingagents. The compositions may be presented in unit-dose or multi-dosecontainers, for example sealed ampoules and vials, and may be stored inpowder form or in a freeze-dried (lyophilized) condition requiring onlythe addition of the sterile liquid carrier, for example, saline orsterile pyrogen-free water, immediately prior to use. Extemporaneousinjection solutions and suspensions may be prepared from sterilepowders, granules and tablets of the kind previously described.

Pharmaceutical compositions for parenteral administration includeaqueous and non-aqueous (oily) sterile injection solutions of the activecompounds which may contain antioxidants, buffers, bacteriostats andsolutes which render the formulation isotonic with the blood of theintended recipient; and aqueous and non-aqueous sterile suspensionswhich may include suspending agents and thickening agents. Suitablelipophilic solvents or vehicles include fatty oils such as sesame oil,or synthetic fatty acid esters, such as ethyl oleate or triglycerides,or liposomes. Aqueous injection suspensions may contain substances whichincrease the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may alsocontain suitable stabilizers or agents which increase the solubility ofthe compounds to allow for the preparation of highly concentratedsolutions.

Pharmaceutical compositions may also be formulated as a depotpreparation. Such long acting formulations may be administered byimplantation (for example subcutaneously or intramuscularly) or byintramuscular injection. Thus, for example, the compounds may beformulated with suitable polymeric or hydrophobic materials (forexample, as an emulsion in an acceptable oil) or ion exchange resins, oras sparingly soluble derivatives, for example, as a sparingly solublesalt.

For buccal or sublingual administration, the compositions may take theform of tablets, lozenges, pastilles, or gels formulated in conventionalmanner. Such compositions may comprise the active ingredient in aflavored basis such as sucrose and acacia or tragacanth.

Pharmaceutical compositions may also be formulated in rectalcompositions such as suppositories or retention enemas, e.g., containingconventional suppository bases such as cocoa butter, polyethyleneglycol, or other glycerides.

Pharmaceutical compositions may be administered topically, that is bynon-systemic administration. This includes the application of a compoundof the present invention externally to the epidermis or the buccalcavity and the instillation of such a compound into the ear, eye andnose, such that the compound does not significantly enter the bloodstream. In contrast, systemic administration refers to oral,intravenous, intraperitoneal and intramuscular administration.

Pharmaceutical compositions suitable for topical administration includeliquid or semi-liquid preparations suitable for penetration through theskin to the site of inflammation such as gels, liniments, lotions,creams, ointments or pastes, and drops suitable for administration tothe eye, ear or nose. The active ingredient may comprise, for topicaladministration, from 0.001% to 10% w/w, for instance from 1% to 2% byweight of the formulation.

Pharmaceutical compositions for administration by inhalation areconveniently delivered from an insufflator, nebulizer pressurized packsor other convenient means of delivering an aerosol spray. Pressurizedpacks may comprise a suitable propellant such asdichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In thecase of a pressurized aerosol, the dosage unit may be determined byproviding a valve to deliver a metered amount. Alternatively, foradministration by inhalation or insufflation, pharmaceuticalpreparations may take the form of a dry powder composition, for examplea powder mix of the compound and a suitable powder base such as lactoseor starch.

The powder composition may be presented in unit dosage form, in forexample, capsules, cartridges, gelatin or blister packs from which thepowder may be administered with the aid of an inhalator or insufflator.

It should be understood that in addition to the ingredients particularlymentioned above, the compounds and compositions described herein mayinclude other agents conventional in the art having regard to the typeof formulation in question, for example those suitable for oraladministration may include flavoring agents.

Methods of Dosing and Treatment Regimens

In one embodiment, the compounds described herein, or a pharmaceuticallyacceptable salt thereof, are used in the preparation of medicaments forthe treatment of diseases or conditions in a mammal that would benefitfrom inhibition or reduction of LOXL2 activity. Methods for treating anyof the diseases or conditions described herein in a mammal in need ofsuch treatment, involves administration of pharmaceutical compositionsthat include at least one compound described herein or apharmaceutically acceptable salt, active metabolite, prodrug, orpharmaceutically acceptable solvate thereof, in therapeuticallyeffective amounts to said mammal.

In certain embodiments, the compositions containing the compound(s)described herein are administered for prophylactic and/or therapeutictreatments. In certain therapeutic applications, the compositions areadministered to a patient already suffering from a disease or condition,in an amount sufficient to cure or at least partially arrest at leastone of the symptoms of the disease or condition. Amounts effective forthis use depend on the severity and course of the disease or condition,previous therapy, the patient's health status, weight, and response tothe drugs, and the judgment of the treating physician. Therapeuticallyeffective amounts are optionally determined by methods including, butnot limited to, a dose escalation and/or dose ranging clinical trial.

In prophylactic applications, compositions containing the compoundsdescribed herein are administered to a patient susceptible to orotherwise at risk of a particular disease, disorder or condition. Suchan amount is defined to be a “prophylactically effective amount ordose.” In this use, the precise amounts also depend on the patient'sstate of health, weight, and the like. When used in patients, effectiveamounts for this use will depend on the severity and course of thedisease, disorder or condition, previous therapy, the patient's healthstatus and response to the drugs, and the judgment of the treatingphysician. In one aspect, prophylactic treatments include administeringto a mammal, who previously experienced at least one symptom of thedisease being treated and is currently in remission, a pharmaceuticalcomposition comprising a compound described herein, or apharmaceutically acceptable salt thereof, in order to prevent a returnof the symptoms of the disease or condition.

In certain embodiments wherein the patient's condition does not improve,upon the doctor's discretion the administration of the compounds areadministered chronically, that is, for an extended period of time,including throughout the duration of the patient's life in order toameliorate or otherwise control or limit the symptoms of the patient'sdisease or condition.

In certain embodiments wherein a patient's status does improve, the doseof drug being administered is temporarily reduced or temporarilysuspended for a certain length of time (i.e., a “drug holiday”). Inspecific embodiments, the length of the drug holiday is between 2 daysand 1 year, including by way of example only, 2 days, 3 days, 4 days, 5days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, ormore than 28 days. The dose reduction during a drug holiday is, by wayof example only, by 10%-100%, including by way of example only 10%, 15%,20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, and 100%.

Once improvement of the patient's conditions has occurred, a maintenancedose is administered if necessary. Subsequently, in specificembodiments, the dosage or the frequency of administration, or both, isreduced, as a function of the symptoms, to a level at which the improveddisease, disorder or condition is retained. In certain embodiments,however, the patient requires intermittent treatment on a long-termbasis upon any recurrence of symptoms.

The amount of a given agent that corresponds to such an amount variesdepending upon factors such as the particular compound, diseasecondition and its severity, the identity (e.g., weight, sex) of thesubject or host in need of treatment, but nevertheless is determinedaccording to the particular circumstances surrounding the case,including, e.g., the specific agent being administered, the route ofadministration, the condition being treated, and the subject or hostbeing treated.

In general, however, doses employed for adult human treatment aretypically in the range of 0.01 mg-5000 mg per day. In one aspect, dosesemployed for adult human treatment are from about 1 mg to about 1000 mgper day. In one embodiment, the desired dose is conveniently presentedin a single dose or in divided doses administered simultaneously or atappropriate intervals, for example as two, three, four or more sub-dosesper day.

In one embodiment, the daily dosages appropriate for the compounddescribed herein, or a pharmaceutically acceptable salt thereof, arefrom about 0.01 to about 50 mg/kg per body weight. In some embodiments,the daily dosage or the amount of active in the dosage form are lower orhigher than the ranges indicated herein, based on a number of variablesin regard to an individual treatment regime. In various embodiments, thedaily and unit dosages are altered depending on a number of variablesincluding, but not limited to, the activity of the compound used, thedisease or condition to be treated, the mode of administration, therequirements of the individual subject, the severity of the disease orcondition being treated, and the judgment of the practitioner.

Toxicity and therapeutic efficacy of such therapeutic regimens aredetermined by standard pharmaceutical procedures in cell cultures orexperimental animals, including, but not limited to, the determinationof the LD₅₀ and the ED₅₀. The dose ratio between the toxic andtherapeutic effects is the therapeutic index and it is expressed as theratio between LD₅₀ and ED₅₀. In certain embodiments, the data obtainedfrom cell culture assays and animal studies are used in formulating thetherapeutically effective daily dosage range and/or the therapeuticallyeffective unit dosage amount for use in mammals, including humans. Insome embodiments, the daily dosage amount of the compounds describedherein lies within a range of circulating concentrations that includethe ED₅₀ with minimal toxicity. In certain embodiments, the daily dosagerange and/or the unit dosage amount varies within this range dependingupon the dosage form employed and the route of administration utilized.

In any of the aforementioned aspects are further embodiments in whichthe effective amount of the compound described herein, or apharmaceutically acceptable salt thereof, is: (a) systemicallyadministered to the mammal; and/or (b) administered orally to themammal; and/or (c) intravenously administered to the mammal; and/or (d)administered by injection to the mammal; and/or (e) administeredtopically to the mammal; and/or (f) administered non-systemically orlocally to the mammal.

In any of the aforementioned aspects are further embodiments comprisingsingle administrations of the effective amount of the compound,including further embodiments in which (i) the compound is administeredonce a day; or (ii) the compound is administered to the mammal multipletimes over the span of one day.

In any of the aforementioned aspects are further embodiments comprisingmultiple administrations of the effective amount of the compound,including further embodiments in which (i) the compound is administeredcontinuously or intermittently: as in a single dose; (ii) the timebetween multiple administrations is every 6 hours; (iii) the compound isadministered to the mammal every 8 hours; (iv) the compound isadministered to the mammal every 12 hours; (v) the compound isadministered to the mammal every 24 hours. In further or alternativeembodiments, the method comprises a drug holiday, wherein theadministration of the compound is temporarily suspended or the dose ofthe compound being administered is temporarily reduced; at the end ofthe drug holiday, dosing of the compound is resumed. In one embodiment,the length of the drug holiday varies from 2 days to 1 year.

In certain instances, it is appropriate to administer at least onecompound described herein, or a pharmaceutically acceptable saltthereof, in combination with one or more other therapeutic agents. Incertain embodiments, the pharmaceutical composition further comprisesone or more anti-cancer agents.

In one embodiment, the therapeutic effectiveness of one of the compoundsdescribed herein is enhanced by administration of an adjuvant (i.e., byitself the adjuvant has minimal therapeutic benefit, but in combinationwith another therapeutic agent, the overall therapeutic benefit to thepatient is enhanced). Or, in some embodiments, the benefit experiencedby a patient is increased by administering one of the compoundsdescribed herein with another agent (which also includes a therapeuticregimen) that also has therapeutic benefit.

In one specific embodiment, a compound described herein, or apharmaceutically acceptable salt thereof, is co-administered with asecond therapeutic agent, wherein the compound described herein, or apharmaceutically acceptable salt thereof, and the second therapeuticagent modulate different aspects of the disease, disorder or conditionbeing treated, thereby providing a greater overall benefit thanadministration of either therapeutic agent alone.

In any case, regardless of the disease, disorder or condition beingtreated, the overall benefit experienced by the patient may be additiveof the two therapeutic agents or the patient may experience asynergistic benefit.

In certain embodiments, different therapeutically-effective dosages ofthe compounds disclosed herein will be utilized in formulatingpharmaceutical composition and/or in treatment regimens when thecompounds disclosed herein are administered in combination with one ormore additional agent, such as an additional therapeutically effectivedrug, an adjuvant or the like. Therapeutically-effective dosages ofdrugs and other agents for use in combination treatment regimens isoptionally determined by means similar to those set forth hereinabovefor the actives themselves. Furthermore, the methods ofprevention/treatment described herein encompasses the use of metronomicdosing, i.e., providing more frequent, lower doses in order to minimizetoxic side effects. In some embodiments, a combination treatment regimenencompasses treatment regimens in which administration of a compounddescribed herein, or a pharmaceutically acceptable salt thereof, isinitiated prior to, during, or after treatment with a second agentdescribed herein, and continues until any time during treatment with thesecond agent or after termination of treatment with the second agent. Italso includes treatments in which a compound described herein, or apharmaceutically acceptable salt thereof, and the second agent beingused in combination are administered simultaneously or at differenttimes and/or at decreasing or increasing intervals during the treatmentperiod. Combination treatment further includes periodic treatments thatstart and stop at various times to assist with the clinical managementof the patient.

It is understood that the dosage regimen to treat, prevent, orameliorate the condition(s) for which relief is sought, is modified inaccordance with a variety of factors (e.g. the disease, disorder orcondition from which the subject suffers; the age, weight, sex, diet,and medical condition of the subject). Thus, in some instances, thedosage regimen actually employed varies and, in some embodiments,deviates from the dosage regimens set forth herein.

For combination therapies described herein, dosages of theco-administered compounds vary depending on the type of co-drugemployed, on the specific drug employed, on the disease or conditionbeing treated and so forth. In additional embodiments, whenco-administered with one or more other therapeutic agents, the compoundprovided herein is administered either simultaneously with the one ormore other therapeutic agents, or sequentially.

In combination therapies, the multiple therapeutic agents (one of whichis one of the compounds described herein) are administered in any orderor even simultaneously. If administration is simultaneous, the multipletherapeutic agents are, by way of example only, provided in a single,unified form, or in multiple forms (e.g., as a single pill or as twoseparate pills).

The compounds described herein, or a pharmaceutically acceptable saltthereof, as well as combination therapies, are administered before,during or after the occurrence of a disease or condition, and the timingof administering the composition containing a compound varies. Thus, inone embodiment, the compounds described herein are used as aprophylactic and are administered continuously to subjects with apropensity to develop conditions or diseases in order to prevent theoccurrence of the disease or condition. In another embodiment, thecompounds and compositions are administered to a subject during or assoon as possible after the onset of the symptoms. In specificembodiments, a compound described herein is administered as soon as ispracticable after the onset of a disease or condition is detected orsuspected, and for a length of time necessary for the treatment of thedisease. In some embodiments, the length required for treatment varies,and the treatment length is adjusted to suit the specific needs of eachsubject. For example, in specific embodiments, a compound describedherein or a formulation containing the compound is administered for atleast 2 weeks, about 1 month to about 5 years.

In some embodiments, a compound described herein, or a pharmaceuticallyacceptable salt thereof, is administered in combination withchemotherapy, hormone blocking therapy, radiation therapy, monoclonalantibodies, or combinations thereof.

Chemotherapy includes the use of anti-cancer agents.

In one aspect, the compound described herein, or a pharmaceuticallyacceptable salt thereof, is administered or formulated in combinationwith one or more anti-cancer agents.

EXAMPLES

The following examples are provided for illustrative purposes only andnot to limit the scope of the claims provided herein.

Synthesis of Int-A

Step 1: Methyl 3-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate(A-2)

To a solution of 2-chloro-6-(trifluoromethyl)isonicotinonitrile A-1 (4.0g, 19.4 mmol) and methyl 3-hydroxybenzoate (3.24 g, 21.3 mmol) in amixture of THF/DMF (4:1, 55 ml), was added potassium carbonate (8.0 g,58 mmol). The reaction mixture was heated at 60° C. for 2 h.

The THF was evaporated under reduced pressure and the remaining reactionmixture was partitioned between water (200 mL) and ethyl acetate (100mL). The organic layer was separated and the aqueous layer wasre-extracted with EtOAc (1×100 ml). The combined organic layers weredried (Na₂SO₄), filtered, and then concentrated under reduced pressure.The crude residue was purified (silica gel; eluting with 0-50% EtOAc inhexanes), to afford compound A-2 as a light yellow solid (5.63 g, 91%).¹H NMR (300 MHz, DMSO-d₆): δ 8.21 (m, 1H), 8.07 (m, 1H), 7.87 (m, 1H),7.77 (m, 1H), 7.64 (m, 1H), 7.55 (m, 1H), 3.85 (s, 3H); LCMS Mass: 323.0(M⁺+1).

Step 2: Methyl3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate (A-3)

To a stirred solution of methyl3-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate A-2 (1.5 g,4.65 mmol) in THF/MeOH (1:1, 140 mL) at 0° C., was added portion-wiseCoCl₂ (1.8 g, 13.98 mmol) followed by NaBH₄ (1.77 g, 46.5 mmol). Thereaction mixture was stirred at 0° C. for 20 minutes. The mixture wasdiluted with EtOAc (100 mL) and filtered through celite. The filtratewas concentrated and the resulting residue was partitioned between water(200 mL) and EtOAc (200 mL). The water-organic layer was filteredthrough celite and the organic layer was separated, dried (Na₂SO₄),filtered, and then concentrated under reduced pressure to obtaincompound A-3 as an amber oil (1.38 g, 92%) which did not require furtherpurification. ¹H NMR (300 MHz, DMSO-d₆): δ 7.83 (m, 1H), 7.67 (m, 1H),7.65 (br m, 1H), 7.60 (m, 1H), 7.47 (m, 1H), 7.33 (br m, 1H), 3.80-3.83(m, 5H); LCMS Mass: 327.0 (M⁺+1).

Step 3: Methyl3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate(A-4)

To a stirred solution of ester A-3 (1.38 g, 4.24 mmol) in THF (25 mL) at0° C., was added di-tert-butyl dicarbonate (1.29 g, 5.94 mmol) and DIEA(2.21 mL, 12.74 mmol). The mixture was warmed to RT and stirred for afurther 4 h. The mixture was concentrated and the residue partitionedbetween EtOAc (50 mL) and water (50 mL). The organic layer wasseparated, dried (Na₂SO₄), filtered, and concentrated in vacuo. Theresidue was purified (silica gel; 0-60% EtOAc in hexanes), to affordcompound A-4 as an amber oil (1.42 g, 78%). ¹H NMR (300 MHz, DMSO-d₆): δ7.85 (m, 1H), 7.69 (m, 1H), 7.58-7.62 (m, 2H), 7.48-7.51 (m, 2H), 7.13(br m, 1H), 4.20 (m, 2H), 3.84 (s, 3H), 1.36 (s, 9H); LCMS Mass: 427.0(M⁺+1).

Step 4:3-((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoicacid (Int-A)

To a stirred solution of ester A-4 (1.42 g, 3.34 mmol) in a mixture ofTHF/H₂O (6:1, 21 mL) was added aqueous 4M LiOH (17 mL, 68 mmol). Themixture was stirred at RT for 16 h, then diluted with water (30 ml) andacidified to pH 3-4 using aq. sat. citric acid. The mixture wasextracted with EtOAc (2×50 mL), and the combined organic layers weredried (Na₂SO₄), filtered, and concentrated under reduced pressure toafford Int-A as an off white solid (1.2 g, 87%). ¹H NMR (300 MHz,DMSO-d₆): δ 13.17 (br s, 1H), 7.83 (m, 1H), 7.66 (br m, 1H), 7.53-7.62(m, 2H), 7.44-7.51 (m, 2H), 7.12 (br m, 1H), 4.25 (m, 2H), 1.36 (s, 9H);LCMS Mass: 413.0 (M⁺+1).

Synthesis of Int-B

3-(((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)benzoicacid (Int-B)

The title compound (Int-B) was prepared using the procedure describedfor Int-A, using 3-(hydroxymethy)benzoic acid methyl ester in Step 1. ¹HNMR (300 MHz, DMSO-d₆): δ 12.99 (s, 1H), 8.04 (s, 1H), 7.88 (m, 1H),7.70 (m, 1H), 7.45-7.60 (m, 2H), 7.35 (m, 1H), 6.99 (m, 1H), 5.42 (s,2H), 4.15-4.22 (m, 2H), 1.36 (s, 9H); LCMS Mass: 427.0 (M⁺+1).

Synthesis of Int-C

Step 1: (R)-tert-Butyl3-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)pyrrolidine-carboxylate(C-2)

To a stirred solution of (R)-1-N-boc-3-hydroxypyrrolidine (250 mg, 1.34mmol) in THF (4 mL) at 0° C., was added NaH (64 mg of a 60% dispersionin mineral oil, 1.60 mmol). The mixture was stirred at 0° C. for 20 min.A solution of 2-chloro-6-(trifluoromethyl)isonicotinonitrile C-1 (276mg, 1.34 mmol) in THF (3 mL) was added, and the mixture was warmed to RTand stirred for 6 h. The mixture was concentrated under reduced pressureand the residue partitioned between DCM (50 mL) and water (50 mL). Theorganic layer was separated, dried (MgSO₄), filtered, and thenconcentrated in vacuo. The crude residue was purified (silica gel;eluting with 0-30% EtOAc in hexanes), to afford compound C-2 as acolorless oil (317 mg, 66%). ¹H NMR (300 MHz, DMSO-d₆): δ 8.04 (s, 1H),7.81 (s, 1H), 5.49 (m, 1H), 3.58 (m, 1H), 3.20-3.45 (m, 3H), 2.18 (m,1H), 2.09 (m, 1H); LCMS Mass: 258.0 (M⁺+1−Boc).

Step 2: (R)-2-(Pyrrolidin-3-yloxy)-6-(trifluoromethyl)isonicotinonitrilehydrochloride (Int-C)

To a stirred solution of C-2 (313 mg, 0.876 mmol) in DCM (3 mL) at RT,was added 2M HCl in Et₂O (3 mL, 6.0 mmol). The mixture was stirred at RTfor 18 h. The mixture was concentrated under reduced pressure to affordcompound Int-C (229 mg, 89%) as a white solid. ¹H NMR (300 MHz,DMSO-d₆): δ 9.45 (br s, 2H), 8.09 (s, 1H), 7.80 (s, 1H), 5.58 (m, 1H),3.53 (m, 1H), 3.30-3.40 (m, 3H), 2.10-2.40 (m, 2H); LCMS Mass: 258.0(M⁺+1).

Synthesis of Int-D

(S)-2-(Pyrrolidin-3-yloxy)-6-(trifluoromethyl)isonicotinonitrilehydrochloride (Int-D)

The title compound (Int-D) was prepared using the procedure describedfor Int-C, using (S)-1-N-boc-3-hydroxypyrrolidine in Step 1. ¹H NMR (300MHz, DMSO-d₆): δ 9.40 (br s, 2H), 8.10 (s, 1H), 7.80 (s, 1H), 5.58 (m,1H), 3.51 (m, 1H), 3.30-3.40 (m, 3H), 2.10-2.40 (m, 2H); LCMS Mass:258.0 (M⁺+1).

Synthesis of Int-E

(R)-2-(Piperidin-3-yloxy)-6-(trifluoromethyl)isonicotinonitrilehydrochloride (Int-E)

The title compound (Int-E) was prepared using the procedure describedfor Int-C, using (R)-1-N-boc-3-hydroxypiperidine in Step 1. ¹H NMR (300MHz, DMSO-d₆): δ 9.28 (br s, 1H), 8.94 (br s, 1H), 8.08 (s, 1H), 7.75(s, 1H), 5.31 (m, 1H), 3.20-3.50 (m, 2H), 3.00-3.10 (m, 2H), 1.80-2.00(m, 3H), 1.70 (m, 1H); LCMS Mass: 272.0 (M⁺+1).

Synthesis of Int-F

(S)-2-(Piperidin-3-yloxy)-6-(trifluoromethyl)isonicotinonitrilehydrochloride (Int-F)

The title compound (Int-F) was prepared using the procedure describedfor Int-C, using (S)-1-N-boc-3-hydroxypiperidine in Step 1. ¹H NMR (300MHz, DMSO-d₆): δ 9.26 (br s, 1H), 8.90 (br s, 1H), 8.08 (s, 1H), 7.74(s, 1H), 5.30 (m, 1H), 3.20-3.50 (m, 2H), 3.00-3.10 (m, 2H), 1.80-2.00(m, 3H), 1.71 (m, 1H); LCMS Mass: 272.0 (M⁺+1).

Synthesis of Int-G

2-(Piperidin-4-yloxy)-6-(trifluoromethyl)isonicotinonitrilehydrochloride (Int-G)

The title compound (Int-G) was prepared using the procedure describedfor Int-C, using 1-boc-4-hydroxypiperidine in Step 1. ¹H NMR (300 MHz,DMSO-d₆): δ 8.89 (br s, 2H), 8.04 (s, 1H), 7.81 (s, 1H), 5.24 (m, 1H),3.05-3.30 (m, 4H), 2.10-2.25 (m, 2H), 1.85-2.00 (m, 2H); LCMS Mass:272.0 (M⁺+1).

Synthesis of Int-H

(S)-2-(Piperidin-3-ylmethoxy)-6-(trifluoromethyl)isonicotinonitrilehydrochloride (Int-H)

The title compound (Int-H) was prepared using the procedure describedfor Int-C, using (S)—N-boc-3-piperidinemethanol in Step 1. ¹H NMR (300MHz, DMSO-d₆): δ 9.02 (br s, 1H), 8.85 (br s, 1H), 8.05 (s, 1H), 7.81(s, 1H), 4.16-4.35 (m, 2H), 3.23 (m, 1H), 2.65-2.80 (m, 2H), 2.24 (m,1H), 1.60-1.90 (m, 3H), 1.25-1.40 (m, 2H); LCMS Mass: 286.0 (M⁺+1).

Synthesis of Int-I

2-(Piperidin-4-ylmethoxy)-6-(trifluoromethyl)isonicotinonitrilehydrochloride (Int-I)

The title compound (Int-I) was prepared using the procedure describedfor Int-C, using 1-boc-4-(hydroxymethyl)piperidine in Step 1. ¹H NMR(300 MHz, DMSO-d₆): δ 8.96 (br s, 1H), 8.63 (br s, 1H), 8.04 (s, 1H),7.78 (s, 1H), 4.15-4.25 (m, 2H), 3.20-3.30 (m, 2H), 2.80-2.95 (m, 2H),2.06 (m, 1H), 1.80-1.95 (m, 2H), 1.40-1.60 (m, 2H); LCMS Mass: 286.0(M⁺+1).

Synthesis of Int-J

5-((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)nicotinicacid (Int-J)

The title compound (Int-J) was prepared using the procedure describedfor Int-A, using 5-hydroxy-nicotinic acid methyl ester in Step 1. ¹H NMR(300 MHz, DMSO-d₆): δ 8.92 (m, 1H), 8.70 (m, 1H), 8.05 (m, 1H), 7.61 (m,1H), 7.55 (s, 1H), 7.21 (s, 1H), 4.24-4.29 (m, 2H), 1.39 (s, 9H); LCMSMass: 414.0 (M⁺+1).

Synthesis of Int-K

3-((4-(((tert-Butoxycarbonyl)amino)methyl-d₂)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoicacid (Int-K)

The title compound (Int-K) was prepared using the procedure describedfor Int-A, using NaBD₄, THF-d₈, and MeOH-d₄ in Step 2. ¹H NMR (300 MHz,DMSO-d₆): δ 13.00 (br s, 1H), 7.82 (m, 1H), 7.66 (m, 1H), 7.55-7.60 (m,2H), 7.43-7.52 (m, 2H), 7.12 (m, 1H), 1.36 (s, 9H); LCMS Mass: 415.0(M⁺+1).

Synthesis of Int-L

3-(((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)benzoicacid (Int-L)

The title compound (Int-L) was prepared using the procedure describedfor Int-A, using methyl 3-(aminomethyl)benzoate hydrochloride in Step 1.¹H NMR (500 MHz, DMSO-d₆): δ 12.82 (br s, 1H), 7.92 (s, 1H), 7.79 (m,1H), 7.71 (m, 1H), 7.55 (m, 1H), 7.41 (m, 2H), 6.79 (s, 1H), 6.59 (s,1H), 4.51 (m, 2H), 4.04 (m, 2H), 1.37 (s, 9H); LCMS Mass: 426.0 (M⁺+1).

Synthesis of Int-M

Step 1: Ethyl 3-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)thio)benzoate(M-2)

The title compound (M-2) (680 mg, 100%) was prepared from2-chloro-6-(trifluoromethyl)isonicotinonitrile (M-1) and ethyl3-sulfanylbenzoate, using the procedure described for Int-A, Step 1.LCMS Mass: 353.0 (M⁺+1).

Step 2: Ethyl3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)thio)benzoate (M-3)

To a stirred solution of compound M-2 (680 mg, 1.93 mmol) in THF (10 mL)and acetic acid (6 mL) at 0° C., was added portion-wise CoCl₂ (626 mg,4.82 mmol) followed by NaBH₄ (365 mg, 9.65 mmol). The reaction mixturewas stirred at 0° C. for 20 minutes then warmed to RT and stirred for 10min. The mixture was diluted with EtOAc (30 mL) and filtered throughcelite. The filtrate was concentrated and the resulting residue waspartitioned between water and EtOAc, and stirred for 15 min. Thewater-organic layer was filtered through celite and the organic layerwas separated, washed with brine, dried (Na₂SO₄), filtered, and thenconcentrated under reduced pressure to obtain compound M-3 (565 mg)which was used without further purification. LCMS Mass: 357.0 (M⁺+1).

Step 3: Ethyl3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)thio)benzoate(M-4)

The title compound (M-4) (410 mg, 57%) was prepared from compound M-1using the procedure described for Int-A, Step 3. LCMS Mass: 457.0(M⁺+1).

Step 4:3-((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)thio)benzoicacid (Int-M)

The title compound (Int-M) (340 mg, 88%) was prepared from compound M-4using the procedure described for Int-A, Step 4. ¹H NMR (300 MHz,DMSO-d₆): δ 8.00-8.10 (m, 2H), 7.82 (m, 1H), 7.64 (m, 1H), 7.51 (m, 1H),7.44 (m, 1H), 7.03 (m, 1H), 4.09-4.18 (m, 2H), 1.30 (s, 9H); LCMS Mass:429.0 (M⁺+1).

Synthesis of Int-N

Step 1: Ethyl 4-cyano-6-(trifluoromethyl)picolinate (N-2)

To a stirred solution of ethyl 4-bromo-6-(trifluoromethyl)picolinate N-1(1 g, 3.35 mmol) in DMF (10 mL) at RT, were added Zn(CN)₂ (589 mg, 5.03mmol) followed by Pd(PPh₃)₄ (387 mg, 0.33 mmol). The mixture wasdegassed under argon for 10 min. The reaction mixture was placed in aBiotage microwave synthesizer and stirred at 160° C. for 1 h. Thereaction mixture was cooled to RT, diluted with water (30 mL) andextracted with EtOAc (2×50 mL). The combined organic extracts werewashed with brine (25 mL), dried (Na₂SO₄), filtered, and concentratedunder reduced pressure. The residue was purified (silica gel; elutingwith 4% EtOAc in hexanes), to afford compound N-2 (400 mg, 49%) as whitesolid. ¹H NMR (500 MHz, CDCl₃): δ 8.51 (s, 1H), 8.07 (d, J=1.2 Hz, 1H),4.54 (q, J=7.2 Hz, 2H), 1.47 (t, J=7.2 Hz, 3H).

Step 2: Ethyl4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)picolinate(N-3)

To a stirred solution of compound N-2 (250 mg, 1.02 mmol) in ethanol (10mL) at RT, was added PtO₂ (25 mg). The reaction mixture was stirred atRT under hydrogen (1 atmosphere pressure) for 1 h. The reaction mixturewas filtered through a pad of celite and the celite was washed withethanol (10 mL). The combined filtrate was concentrated under reducedpressure to obtain the desired amine.

The amine was dissolved in CH₂Cl₂ (10 mL), cooled to 0° C., and to thiswere added di-tert-butyl-dicarbonate (0.35 mL, 1.54 mmol) followed byTEA (0.43 mL, 3.07 mmol). The reaction mixture was warmed to RT andstirred for 3 h. The mixture was diluted with water (20 mL) andextracted with EtOAc (2×30 mL). The combined organic extracts werewashed with brine (20 mL), dried (Na₂SO₄), filtered, and concentratedunder reduced pressure. The residue was purified (silica gel; elutingwith 15% EtOAc in hexanes), to afford compound N-3 (180 mg, 50%) as paleyellow oil. ¹H NMR (500 MHz, CDCl₃): δ 8.20 (s, 1H), 7.77 (s, 1H), 5.11(br s, 1H), 4.46-4.54 (m, 4H), 1.50 (s, 9H), 1.46 (t, J=7.1 Hz, 3H);LCMS Mass: 349.1 (M⁺+1).

Step 3: tert-Butyl((2-(hydroxymethyl)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(N-4)

To a stirred solution of compound N-3 (180 mg, 0.52 mmol) in ethanol (10mL) at 0° C. under an inert atmosphere, was added NaBH₄ (79 mg, 2.07mmol) portion-wise. The reaction mixture was warmed to RT and stirredfor 4 h. The reaction mixture was quenched with saturated aq. NH₄Clsolution (15 mL) and extracted with EtOAc (2×20 mL). The combinedorganic extracts were washed with brine (15 mL), dried (Na₂SO₄),filtered, and concentrated under reduced pressure. The residue waspurified (silica gel; eluting with 30% EtOAc in hexanes) to affordcompound N-4 (100 mg, 63%) as colorless viscous syrup. ¹H NMR (400 MHz,CDCl₃): δ 7.50 (s, 1H), 7.40 (s, 1H), 5.02 (br s, 1H), 4.82 (d, J=5.3Hz, 2H), 4.41 (br d, J=6.3 Hz, 2H), 3.19 (t, J=5.4 Hz, 1H), 1.47 (s,9H); LCMS Mass: 306.9 (M⁺+1).

Step 4: tert-Butyl((2-(chloromethyl)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(Int-N)

To a stirred solution of tert-butyl((2-(hydroxymethyl)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate N-4(60 mg, 0.2 mmol) in CHCl₃ (5 mL) at 0° C., were added thionyl chloride(0.02 mL, 0.29 mmol) followed by DMF (cat), drop-wise. The reactionmixture was warmed to RT and stirred for 8 h. The reaction mixture waspoured into ice-cold water (10 mL), basified with saturated aq.NaHCO₃solution to pH −8, and extracted with CH₂Cl₂ (2×10 mL). Thecombined organic extracts washed with brine (7 mL), dried (Na₂SO₄),filtered, and concentrated under reduced pressure to afford Int-N (45mg) as pale yellow oil, which was used without further purification. ¹HNMR (400 MHz, CDCl₃): δ 7.63 (s, 1H), 7.53 (s, 1H), 5.09 (br s, 1H),4.72 (s, 2H), 4.42 (br d, J=5.9 Hz, 2H), 1.48 (br s, 9H); LCMS Mass:325.2 (M⁺+1).

Synthesis of Int-O

4-((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)picolinicacid (Int-O)

The title compound (Int-O) was prepared using the procedure describedfor Int-A, using 4-hydroxy-pyridine-2-carboxylic acid methyl ester inStep 1. LCMS Mass: 414.0 (M⁺+1).

Example 1:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylbenzamidehydrochloride (Compound 1-7)

Step 1: tert-Butyl((2-(3-(phenylcarbamoyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(1)

To a stirred solution of Int-A (750 mg, 1.82 mmol) in a mixture ofDCM/DMF (3:1, 12 mL), was added HATU (1.04 g, 2.74 mmol) and the mixturewas stirred at RT for 20 min. Aniline (219 mg, 2.35 mmol) and DIEA (702mg, 5.44 mmol) were added and the mixture stirred at RT for 18 h. TheDCM was evaporated under reduced pressure and the remaining reactionmixture was partitioned between water (100 mL) and EtOAc (100 mL). Theorganic layer was separated, dried (Na₂SO₄), filtered, and thenconcentrated under reduced pressure. The crude residue was purified(silica gel; eluting with 0-60% EtOAc in hexanes), to afford compound 1(630 mg, 71%) as an off-white solid. ¹H NMR (300 MHz, DMSO-d₆): δ 10.27(s, 1H), 7.86 (m, 2H), 7.72-7.77 (m, 2H), 7.57-7.64 (m, 2H), 7.51 (m,1H), 7.44 (m, 1H), 7.30-7.36 (m, 2H), 7.06-7.13 (m, 2H), 4.25 (m, 2H),1.35 (s, 9H); LCMS Mass: 510.0 (M⁺+Na) and 432.0 (MH⁺−C₄H₈).

Step 2:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylbenzamidehydrochloride (Compound 1-7)

To a stirred mixture of amide 1 (630 mg, 1.29 mmol) in DCM (27 mL) atRT, was added 2 M HCl in Et₂O (9.69 mL, 19.38 mmol). The mixture wasstirred at RT for 18 h. Additional 2 M HCl in Et₂O (9 mL, 18.0 mmol) wasadded and the mixture stirred for a further 2 h. The mixture wasconcentrated under reduced pressure to afford the title compound 1-7(375 mg, 69%) as a white solid. ¹H NMR (300 MHz, DMSO-d₆): δ 10.35 (s,1H), 8.56 (br s, 3H), 7.84-7.90 (m, 2H), 7.74-7.79 (m, 3H), 7.65 (m,1H), 7.52 (m, 1H), 7.45 (m, 1H), 7.31-7.38 (m, 2H), 7.09 (m, 1H), 4.23(m, 2H); LCMS Mass: 388.0 (M⁺+1).

Example 2:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-fluorobenzyl)benzamidehydrochloride (Compound 1-9)

The title compound (1-9) was prepared using the procedure for Example 1,using 4-fluorobenzyl amine in Step 1. LCMS Mass: 420.0 (M⁺+1).

Example 3:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(benzo[b]thiophen-2-ylmethyl)benzamidehydrochloride (Compound 1-10)

The title compound (1-10) was prepared using the procedure for Example1, using 1-benzothiophen-2yl-methylamine in Step 1. LCMS Mass: 458.0(M⁺+1).

Example 4:(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3,4-dihydroisoquinolin-2(1H)-yl)methanonehydrochloride (Compound 1-11)

The title compound (1-11) was prepared using the procedure for Example1, using 1,2,3,4-tetrahydroisoquinoline in Step 1. LCMS Mass: 428.0(M⁺+1).

Example 5:(3-(1H-Pyrazol-1-yl)azetidin-1-yl)(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)methanonetrifluoroacetate (Compound 1-12)

The title compound (1-12) was prepared using the procedure for Example1, using 1-(azetidin-3-yl)-1H-pyrazole in Step 1. Compound 1-12 waspurified via preparative HPLC (Waters XTerra® Prep MS C-18 OBD 5 μM50×100 mm column; eluting with 10-90% ACN/H₂O containing 0.1% TFA, over20 min). LCMS Mass: 418.0 (M⁺+1).

Example 6:N-((2H-Tetrazol-5-yl)methyl)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamidehydrochloride (Compound 1-13)

The title compound (1-13) was prepared using the procedure for Example1, using (2H-tetrazol-5-ylmethyl)amine hydrochloride in Step 1. LCMSMass: 394.0 (M⁺+1).

Example 7:N-(2-(1H-1,2,4-Triazol-1-yl)ethyl)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamidehydrochloride (Compound 1-14)

The title compound (1-14) was prepared using the procedure for Example1, using 2-(1H-1,2,4-triazol-1-yl)ethanamine in Step 1. ¹H NMR (300 MHz,DMSO-d₆): δ 8.65-8.80 (m, 5H), 8.08 (s, 1H), 7.85 (s, 1H), 7.72 (m, 1H),7.51-7.60 (m, 3H), 7.35 (m, 1H), 4.37 (m, 2H), 4.21 (m, 2H), 3.62-3.66(m, 2H); LCMS Mass: 407.0 (M⁺+1).

Example 8:N-(2-(1H-Tetrazol-1-yl)ethyl)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamidehydrochloride (Compound 1-15)

The title compound (1-15) was prepared using the procedure for Example1, using 2-(1H-1,2,3,4-tetrazol-1-yl)ethanamine in Step 1. ¹H NMR (300MHz, DMSO-d₆): δ 9.39 (s, 1H), 8.75 (m, 1H), 8.55 (br s, 3H), 7.83 (s,1H), 7.67 (m, 1H), 7.54-7.57 (m, 2H), 7.48 (m, 1H), 7.37 (m, 1H),4.60-4.64 (m, 2H), 4.20-4.24 (m, 2H), 3.67-3.71 (m, 2H); LCMS Mass:408.0 (M⁺+1).

Example 9:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-hydroxyethyl)benzamidehydrochloride (Compound 1-16)

The title compound (1-16) was prepared using the procedure for Example1, using 2-aminoethanol in Step 1. ¹H NMR (300 MHz, DMSO-d₆): δ8.50-8.60 (br m, 4H), 7.83 (s, 1H), 7.78 (m, 1H), 7.65 (m, 1H), 7.54 (m,1H), 7.48 (m, 1H), 7.34 (m, 1H), 4.74 (br s, 1H), 4.19-4.23 (m, 2H),3.47-3.51 (m, 2H), 3.29-3.33 (m, 2H); LCMS Mass: 356.0 (M⁺+1).

Example 10:(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-17)

The title compound (1-17) was prepared using the procedure for Example1, using (S)-3-pyrrolidinol hydrochloride in Step 1. ¹H NMR (300 MHz,DMSO-d₆): δ 8.60 (br s, 3H), 7.83 (s, 1H), 7.49-7.52 (m, 2H), 7.39 (m,1H), 7.25-7.33 (m, 2H), 4.18-4.31 (m, 3H), 3.20-3.60 (m, 5H), 1.70-2.00(m, 2H); LCMS Mass: 382.0 (M⁺+1).

Example 11:(R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-18)

The title compound (1-18) was prepared using the procedure for Example1, using (R)-3-pyrrolidinol hydrochloride in Step 1. ¹H NMR (300 MHz,DMSO-d₆): δ 8.63 (br s, 3H), 7.85 (s, 1H), 7.49-7.56 (m, 2H), 7.40 (m,1H), 7.27-7.34 (m, 2H), 4.15-4.25 (m, 3H), 3.18-3.58 (m, 5H), 1.70-1.95(m, 2H); LCMS Mass: 382.0 (M⁺+1).

Example 12:Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-19)

The title compound (1-19) was prepared using the procedure for Example1, using racemic-trans-4-fluoro-3-hydroxypyrrolidine hydrochloride inStep 1. ¹H NMR (300 MHz, DMSO-d₆): δ 8.62 (br s, 3H), 7.86 (s, 1H),7.51-7.57 (m, 2H), 7.41 (m, 1H), 7.30-7.40 (m, 2H), 5.62 (m, 1H), 4.95(m, 1H), 4.12-4.30 (br m, 3H), 3.45-3.92 (m, 4H); LCMS Mass: 400.0(M⁺+1).

Example 13:(S,S)-trans-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-20)

Two separate equal reaction batches were set up as follows: To a stirredsolution of Int-A (750 mg, 1.82 mmol) in a mixture of DCM/DMF (3:1, 11mL), was added HATU (1.0 g, 2.63 mmol) and the mixture was stirred at RTfor 20 min. Racemic-trans-4-fluoro-3-hydroxypyrrolidine hydrochloride(304 mg, 2.14 mmol) and DIEA (938 mg, 7.27 mmol) were added and themixture stirred at RT for 2.5 h. At this point both reaction batcheswere combined and the DCM was evaporated under reduced pressure. Theremaining reaction mixture was partitioned between water (200 mL) andEtOAc (200 mL). The organic layer was separated, dried (Na₂SO₄),filtered, and then concentrated under reduced pressure. The cruderesidue was purified (silica gel; eluting with 10-100% EtOAc inhexanes), to afford compound 1 (1.58 g, 87%) as a white solid. ¹H NMR(300 MHz, DMSO-d₆): δ 7.60 (m, 1H), 7.47-7.56 (m, 2H), 7.36-7.44 (m,2H), 7.31 (m, 1H), 7.14 (s, 1H), 5.56 (m, 1H), 4.93 (m, 1H), 4.10-4.30(m, 3H), 3.45-3.90 (m, 4H), 1.38 (s, 9H); LCMS Mass: 522.0 (M⁺+Na).

Step 2: (R,R)-trans-tert-butyl((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(2) and (S,S)-trans-tert-butyl((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(3)

Compound 2 (102 mg) and compound 3 (88 mg) were both obtained fromcompound 1 (300 mg, 0.60 mmol) via chiral HPLC separation (Chiral PakADH, 250×20 mm, 5 μm column, eluting isocratically with 10%MeOH:isopropanol (1:1) and 90% hexanes (containing 0.1% DEA), flow rate18 mL/min), wherein compound 2 was the first to elute and compound 3 wasthe second to elute.

Compound 2: ¹H NMR (400 MHz, DMSO-d₆): δ 7.59 (m, 1H), 7.47-7.56 (m,2H), 7.35-7.45 (m, 2H), 7.31 (m, 1H), 7.16 (s, 1H), 5.56 (m, 1H), 4.94(m, 1H), 4.25-4.30 (m, 2H), 4.17 (m, 1H), 3.45-3.90 (m, 4H), 1.39 (s,9H); LCMS Mass: 500.0 (M⁺+1). Chiral HPLC analysis: R_(t)=11.84 min(Chiral Pak ADH, 250×4.6 mm, 5 μm column, eluting isocratically with 10%MeOH:EtOH (1:1) and 90% hexanes (containing 0.1% DEA) over 25 mins; flowrate 1.0 mL/min).

Compound 3: ¹H NMR (400 MHz, DMSO-d₆): δ 7.59 (m, 1H), 7.47-7.56 (m,2H), 7.35-7.45 (m, 2H), 7.31 (m, 1H), 7.16 (s, 1H), 5.56 (m, 1H), 4.95(m, 1H), 4.25-4.30 (m, 2H), 4.17 (m, 1H), 3.45-3.90 (m, 4H), 1.39 (s,9H); LCMS Mass: 500.0 (M⁺+1). Chiral HPLC analysis: R_(t)=14.71 min(Chiral Pak ADH, 250×4.6 mm, 5 μm column, eluting isocratically with 10%MeOH:EtOH (1:1) and 90% hexanes (containing 0.1% DEA) over 25 mins; flowrate 1.0 mL/min).

Step 3:(S,S)-trans-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-20)

The title compound (1-20) (77 mg, 100%) was prepared from compound 3 (88mg, 0.176 mmol) using the procedure for Example 1, Step 2. ¹H NMR (300MHz, DMSO-d₆): δ 8.61 (br s, 3H), 7.84 (s, 1H), 7.51-7.57 (m, 2H), 7.43(m, 1H), 7.28-7.37 (m, 2H), 5.57 (br m, 1H), 4.95 (m, 1H), 4.12-4.30 (brm, 3H), 3.30-3.92 (m, 4H); LCMS Mass: 400.0 (M⁺+1).

Example 14:(R,R)-trans-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-21)

The title compound (1-21) (89 mg, 100%) was prepared from compound 2(102 mg, 0.204 mmol) (from Example 13, Step 2) using the procedure forExample 1, Step 2. ¹H NMR (300 MHz, DMSO-d₆): δ 8.61 (br s, 3H), 7.84(s, 1H), 7.51-7.57 (m, 2H), 7.43 (m, 1H), 7.28-7.37 (m, 2H), 5.62 (br m,1H), 4.95 (m, 1H), 4.12-4.30 (br m, 3H), 3.30-3.92 (m, 4H); LCMS Mass:400.0 (M⁺+1).

Example 15:(R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-aminopyrrolidin-1-yl)methanonedihydrochloride (Compound 1-22)

The title compound (1-22) was prepared using the procedure for Example1, using (R)-tert-butyl pyrrolidin-3-ylcarbamate in Step 1. LCMS Mass:381.0 (M⁺+1).

Example 16:Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(-3-(dimethylamino)-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-23)

The title compound (1-23) was prepared using the procedure for Example1, using racemic-trans-4-(dimethylamino)-3-pyrrolidinol in Step 1. LCMSMass: 425.0 (M⁺+1).

Example 17:(S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)pyrrolidine-2-carboxylicacid hydrochloride (Compound 1-24)

Step 1: (S)-Methyl1-(3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)pyrrolidine-2-carboxylate(1)

The title compound (1) (117 mg, 92%) was prepared from Int-A and(S)-methyl pyrrolidine-2-carboxylate hydrochloride, using the procedurefor Example 1, Step 1. LCMS Mass: 546.0 (M⁺+Na).

Step 2:(S)-1-(3-((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)pyrrolidine-2-carboxylicacid (2)

To a stirred solution of ester 1 (117 mg, 0.223 mmol) in a mixture ofTHF (1.5 mL) and water (0.75 mL) at RT, was added aq. 4M LiOH solution(1.1 mL, 4.4 mmol). The reaction mixture was stirred at RT for 16 h. TheTHF was removed under reduced pressure and the remaining mixture wasdiluted with water and acidified to pH 3-4 with sat. aq. citric acidsolution. The precipitate was isolated via filtration and dried underhigh vacuum to afford compound 2 (87 mg, 77%) as an off-white solid. ¹HNMR (300 MHz, DMSO-d₆): δ 7.47-7.64 (m, 3H), 7.41 (m, 1H), 7.31 (m, 1H),7.13-7.25 (m, 2H), 4.35 (m, 1H), 4.20-4.25 (m, 2H), 3.45-3.53 (m, 2H),2.22 (m, 1H), 1.75-1.90 (m, 3H), 1.25-1.37 (br m, 9H); LCMS Mass: 532.0(M⁺+Na).

Step 3:(S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)pyrrolidine-2-carboxylicacid hydrochloride (Compound 1-24)

The title compound (1-24) (31 mg, 41%) was prepared from acid 2, usingthe procedure for Example 1, Step 2. LCMS Mass: 410.0 (M⁺+1).

Example 18:(R)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)pyrrolidine-2-carboxylicacid hydrochloride (Compound 1-25)

The title compound (1-25) was prepared using the procedure for Example17, using (R)-methyl pyrrolidine-2-carboxylate hydrochloride in Step 1.LCMS Mass: 410.0 (M⁺+1).

Example 19:(R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-(hydroxymethyl)pyrrolidin-1-yl)methanonehydrochloride (Compound 1-26)

The title compound (1-26) was prepared using the procedure for Example1, using (R)-pyrrolidin-3-ylmethanol hydrochloride in Step 1. ¹H NMR(300 MHz, DMSO-d₆): δ 8.60 (br s, 3H), 7.83 (s, 1H), 7.48-7.55 (m, 2H),7.39 (m, 1H), 7.25-7.34 (m, 2H), 4.19-4.24 (m, 2H), 3.17-3.60 (m, 6H),2.28 (m, 1H), 1.85 (m, 1H), 1.61 (m, 1H); LCMS Mass: 396.0 (M⁺+1).

Example 20:8-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-onehydrochloride (Compound 1-27)

The title compound (1-27) was prepared using the procedure for Example1, using 1-oxa-3,8-diazaspiro[4.5]decan-2-one hydrochloride in Step 1.LCMS Mass: 451.0 (M⁺+1).

Example 21:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(2-oxooxazolidin-3-yl)ethyl)benzamide(Compound 1-28)

The title compound (1-28) was prepared using the procedure for Example1, using 3-(2-aminoethyl)-1,3-oxazolidin-2-one hydrochloride in Step 1.LCMS Mass: 425.0 (M⁺+1).

Example 22:Racemic-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((5-oxopyrrolidin-2-yl)methyl)benzamidehydrochloride (Compound 1-29)

The title compound (1-29) was prepared using the procedure for Example1, using racemic-5-(aminomethyl)-2-pyrrolidone in Step 1. LCMS Mass:409.0 (M⁺+1).

Example 23:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(methylsulfonyl)ethyl)benzamidehydrochloride (Compound 1-30)

The title compound (1-30) was prepared using the procedure for Example1, using 2-(methylsulfonyl)ethanamine hydrochloride in Step 1. ¹H NMR(300 MHz, DMSO-d₆): δ 8.87 (m, 1H), 8.64 (br s, 3H), 7.85 (s, 1H), 7.76(m, 1H), 7.51-7.64 (m, 3H), 7.37 (m, 1H), 4.21 (s, 2H), 3.60-3.64 (m,2H), 3.33-3.37 (m, 2H), 3.01 (s, 3H); LCMS Mass: 418.0 (M⁺+1).

Example 24:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(1-(hydroxymethyl)cyclopropyl)benzamidehydrochloride (Compound 1-31)

The title compound (1-31) was prepared using the procedure for Example1, using (1-aminocyclopropyl)methanol in Step 1. ¹H NMR (300 MHz,DMSO-d₆): δ 8.74 (s, 1H), 8.59 (br s, 3H), 7.83 (s, 1H), 7.77 (m, 1H),7.64 (m, 1H), 7.47-7.55 (m, 2H), 7.33 (m, 1H), 4.74 (m, 1H), 4.21 (s,2H), 3.47-3.51 (m, 2H), 0.65-0.78 (m, 4H); LCMS Mass: 382.0 (M⁺+1).

Example 25:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-hydroxy-2-methylpropyl)benzamidehydrochloride (Compound 1-32)

The title compound (1-32) was prepared using the procedure for Example1, using 1-amino-2-methylpropan-2-ol in Step 1. LCMS Mass: 384.0 (M⁺+1).

Example 26:(R)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2,3-dihydroxypropyl)benzamidehydrochloride (Compound 1-33)

The title compound (1-33) was prepared using the procedure for Example1, using (R)-3-amino-1,2-propanediol in Step 1. LCMS Mass: 386.0 (M⁺+1).

Example 27:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-sulfamoylethyl)benzamidehydrochloride (Compound 1-34)

The title compound (1-34) was prepared using the procedure for Example1, using 2-aminoethane-1-sulfonamide in Step 1. ¹H NMR (300 MHz,DMSO-d₆): δ 8.76 (m, 1H), 8.54 (br s, 3H), 7.82 (s, 1H), 7.75 (m, 1H),7.62 (m, 1H), 7.57 (m, 1H), 7.49 (m, 1H), 7.37 (m, 1H), 6.94 (s, 2H),4.19-4.23 (m, 2H), 3.59-3.63 (m, 2H), 3.20-3.24 (m, 2H); LCMS Mass:419.0 (M⁺+1).

Example 28:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(dimethylamino)ethyl)benzamidedihydrochloride (Compound 1-35)

The title compound (1-35) was prepared using the procedure for Example1, using 2-(dimethylamino)ethylamine in Step 1. LCMS Mass: 383.0 (M⁺+1).

Example 29:Racemic-trans-(3-(((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-36)

The title compound (1-36) was prepared using the procedure for Example1, using Int-B and racemic-trans-4-fluoro-3-hydroxypyrrolidinehydrochloride in Step 1. LCMS Mass: 414.0 (M⁺+1).

Example 30:3-((4-(Aminomethyl-d₂)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylbenzamidehydrochloride (Compound 1-8)

The title compound (1-8) was prepared using the procedure for Example 1,using Int-K in Step 1. ¹H NMR (300 MHz, DMSO-d₆): δ 10.33 (s, 1H), 8.51(br s, 3H), 7.84-7.91 (m, 2H), 7.72-7.79 (m, 3H), 7.62 (m, 1H), 7.51 (m,1H), 7.43 (m, 1H), 7.31-7.38 (m, 2H), 7.09 (m, 1H); LCMS Mass: 390.0(M⁺+1).

Example 31:(R)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpyrrolidine-1-carboxamidetrifluoroacetate (Compound 1-39)

Step 1:(R)-3-((4-Cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpyrrolidine-1-carboxamide(1)

To a stirred solution of Int-C (225 mg, 0.766 mmol) and DIEA (248 mg,1.92 mmol) in THF (4 mL) at RT, was added phenyl isocyanate (137 mg,1.15 mmol). The mixture was stirred at RT for 3.5 h. The mixture wasconcentrated under reduced pressure and the residue purified (silicagel; eluting with 0-25% EtOAc in DCM), to afford compound 1 (288 mg,100%) as a colorless oil. ¹H NMR (300 MHz, DMSO-d₆): δ 8.23 (s, 1H),8.04 (s, 1H), 7.82 (s, 1H), 7.44-7.51 (m, 2H), 7.16-7.25 (m, 2H), 6.91(m, 1H), 5.60 (m, 1H), 3.74 (m, 1H), 3.57-3.68 (m, 2H), 3.48 (m, 1H),2.10-2.40 (m, 2H); LCMS Mass: 377.0 (M⁺+1).

Step 2:(R)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpyrrolidine-1-carboxamidetrifluoroacetate (Compound 1-39)

A mixture of carboxamide 1 (288 mg, 0.765 mmol), 10 wt % Pd on carbon(0.076 mmol), and EtOAc:MeOH (1:1, 6 mL), was stirred at RT under 1atmosphere of H2 gas. After 3 h, the mixture was filtered through celiteand the filtrate concentrated under reduced pressure. The residue waspurified via preparative HPLC (Waters XTerra® Prep MS C-18 OBD 5 μM50×100 mm column; eluting with 10-90% ACN/H₂O containing 0.1% TFA, over20 min) to afford compound 1-39 (265 mg, 70%) as a white solid. ¹H NMR(300 MHz, DMSO-d₆): δ 8.33 (br s, 3H), 8.24 (s, 1H), 7.63 (s, 1H),7.45-7.51 (m, 2H), 7.17-7.25 (m, 3H), 6.92 (m, 1H), 5.57 (m, 1H),4.10-4.22 (m, 2H), 3.41-3.78 (m, 4H), 2.10-2.40 (m, 2H); LCMS Mass:381.0 (M⁺+1).

Example 32:(S)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpyrrolidine-1-carboxamidetrifluoroacetate (Compound 1-40)

The title compound (1-40) was prepared using the procedure for Example31, using Int-D in Step 1. LCMS Mass: 381.0 (M⁺+1).

Example 33:(R)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpiperidine-1-carboxamidetrifluoroacetate (Compound 1-43)

The title compound (1-43) was prepared using the procedure for Example31, using Int-E in Step 1. LCMS Mass: 395.0 (M⁺+1).

Example 34:(S)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpiperidine-1-carboxamidetrifluoroacetate (Compound 1-44)

The title compound (1-44) was prepared using the procedure for Example31, using Int-F in Step 1. LCMS Mass: 395.0 (M⁺+1).

Example 35:(S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-phenylethanonetrifluoroacetate (Compound 1-46)

Step 1:(S)-2-((1-(2-(3,4-Dichlorophenyl)acetyl)piperidin-3-yl)oxy)-6-(trifluoromethyl)isonicotinonitrile(1)

A solution of 3,4-dichlorophenylacetic acid (150 mg, 0.731 mmol) andHATU (370 mg, 0.974 mmol) in DMF (3 mL) was stirred at RT for 20 min.Int-F (150 mg, 0.487 mmol) and DIEA (252 mg, 1.95 mmol) were added andthe mixture stirred at RT for 18 h. Water (50 mL), brine (20 mL) and aq.2M HCl solution (10 mL) were added and the mixture was extracted withEtOAc (4×10 mL). The combined organic layers were dried (MgSO₄),filtered, and then concentrated under reduced pressure. The cruderesidue was purified (silica gel; eluting with 0-50% EtOAc in hexanes),to afford compound 1 (180 mg, 81%) as a colorless oil. ¹H NMR (300 MHz,DMSO-d₆): δ 8.02 (s, 1H), 7.67 (m, 1H), 7.37-7.60 (m, 2H), 7.16 (m, 1H),5.05 (m, 1H), 3.30-4.00 (m, 6H), 1.96 (m, 1H), 1.85 (m, 1H), 1.65 (m,1H), 1.51 (m, 1H); LCMS Mass: 458.0 (M⁺+1).

Step 2:(S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-phenylethanonetrifluoroacetate (Compound 1-46)

The title compound (1-46) (68 mg, 34%) was prepared from(S)-2-((1-(2-(3,4-dichlorophenyl)acetyl)piperidin-3-yl)oxy)-6-(trifluoromethyl)isonicotinonitrile1 using the procedure for Example 31, Step 2. ¹H NMR (300 MHz, DMSO-d₆):δ 8.33 (br s, 3H), 7.61 (m, 1H), 7.07-7.37 (m, 6H), 5.03 (m, 1H),4.10-4.22 (m, 2H), 3.30-4.00 (br m, 6H), 1.30-2.00 (br m, 4H); LCMSMass: 394.0 (M⁺+1).

Example 36:(S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-(3,4-dichlorophenyl)ethanonetrifluoroacetate (Compound 1-47)

To a stirred solution of(S)-2-((1-(2-(3,4-dichlorophenyl)acetyl)piperidin-3-yl)oxy)-6-(trifluoromethyl)isonicotinonitrile1 (75 mg, 0.164 mmol) (from Example 35, Step 1) in MeOH/THF (1:1, 2 mL)at 0° C., was added CoCl₂ (43 mg, 0.333 mmol) and NaBH₄ (62 mg, 1.64mmol). The mixture was warmed to RT and stirred for a further 4 h. Themixture was partially concentrated then diluted with EtOAc (40 mL),before filtering through celite. The celite was rinsed with EtOAc (30mL) and the combined filtrates washed with water (2×100 mL), dried(MgSO₄), filtered, and then concentrated under reduced pressure. Theresidue was purified via preparative HPLC (Waters XTerra® Prep MS C-18OBD 5 μM 50×100 mm column; eluting 10-90% ACN/H₂O containing 0.1% TFA,over 20 min) to afford compound 1-47 (36 mg, 38%) as a yellow oil. ¹HNMR (300 MHz, DMSO-d₆): δ 8.35 (br s, 3H), 7.37-7.60 (m, 3H), 7.10-7.20(m, 2H), 5.03 (m, 1H), 4.10-4.20 (m, 2H), 3.50-4.00 (m, 5H), 3.40 (m,1H), 1.96 (m, 1H), 1.82 (m, 1H), 1.62 (m, 1H), 1.52 (m, 1H); LCMS Mass:462.0 (M⁺+1).

Example 37:(S)-2-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidine-1-carbonyl)-4H-chromen-4-onetrifluoroacetate (Compound 1-48)

The title compound (1-48) was prepared using the procedure for Example35, using 4-oxo-4H-chromene-2-carboxylic acid in Step 1. LCMS Mass:448.0 (M⁺+1).

Example 38:(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)(pyridin-3-yl)methanonetrifluoroacetate (Compound 1-49)

The title compound (1-49) was prepared using the procedure for Example35, using nicotinic acid in Step 1. LCMS Mass: 381.0 (M⁺+1).

Example 39:(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)(pyrimidin-5-yl)methanonetrifluoroacetate (Compound 1-50)

The title compound (1-50) was prepared using the procedure for Example35, using pyrimidine-5-carboxylic acid in Step 1. LCMS Mass: 382.0(M⁺+1).

Example 40:(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanonetrifluoroacetate (Compound 1-51)

The title compound (1-51) was prepared using the procedure for Example35, using 5-methyl-1,3,4-oxadiazole-2-carboxylic acid in Step 1. LCMSMass: 386.0 (M⁺+1).

Example 41:(S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-methylpropan-1-onetrifluoroacetate (Compound 1-52)

The title compound (1-52) was prepared using the procedure for Example35, using isobutyric acid in Step 1. LCMS Mass: 346.0 (M⁺+1).

Example 42:(S)-3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)-N-phenylpiperidine-1-carboxamidetrifluoroacetate (Compound 1-45)

The title compound (1-45) was prepared using the procedure for Example31, using Int-H in Step 1. LCMS Mass: 409.0 (M⁺+1).

Example 43:4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpiperidine-1-carboxamidetrifluoroacetate (Compound 1-41)

The title compound (1-41) was prepared using the procedure for Example31, using Int-G in Step 1. LCMS Mass: 395.0 (M⁺+1).

Example 44:4-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)-N-phenylpiperidine-1-carboxamidetrifluoroacetate (Compound 1-42)

The title compound (1-42) was prepared using the procedure for Example31, using Int-I in Step 1. LCMS Mass: 409.0 (M⁺+1).

Example 45:5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(methylsulfonyl)ethyl)nicotinamidehydrochloride (Compound 1-53)

The title compound (1-53) was prepared using the procedure for Example1, using Int-J and 2-(methylsulfonyl)ethanamine hydrochloride in Step 1.LCMS Mass: 419.0 (M⁺+1).

Example 46:(R)-(5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)pyridin-3-yl)(3-aminopyrrolidin-1-yl)methanonedihydrochloride (Compound 1-54)

The title compound (1-54) was prepared using the procedure for Example1, using Int-J and (R)-tert-butyl pyrrolidin-3-ylcarbamate in Step 1.LCMS Mass: 382.0 (M⁺+1).

Example 47:Racemic-trans-(5-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)pyridin-3-yl)(-3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-55)

The title compound (1-55) was prepared using the procedure for Example1, using Int-J and racemic-trans-4-fluoro-3-hydroxypyrrolidinehydrochloride in Step 1. LCMS Mass: 401.0 (M⁺+1).

Example 48:(2-((1H-Indol-4-yl)oxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine(Compound 1-58)

To a stirred solution of2-((1H-indol-4-yl)oxy)-6-(trifluoromethyl)isonicotinonitrile 1 (100 mg,0.33 mmol) (from Example 49, Step 1) in THF/MeOH (1:1, 4 mL) at 0° C.were added CoCl₂ (85 mg, 0.66 mmol) and NaBH₄ (125 mg, 3.3 mmol) underinert atmosphere, and the mixture stirred at 0° C. for 3 h. The reactionmixture was quenched with water (10 mL) and filtered through celite. Thefiltrate was extracted with 10% MeOH/CH₂Cl₂ (2×10 mL). The organic layerwas washed with brine (15 mL), dried (Na₂SO₄), filtered and concentratedunder reduced pressure. The crude was purified by preparative HPLC toafford compound 1-58 (25 mg, 24%) as an off-white solid. ¹H NMR (400MHz, DMSO-d₆): δ 11.31 (br s, 1H), 7.60 (s, 1H), 7.33-7.28 (m, 2H), 7.16(s, 1H), 7.11 (t, J=7.9 Hz, 1H), 6.79 (d, J=7.1 Hz, 1H), 6.12-6.09 (m,1H), 3.79 (s, 2H), 2.02 (br s, 2H); m/z 308.3 (M+H⁺).

Example 49:(2-((1-(1-Methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)oxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine hydrochloride (Compound 1-37)

Step 1: 2-((1H-Indol-4-yl)oxy)-6-(trifluoromethyl) isonicotinonitrile(2)

To a stirred solution of 1H-indol-4-ol 1 (500 mg, 3.76 mmol) inN-methyl-2-pyrrolidone (12.5 mL) were added 2-chloro-6-(trifluoromethyl)isonicotinonitrile (774 mg, 3.76 mmol), K₂CO₃ (1.04 g, 7.52 mmol) andTMS-C₁ (0.5 mL, 3.76 mmol). The reaction mixture was heated to 150° C.in a microwave synthesizer for 45 min. The reaction mixture was quenchedwith water (40 mL) and extracted with Et₂O (2×50 mL). The combinedorganic extracts were washed with brine (20 mL), dried (Na₂SO₄),filtered and concentrated under reduced pressure. The crude was purified(silica gel; eluting 4% EtOAc/hexanes) to afford compound 2 (180 mg,16%) as an off-white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 11.37 (br s,1H), 8.16 (d, J=0.7 Hz, 1H), 7.90 (s, 1H), 7.37-7.32 (m, 2H), 7.14 (t,J=7.9 Hz, 1H), 6.86 (dd, J=7.6, 0.6 Hz, 1H), 6.14-6.13 (m, 1H); LC-MS(ESI): 72.74%; m/z 303.9 (M+H⁺).

Step 2: 2-((1-(1-Methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)oxy)-6-(trifluoromethyl) isonicotinonitrile (3)

To a stirred solution of compound 2 (100 mg, 0.33 mmol) in toluene (5mL) were added 4-bromo-1-methyl-1H-pyrazole (68 mg, 0.36 mmol),N,N′-dimethylethylenediamine (0.014 mL, 0.13 mmol), potassium phosphate(176 mg, 0.82 mmol) and CuI (6.2 mg, 0.03 mmol). The reaction mixturewas degassed under Ar for 30 min at RT, and then heated to 140° C. for12 h. The mixture was diluted with EtOAc (30 mL) and filtered throughcelite. The filtrate was concentrated under reduced pressure and thecrude was purified (silica gel; using 20% EtOAc/hexanes) to affordcompound 3 (65 mg, 51%) as sticky solid. ¹H NMR (500 MHz, DMSO-d₆): δ8.26 (s, 1H), 8.20 (s, 1H), 8.01 (s, 1H), 7.85 (s, 1H), 7.52 (d, J=3.5Hz, 1H), 7.44 (d, J=8.1 Hz, 1H), 7.25 (t, J=8.0 Hz, 1H), 6.98 (d, J=7.5Hz, 1H), 6.38 (d, J=2.9 Hz, 1H), 3.92 (s, 3H); LC-MS (ESI): 97.13%; m/z383.9 (M+H⁺).

Step 3: (2-((1-(1-Methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)oxy)-6-(trifluoromethyl) pyridin-4-yl) methanamine hydrochloride(Compound 1-37)

To a stirred solution of compound 3 (65 mg, 0.17 mmol) in THF/MeOH (1:1,4 mL) at 0° C. were added CoCl₂ (44 mg, 0.33 mmol) and NaBH₄ (64 mg, 1.7mmol) portion wise under inert atmosphere. The reaction was warmed to RTand stirred for 5 h. The reaction mixture was filtered through a pad ofcelite and the residue was washed with 10% MeOH/CH₂Cl₂ (20 mL). Thefiltrate was washed with brine (10 mL), dried (Na₂SO₄), filtered andconcentrated under reduced pressure to obtain the desired amine.

To this amine in CH₂Cl₂ (2 mL) was added 2M HCl in Et₂O (5 mL, 10 mmol)at 0° C. under inert atmosphere and stirred for 20 min. The obtainedsolid was filtered and dried under vacuum to afford compound 1-37 (20mg, 30%) as pale yellow solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.56 (br s,3H), 8.24 (s, 1H), 7.82 (s, 2H), 7.51-7.38 (m, 3H), 7.23 (t, J=8.0 Hz,1H), 6.91 (d, J=7.3 Hz, 1H), 6.30 (dd, J=3.2, 0.6 Hz, 1H), 4.21-4.16 (m,2H), 3.91 (s, 3H); MS (Agilent 6310 Ion Trap): m/z 388.3 (M+H⁺).

Example 50:2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-N-methyl-N-phenylacetamidehydrochloride (Compound 1-38)

Step 1:2-(4-((4-Cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-N-methyl-N-phenylacetamide(2)

To a stirred solution of 2-((1H-indol-4-yl) oxy)-6-(trifluoromethyl)isonicotinonitrile 1 (100 mg, 0.33 mmol) (from Example 49, Step 1) inDMF (3 mL) at 0° C., were added 2-bromo-N-methyl-N-phenylacetamide (113mg, 0.49 mmol), Cs₂CO₃ (214 mg, 0.66 mmol) and n-Bu₄NBr (5.3 mg, 0.02mmol). The mixture was warmed to RT and stirred for 12 h. The reactionmixture was quenched with water (20 mL) and extracted with EtOAc (2×30mL). The combined organic extracts were washed with brine (15 mL), dried(Na₂SO₄), filtered and concentrated under reduced pressure. The crudewas purified (silica gel; eluting 10-15% EtOAc/hexanes) to affordcompound 2 (130 mg, 87%) as an off-white solid. ¹H NMR (500 MHz,DMSO-d₆): δ 8.18 (s, 1H), 7.93 (s, 1H), 7.57-7.55 (m, 4H), 7.46-7.44 (m,1H), 7.22-7.12 (m, 3H), 6.89 (d, J=7.8 Hz, 1H), 6.14 (br s, 1H), 4.78(br s, 2H), 3.21 (br s, 3H); LC-MS (ESI): m/z 451.1 (M+H⁺).

Step 2: 2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-N-methyl-N-phenylacetamidehydrochloride (Compound 1-38)

To a stirred solution of compound 2 (130 mg, 0.29 mmol) in THF/MeOH(1:1, 6 mL) at 0° C. were added cobalt (II) chloride (74 mg, 0.58 mmol)and NaBH₄ (109 mg, 2.88 mmol) portion wise under inert atmosphere. Themixture was warmed to RT and stirred for 4 h. The reaction mixture wasfiltered through a pad of celite and the celite was washed with 10%MeOH/CH₂Cl₂ (30 mL). The filtrate was washed with brine (10 mL), dried(Na₂SO₄), filtered and concentrated under reduced pressure to obtain thedesired amine.

To this amine in CH₂Cl₂ (2 mL) was added 2 M HCl in Et₂O (3 mL, 6 mmol)at 0° C. under inert atmosphere and stirred for 30 min. The obtainedsolid was filtered and dried under vacuum to afford compound 1-38 (91mg, 70%) as an off-white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.37 (br s,3H), 7.78 (s, 1H), 7.59-7.47 (m, 5H), 7.40 (s, 1H), 7.24-7.13 (m, 3H),6.84 (d, J=8.4 Hz, 1H), 6.11 (d, J=3.0 Hz, 1H), 4.78 (br s, 2H), 4.20(br s, 2H), 3.22 (br s, 3H); MS (Agilent 6310 Ion Trap): m/z 455.3(M+H⁺).

Example 51:2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-1-(piperidin-1-yl)ethanone(Compound 1-56)

Step 1: 4-(Benzyloxy)-1H-indole (2)

To a stirred solution of 1H-indol-4-ol 1 (1 g, 7.52 mmol) in acetone (50mL) were added benzyl bromide (1.54 g, 8.95 mmol) and K₂CO₃ (3.11 g,22.56 mmol) at RT under inert atmosphere. The reaction mixture washeated to reflux temperature and stirred for 12 h. The mixture wasdiluted with water (60 mL) and extracted with EtOAc (2×60 mL). Thecombined organic extracts were washed with brine (20 mL), dried(Na₂SO₄), filtered, and concentrated under reduced pressure. The crudewas purified (silica gel; eluting 1-6% EtOAc/hexanes) to afford compound2 (650 mg, 41%) as colorless sticky solid. ¹H NMR (500 MHz, DMSO-d₆): δ11.08 (br s, 1H), 7.49 (d, J=7.5 Hz, 2H), 7.39 (t, J=7.5 Hz, 2H),7.34-7.29 (m, 1H), 7.21 (t, J=2.6 Hz, 1H), 7.01-6.92 (m, 2H), 6.55 (d,J=7.2 Hz, 1H), 6.45-6.43 (m, 1H), 5.20 (s, 2H); LC-MS: m/z 224.3 (M+H⁺).

Step 2: 2-(4-(Benzyloxy)-1H-indol-1-yl)-1-(piperidin-1-yl)ethan-1-one(3)

To a stirred solution of compound 2 (200 mg, 0.9 mmol) in DMF (10 mL) atRT were added 2-bromo-1-(piperidin-1-yl)ethan-1-one (277 mg, 1.34 mmol),Cs₂CO₃ (584 mg, 1.8 mmol) and n-Bu₄NBr (catalytic amount). The mixturewas stirred at RT for 12 h. The mixture was diluted with water (30 mL),stirred well and filtered. The obtained solid was dissolved in CH₂Cl₂,dried (Na₂SO₄), filtered and concentrated under reduced pressure. Thecrude was purified (silica gel; eluting 30% EtOAc/hexanes) to affordcompound 3 (150 mg, 48%) as an off-white solid. ¹H NMR (500 MHz,DMSO-d₆): δ 7.64 (d, J=7.2 Hz, 2H), 7.54 (t, J=7.5 Hz, 2H), 7.49-7.44(m, 1H), 7.29 (d, J=2.9 Hz, 1H), 7.15-7.05 (m, 2H), 6.73 (d, J=7.5 Hz,1H), 6.60 (d, J=3.2 Hz, 1H), 5.36 (s, 2H), 5.24 (s, 2H), 3.64 (br t,J=4.9 Hz, 2H), 3.55 (t, J=5.2 Hz, 2H), 1.76-1.65 (m, 4H), 1.58-1.56 (m,2H); LC-MS (ESI): m/z 349.0 (M+H⁺).

Step 3: 2-(4-Hydroxy-1H-indol-1-yl)-1-(piperidin-1-yl)ethan-1-one (4)

To a stirred solution of compound 3 (150 mg, 0.43 mmol) in EtOAc (30 mL)and MeOH (5 mL) was added 10% Pd/C (50% wet, 50 mg) under inertatmosphere. The reaction mixture was evacuated and stirred under H2atmosphere (balloon) at RT for 12 h. The reaction mixture was filteredthrough a pad of celite and washed with EtOAc (10 mL). The filtrate wasconcentrated under reduced pressure to afford compound 4 (80 mg, 72%) asan off-white solid. ¹H NMR (500 MHz, DMSO-d₆): δ 9.32 (s, 1H), 7.06 (d,J=3.2 Hz, 1H), 6.85 (t, J=7.8 Hz, 1H), 6.73 (d, J=8.1 Hz, 1H), 6.44 (d,J=2.9 Hz, 1H), 6.35 (d, J=7.5 Hz, 1H), 5.03 (s, 2H), 3.47 (t, J=5.2 Hz,2H), 3.39 (t, J=4.9 Hz, 2H), 1.61-1.48 (m, 4H), 1.43-1.40 (m, 2H); LC-MS(ESI): m/z 258.9 (M+H⁺).

Step 4:2-((1-(2-Oxo-2-(piperidin-1-yl)ethyl)-1H-indol-4-yl)oxy)-6-(trifluoromethyl)isonicotinonitrile(5)

To a stirred solution of compound 4 (80 mg, 0.31 mmol) inN-methyl-2-pyrrolidone (3 mL) were added2-chloro-6-(trifluoromethyl)isonicotinonitrile (77 mg, 0.37 mmol) andK₂CO₃ (86 mg, 0.62 mmol). The reaction mixture was heated to 150° C. ina microwave synthesizer for 1 h. The mixture was diluted with water (20mL) and extracted with EtOAc (2×30 mL). The combined organic extractswere washed with brine (20 mL), dried (Na₂SO₄), filtered andconcentrated under reduced pressure. The crude was purified (silica gel;eluting 30% EtOAc/hexanes) to afford compound 5 (30 mg, 23%) as anoff-white solid. ¹H NMR (500 MHz, DMSO-d₆): δ 8.19 (s, 1H), 7.94 (s,1H), 7.30 (d, J=8.4 Hz, 1H), 7.27 (d, J=3.2 Hz, 1H), 7.15 (t, J=8.0 Hz,1H), 6.89 (d, J=7.8 Hz, 1H), 6.16 (d, J=3.2 Hz, 1H), 5.19 (s, 2H),3.53-3.50 (m, 2H), 3.43 (t, J=5.5 Hz, 2H), 1.64-1.53 (m, 4H), 1.46-1.42(m, 2H); LC-MS (ESI): m/z 429.1 (M+H⁺).

Step 5:2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-1-(piperidin-1-yl)ethan-1-one(Compound 1-56)

To a stirred solution of compound 5 (30 mg, 0.07 mmol) in THF/MeOH (1:1,8 mL) at 0° C. were added CoCl₂ (18 mg, 0.14 mmol) and NaBH₄ (27 mg, 0.7mmol). The mixture was stirred at 0° C. for 1 h. The mixture wasfiltered, the filtrate was washed with water (15 mL) and extracted withEtOAc (2×20 mL). The combined organic layers were washed with brine (15mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure.The crude was triturated with n-pentane (2×5 mL) and then purified bypreparative HPLC to afford compound 1-56 (10 mg, 33%) as pale brownsolid. ¹H NMR (400 MHz, CD₃OD): δ 7.58 (s, 1H), 7.29-7.26 (m, 1H), 7.22(t, J=7.8 Hz, 1H), 7.16-7.11 (m, 2H), 6.90 (dd, J=7.5, 0.7 Hz, 1H), 6.20(dd, J=3.2, 0.7 Hz, 1H), 5.18 (s, 2H), 4.18 (s, 2H), 3.62-3.54 (m, 4H),1.75-1.68 (m, 2H), 1.66-1.61 (m, 2H), 1.60-1.53 (m, 2H); LC-MS (ESI):m/z 433.1 (M+H⁺).

Example 52: tert-Butyl4-(2-(4-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)acetyl)piperazine-1-carboxylate(Compound 1-57)

Step 1: tert-Butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (2)

To a stirred solution of tert-butyl piperazine-1-carboxylate 4 (1 g,5.38 mmol) in CH₂Cl₂ (15 mL) at 0° C., were added 2-bromoacetyl bromide(864 mg, 4.3 mmol) and TEA (1 mL, 7.53 mmol). The reaction mixture waswarmed to RT and stirred for 4 h. The mixture was quenched with water(50 mL) and extracted with CH₂Cl₂ (2×40 mL). The combined organicextracts were washed with brine (20 mL), dried (Na₂SO₄), filtered andconcentrated under reduced pressure. The crude was purified (silica gel;eluting 25% EtOAc/hexanes) to afford compound 2 (900 mg, 54%) as paleyellow solid. ¹H NMR (500 MHz, DMSO-d₆): δ 4.16 (s, 2H), 3.47-3.42 (m,4H), 3.38-3.35 (m, 2H), 3.31-3.29 (m, 2H), 1.41 (s, 9H); LC-MS (ESI):m/z 328.1 (M⁺+Na).

Step 2: tert-Butyl4-(2-(4-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)acetyl)piperazine-1-carboxylate(3)

To a stirred solution of2-((1H-indol-4-yl)oxy)-6-(trifluoromethyl)isonicotinonitrile 1 (150 mg,0.5 mmol) (from Example 49, Step 1) in DMF (12 mL) at 0° C., were addedtert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate 2 (228 mg, 0.74mmol), Cs₂CO₃ (324 mg, 0.99 mmol) and n-Bu₄NBr (8 mg, 0.02 mmol). Thereaction mixture was warmed to RT and stirred for 12 h. The mixture wasquenched with water (30 mL) and extracted with EtOAc (2×30 mL). Thecombined organic extracts were washed with brine (20 mL), dried(Na₂SO₄), filtered and concentrated under reduced pressure to obtain thecrude. The crude was triturated with Et₂O (2×10 mL) to afford compound 3(150 mg, 57%) as white solid. ¹H NMR (500 MHz, DMSO-d₆): δ 8.32 (s, 1H),8.09 (s, 1H), 7.47 (d, J=8.1 Hz, 1H), 7.40 (d, J=3.2 Hz, 1H), 7.29 (t,J=8.0 Hz, 1H), 7.03 (d, J=7.8 Hz, 1H), 6.31 (d, J=3.2 Hz, 1H), 5.37 (s,2H), 3.72-3.70 (m, 2H), 3.59-3.56 (m, 4H), 3.48-3.46 (m, 2H), 1.56 (s,9H); LC-MS (ESI): m/z 474.0 (M⁺−^(t)Bu).

Step 3: tert-Butyl4-(2-(4-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)acetyl)piperazine-1-carboxylate(Compound 1-57)

To a stirred solution of compound 3 (100 mg, 0.19 mmol) in THF/MeOH(1:1, 10 mL) at 0° C. were added CoCl₂ (61 mg, 0.5 mmol) and NaBH₄ (36mg, 0.94 mmol). The reaction was warmed to RT and stirred for 1 h. Themixture was filtered through a pad of celite. The filtrate was washedwith water (20 mL) and extracted with EtOAc (2×30 mL). The combinedorganic layers were washed with brine (15 mL), dried (Na₂SO₄), filtered,and concentrated under reduced pressure. The crude was purified bypreparative HPLC to afford compound 1-57 (23 mg, 15%) as white solid. ¹HNMR (500 MHz, DMSO-d₆): δ 7.61 (s, 1H), 7.28 (d, J=8.1 Hz, 1H),7.24-7.19 (m, 2H), 7.13 (t, J=8.0 Hz, 1H), 6.81 (d, J=7.5 Hz, 1H), 6.14(d, J=3.2 Hz, 1H), 5.22 (s, 2H), 3.79 (s, 2H), 3.57-3.55 (m, 2H),3.45-3.42 (m, 4H), 3.34-3.32 (m, 2H), 2.21 (b s, 2H), 1.42 (s, 9H);LC-MS (ESI): m/z 478.1 (M⁺−^(t)Bu).

Example 53:5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-3,4-dihydroquinolin-2(1H)-onehydrochloride (Compound 1-59)

Step 1:2-((2-Oxo-1,2,3,4-tetrahydroquinolin-5-yl)oxy)-6-(trifluoromethyl)isonicotinonitrile(2)

To a stirred solution of 5-hydroxy-3,4-dihydroquinolin-2(1H)-one 1 (50mg, 0.31 mmol) in N-methyl-2-pyrrolidone (3 mL) at RT, were added2-chloro-6-(trifluoromethyl)isonicotinonitrile (63 mg, 0.31 mmol) andK₂CO₃ (85 mg, 0.61 mmol). The mixture was stirred at RT for 3 h. Themixture was diluted with water (10 mL) and extracted with EtOAC (2×15mL). The combined organic extracts were washed with brine (10 mL), dried(Na₂SO₄), filtered, and concentrated under reduced pressure. The crudewas triturated with Et₂O (2×5 mL) to afford compound 2 (50 mg, 49%) aswhite solid. ¹H NMR (400 MHz, DMSO-d₆): δ 10.28 (s, 1H), 8.18 (s, 1H),7.97 (s, 1H), 7.23 (t, J=8.0 Hz, 1H), 6.85-6.78 (m, 2H), 2.65 (t, J=7.6Hz, 2H), 2.42-2.35 (m, 2H); LC-MS (ESI): m/z 332.1 (M−1).

Step 2:5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-3,4-dihydroquinolin-2(1H)-onehydrochloride (Compound 1-59)

To a stirred solution of compound 2 (50 mg, 0.15 mmol) in THF/MeOH (1:1,6 mL) at 0° C. were added CoCl₂ (39 mg, 0.3 mmol) and NaBH₄ (57 mg, 1.5mmol) under inert atmosphere; warmed to RT and stirred for 2 h. Themixture was diluted with EtOAc (20 mL), filtered through a pad of celiteand the celite pad was washed with EtOAc (10 mL). The filtrate waswashed with water (15 mL) and brine (10 mL). The organic layer wasseparated, dried (Na₂SO₄), filtered, and concentrated under reducedpressure. The crude was triturated with Et₂O (2×5 mL) to afford thedesired amine as pale brown solid.

To this amine in CH₂Cl₂ (2 mL) was added 2M HCl in Et₂O (0.5 mL) at 0°C. The mixture was warmed to RT and stirred for 15 min. The obtainedsolid was filtered and dried under vacuum to afford compound 1-59 (35mg, 69%) as an off-white solid. ¹H NMR (500 MHz, DMSO-d₆): δ 10.30 (s,1H), 8.43 (br s, 2H), 7.77 (s, 1H), 7.36 (s, 1H), 7.22 (t, J=8.1 Hz,1H), 6.81 (d, J=7.8 Hz, 1H), 6.75 (d, J=8.1 Hz, 1H), 4.19 (br s, 2H),2.60 (t, J=6.9 Hz, 2H), 2.40-2.36 (m, 2H); MS (Agilent 6310 Ion Trap):m/z 338.2 (M+H⁺).

Example 54: (6-(Trifluoromethyl)-[2,3′-bipyridin]-4-yl)methanaminetrifluoroacetate (Compound 1-1)

Step 1: 6-(Trifluoromethyl)-[2,3′-bipyridine]-4-carbonitrile (2)

A mixture of 2-chloro-6-(trifluoromethyl)isonicotinonitrile 1 (125 mg,0.605 mmol), 3-pyridylboronic acid (90 mg, 0.738 mmol), 2M aq. Na₂CO₃solution (0.6 mL), and ACN (3 mL) was purged with nitrogen at RT for 3min. [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexwith DCM (1:1) (5 mol %) was added, and the mixture heated at 100° C.for 4 h. The mixture was concentrated and purified via silica gelchromatography to afford compound 2 (114 mg, 76%) a as white solid. LCMSMass: 250 (M⁺+1).

Step 2: (6-(Trifluoromethyl)-[2,3′-bipyridin]-4-yl)methanaminetrifluoroacetate (Compound 1-1)

The title compound (1-1) (121 mg, 72%) was prepared from6-(trifluoromethyl)-[2,3′-bipyridine]-4-carbonitrile 2 using theprocedure for Example 31, Step 2. ¹H NMR (300 MHz, DMSO-d₆): δ 9.28 (m,1H), 8.75 (m, 1H), 8.49 (m, 1H), 8.43 (br s, 3H), 8.05 (s, 1H), 7.65 (m,1H), 4.26-4.34 (m, 2H); LCMS Mass: 254.0 (M⁺+1).

Example 55:(2-([1,1′-Biphenyl]-3-yloxy)-6-(trifluoromethyl)pyridin-4-yl)methanaminetrifluoroacetate (Compound 1-2)

Step 1:2-([1,1′-Biphenyl]-3-yloxy)-6-(trifluoromethyl)isonicotinonitrile (2)

A stirred mixture of 2-chloro-6-(trifluoromethyl)isonicotinonitrile 1(75 mg, 0.363 mmol), [1,1′-biphenyl]-3-ol (75 mg, 0.435 mmol), K₂CO₃(150 mg, 1.089 mmol), and THF (3 mL), was heated at 75° C. for 32 h.After cooling to RT, the mixture was concentrated and purified viasilica gel chromatography to afford compound 2 (75 mg, 61%) as acolorless oil. ¹H NMR (300 MHz, DMSO-d₆): δ 8.20 (m, 1H), 8.03 (m, 1H),7.50-7.70 (m, 2H), 7.35-7.48 (m, 3H), 7.20 (m, 1H), 6.90-7.08 (m, 3H).

Step 2:(2-([1,1′-Biphenyl]-3-yloxy)-6-(trifluoromethyl)pyridin-4-yl)methanaminetrifluoroacetate (Compound 1-2)

The title compound (1-2) (51 mg, 69%) was prepared from2-([1,1′-biphenyl]-3-yloxy)-6-(trifluoromethyl)isonicotinonitrile 2using the procedure for Example 31, Step 2. ¹H NMR (300 MHz, DMSO-d₆): δ8.36 (br s, 3H), 7.79 (m, 1H), 7.65-7.71 (m, 2H), 7.55-7.62 (m, 2H),7.35-7.61 (m, 5H), 7.18 (m, 1H), 4.19-4.26 (m, 2H); LCMS Mass: 345.0(M⁺+1).

Example 56:(2-(3-Phenoxyphenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanaminetrifluoroacetate (Compound 1-3)

The title compound (1-3) was prepared using the procedure for Example55, using 3-phenoxyphenol in Step 1. LCMS Mass: 361.0 (M⁺+1).

Example 57:(2-(3-(Phenoxymethyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanaminetrifluoroacetate (Compound 1-4)

Step 1:2-(3-(Hydroxymethyl)phenoxy)-6-(trifluoromethyl)isonicotinonitrile (2)

The title compound (2) (250 mg, 59%) was prepared using the procedurefor Example 55, Step 1, using 3-(hydroxymethyl)phenol. ¹H NMR (300 MHz,DMSO-d₆): δ 8.18 (s, 1H), 7.97 (s, 1H), 7.40 (m, 1H), 7.22 (m, 1H), 7.14(m, 1H), 7.08 (m, 1H), 5.29 (m, 1H), 4.49-4.53 (m, 2H); LCMS Mass: 295.0(M⁺+1).

Step 2:2-(3-(Phenoxymethyl)phenoxy)-6-(trifluoromethyl)isonicotinonitrile (3)

To a solution of Ph₃P (49 mg, 0.186 mmol) in THF (1 mL) at 0° C., wasadded diisopropyl azodicarboxylate (38 mg, 0.186 mmol). The mixture waswarmed to RT and stirred for 15 min.2-(3-(Hydroxymethyl)phenoxy)-6-(trifluoromethyl)isonicotinonitrile 2 (50mg, 0.169 mmol) was added and the mixture stirred for a further 15 min.Phenol (16 mg, 0.169 mmol) was added and the mixture stirred at RT for16 h. The mixture was partitioned between EtOAc (10 mL) and water (10mL). The organic layer was separated, dried (Na₂SO₄), filtered, and thenconcentrated under reduced pressure. The residue was purified via silicagel chromatography to afford compound 3 (25 mg, 40%) as a colorless oil.LCMS Mass: 371.0 (M⁺+1).

Step 3:(2-(3-(Phenoxymethyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanaminetrifluoroacetate trifluoroacetate (Compound 1-4)

The title compound (1-4) (17 mg, 59%) was prepared from2-(3-(phenoxymethyl)phenoxy)-6-(trifluoromethyl)isonicotinonitrile 3using the procedure for Example 31, Step 2. ¹H NMR (300 MHz, DMSO-d₆): δ8.38 (br s, 3H), 7.77 (s, 1H), 7.25-7.55 (m, 6H), 7.18 (m, 1H),6.90-7.00 (m, 3H), 5.12 (s, 2H), 4.18-4.22 (m, 2H); LCMS Mass: 375.0(M⁺+1).

Example 58:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylaniline(Compound 1-5)

The title compound (1-5) was prepared using the procedure for Example55, using 3-(phenylamino)phenol in Step 1. Compound 1-5 did not requireHPLC purification, rather the obtained solid was triturated with Et₂O toafford pure 1-5. LCMS Mass: 360.0 (M⁺+1).

Example 59:(2-(3-(1H-Pyrazol-4-yl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanaminetrifluoroacetate (Compound 1-6)

The title compound (1-6) was prepared using the procedure for Example55, using 3-(1H-pyrazol-4-yl)phenol in Step 1. LCMS Mass: 335.0 (M⁺+1).

Example 60:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-cyanoethyl)benzamidehydrochloride (Compound 1-198)

The title compound (1-198) was prepared using the procedure for Example1, using 3-aminopropionitrile in Step 1. LCMS Mass: 365.0 (M⁺+1).

Example 61:1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)azetidine-3-carbonitriletrifluoroacetate (Compound 1-199)

The title compound (1-199) was prepared using the procedure for Example1, using 3-cyanoazetidine hydrochloride in Step 1. LCMS Mass: 377.0(M⁺+1).

Example 62:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(oxetan-3-yl)benzamidetrifluoroacetate (Compound 1-200)

The title compound (1-200) was prepared using the procedure for Example1, using oxetan-3-amine hydrochloride in Step 1, and trifluoroaceticacid in DCM in Step 2. ¹H NMR (300 MHz, DMSO-d₆): δ 8.36 (br s, 3H),7.74-7.81 (m, 2H), 7.58-7.63 (m, 2H), 7.39-7.45 (m, 2H), 4.49-4.57 (m,2H), 4.32-4.40 (m, 2H), 4.20-4.27 (m, 2H), 3.54 (m, 1H).

Example 63:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((1-hydroxycyclobutyl)methyl)benzamidehydrochloride (Compound 1-201)

The title compound (1-201) was prepared using the procedure for Example1, using 1-(aminomethyl)cyclobutanol in Step 1. LCMS Mass: 396.0 (M⁺+1).

Example 64:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-hydroxyethyl)-N-methylbenzamidehydrochloride (Compound 1-202)

The title compound (1-202) was prepared using the procedure for Example1, using 2-(methylamino)ethanol in Step 1. ¹H NMR (300 MHz, DMSO-d₆): δ8.73 (br s, 3H), 7.83-8.01 (m, 2H), 7.51-7.66 (m, 2H), 7.21-7.30 (m,2H), 4.51 (m, 1H), 4.16-4.24 (m, 2H), 3.25-3.36 (m, 2H), 2.94 (s, 3H).

Example 65:(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-(hydroxymethyl)piperidin-1-yl)methanonehydrochloride (Compound 1-203)

The title compound (1-203) was prepared using the procedure for Example1, using (5)-piperidin-3-ylmethanol in Step 1. LCMS Mass: 410.0 (M⁺+1).

Example 66:(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(4-(hydroxymethyl)piperidin-1-yl)methanonehydrochloride (Compound 1-204)

The title compound (1-204) was prepared using the procedure for Example1, using 4-hydroxymethylpiperidine hydrochloride in Step 1. LCMS Mass:410.0 (M⁺+1).

Example 67:(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(4-hydroxy-4-methylpiperidin-1-yl)methanonehydrochloride (Compound 1-205)

The title compound (1-205) was prepared using the procedure for Example1, using 4-hydroxy-4-methylpiperidine hydrochloride in Step 1. LCMSMass: 410.0 (M⁺+1).

Example 68:(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-(methoxymethyl)azetidin-1-yl)methanonehydrochloride (Compound 1-206)

The title compound (1-206) was prepared using the procedure for Example1, using 3-(methoxymethyl)azetidine hydrochloride in Step 1. ¹H NMR (300MHz, DMSO-d₆): δ 8.66 (br s, 3H), 7.85 (m, 1H), 7.78 (m, 1H), 7.66 (m,1H), 7.51-7.59 (m, 2H), 7.39 (m, 1H), 4.20-4.24 (m, 2H), 3.68-3.72 (m,2H), 3.28-3.48 (m, 4H), 3.24 (s, 3H), 2.27 (m, 1H).

Example 69:(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(7-oxa-2-azaspiro[3.5]nonan-2-yl)methanonehydrochloride (Compound 1-207)

The title compound (1-207) was prepared using the procedure for Example1, using 7-oxa-2-azaspiro[3.5]nonane hydrochloride in Step 1. LCMS Mass:422.0 (M⁺+1).

Example 70:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)benzamidehydrochloride (Compound 1-208)

The title compound (1-208) was prepared using the procedure for Example1, using (3S,4S)-3-aminotetrahydro-2H-pyran-4-ol in Step 1. LCMS Mass:412.0 (M⁺+1).

Example 71:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((1R,2S)-2-hydroxycyclopentyl)benzamidehydrochloride (Compound 1-209)

The title compound (1-209) was prepared using the procedure for Example1, using (1S,2R)-2-aminocyclopentanol hydrochloride in Step 1. LCMSMass: 396.0 (M⁺+1).

Example 72:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((1S,2R)-2-hydroxycyclopentyl)benzamidehydrochloride (Compound 1-210)

The title compound (1-210) was prepared using the procedure for Example1, using (1R,2S)-2-aminocyclopentanol hydrochloride in Step 1. LCMSMass: 396.0 (M⁺+1).

Example 73:Racemic-cis-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-211)

Step 1: Racemic-tert-butyl((2-(3-(3-fluoro-4-oxopyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(2)

To a stirred solution of compound 1 (400 mg, 0.8 mmol) (from Example 13,Step 1) in CH₂Cl₂ (15 mL) at 0° C. under an inert atmosphere, was addedDess-Martin periodinane (1.36 g, 3.21 mmol) portion wise. The reactionmixture was gradually warmed to RT and stirred for an additional 5 h.The mixture was diluted with CH₂Cl₂ (50 mL) and washed with ice coldsat. NaHCO₃(20 mL). The organic layer was separated, washed with brine(15 mL), dried (Na₂SO₄), filtered and concentrated in vacuo to affordcompound 2 (390 mg) as a pale brown solid, which was used withoutfurther purification.

Step 2: Racemic-cis-tert-butyl((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(3)

To a stirred solution of compound 2 (390 mg, crude) in MeOH (15 mL) at0° C. under an inert atmosphere, was added NaBH₄ (119 mg, 3.14 mmol)portion wise. The reaction mixture was gradually warmed to RT andstirred for an additional 5 h. The volatiles were removed under reducedpressure (at 35° C.). The residue was dissolved in EtOAc (50 mL), washedwith water (15 mE) and brine (15 mL). The organic layer was separated,dried (Na₂SO₄), filtered and concentrated. The residue was purified(silica gel; eluting 20-50% EtOAc/hexanes) to afford compound 3 (110 mg,28% over two steps) as a pale brown solid. ¹H NMR (500 MHz, DMSO-d₆): δ7.59 (m, 1H), 7.49-7.55 (m, 2H), 7.29-7.43 (m, 3H), 7.15 (s, 1H), 5.48(m, 1H), 4.87 (m, 1H), 4.15-4.34 (m, 3H), 3.46-3.82 (m, 3H), 3.26 (m,1H), 1.39 (s, 9H). Chiral HPLC analysis: Observe two peaks;R_(t)=14.21and 15.31 min (Chiral Pak ADH, 250×4.6 mm, 5 μm column,eluting isocratically with 10% MeOH:EtOH (1:1) and 90% hexanes(containing 0.1% DEA) over 25 mins; flow rate 1.0 mL/min).

Step 3:Racemic-cis-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-211)

To a stirred solution of compound 3 (50 mg, 0.1 mmol) in CH₂Cl₂ (1 mL)at 0° C., was added 2M HCl in Et₂O (1 mL, 2 mmol). The reaction mixturewas gradually warmed to RT and stirred for an additional 12 h. Then thevolatiles were removed, and the residue was triturated with Et₂O (2×2mL) and dried under vacuum to afford compound 1-211 (30 mg, 77%) as apale brown solid. ¹H NMR (500 MHz, DMSO-d₆): δ 8.50 (br s, 3H), 7.83 (s,1H), 7.56 (m, 1H), 7.50 (br s, 1H), 7.43 (m, 1H), 7.30-7.35 (m, 2H),5.50 (m, 1H), 4.89 (m, 1H), 4.21-4.24 (m, 3H), 3.46-3.82 (m, 3H), 3.26(m, 1H); LCMS Mass: 400.0 (M⁺+1).

Example 74:(R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoropyrrolidin-1-yl)methanonehydrochloride (Compound 1-212)

The title compound (1-212) was prepared using the procedure for Example1, using (R)-3-fluoropyrrolidine hydrochloride in Step 1. LCMS Mass:384.0 (M⁺+1).

Example 75:(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoropyrrolidin-1-yl)methanonehydrochloride (Compound 1-213)

The title compound (1-213) was prepared using the procedure for Example1, using (S)-3-fluoropyrrolidine hydrochloride in Step 1. LCMS Mass:384.0 (M⁺+1).

Example 76:(3R,4R)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)-4-fluoropyrrolidin-3-ylmethanesulfonatehydrochloride (Compound 1-214)

Step 1:(3R,4R)-1-(3-((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)-4-fluoropyrrolidin-3-ylmethanesulfonate (2)

To a stirred solution of (R,R)-trans-tert-butyl((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate1 (58 mg, 0.116 mmol) (from Example 13, Step 2) and DIEA (30 mg, 0.232mmol) in DCM (1 mL) at 0° C., was added methanesulfonyl chloride (14 mg,0.118 mmol). The mixture was warmed to RT and stirred for 2 h.Additional methanesulfonyl chloride (5 mg, 0.039 mmol) was added, andthe mixture stirred for 30 min. The mixture was concentrated underpressure and the residue purified (silica gel; eluting 0-100%EtOAc/hexanes) to afford compound 2 (53 mg, 79%) as an white solid. LCMSMass: 578.0 (M⁺+1).

Step 2:(3R,4R)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)-4-fluoropyrrolidin-3-ylmethanesulfonate(Compound 1-214)

The title compound (1-214) (42 mg, 89%) was prepared from compound 2using the procedure for Example 1, Step 2. ¹H NMR (300 MHz, DMSO-d₆): δ8.56 (br s, 3H), 7.82 (s, 1H), 7.30-7.60 (m, 5H), 5.20-5.50 (br m, 2H),4.21 (s, 2H), 3.60-4.10 (m, 4H), 3.31 (s, 3H); LCMS Mass: 478.0 (M⁺+1).

Example 77:(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(2,5-dihydro-1H-pyrrol-1-yl)methanonehydrochloride (Compound 1-215)

The title compound (1-215) was prepared using the procedure for Example1, using 2,5-dihydro-1H-pyrrole hydrochloride in Step 1. ¹H NMR (300MHz, DMSO-d₆): δ 8.62 (br s, 3H), 7.83 (m, 1H), 7.51-7.56 (m, 2H),7.39-7.44 (m, 2H), 7.29 (m, 1H), 5.93 (m, 1H), 5.80 (m, 1H), 4.16-4.30(m, 6H).

Example 78:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(hex-5-yn-1-yl)benzamidetrifluoroacetate (Compound 1-216)

The title compound (1-216) was prepared using the procedure for Example1, using hex-5-ynylamine hydrochloride in Step 1. LCMS Mass: 392.0(M⁺+1).

Example 79:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-(1-phenyl-1H-1,2,3-triazol-4-yl)butyl)benzamidehydrochloride (Compound 1-217)

Step 1: tert-Butyl((2-(3-(hex-5-yn-1-ylcarbamoyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(1)

The title compound (1) (610 mg, 86%) was prepared following theprocedure for Example 1, Step 1, using hex-5-ynylamine hydrochloride.LCMS Mass: 492.0 (M⁺+1).

Step 2: tert-Butyl((2-(3-((4-(1-phenyl-1H-1,2,3-triazol-4-yl)butyl)carbamoyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(2)

To a stirred solution of compound 1 (50 mg, 0.10 mmol) in DMSO (0.6 mL)and water (1.4 mL) at 0° C., were added azidobenzene (0.22 mL of a 0.5Msolution in TBME, 0.11 mmol), CuSO₄ (13 mol %), sodium L-(+)-ascorbate(25 mol %), and benzoic acid (10 mol %). The mixture was warmed to RTand stirred for 20 h. The mixture was partitioned between water andEtOAc.

The organic layer was separated, dried (Na₂SO₄), and concentrated underreduced pressure. The residue was purified (silica gel; eluting 80%EtOAc/hexanes) to afford compound 2 (38 mg, 62%) as a white solid. LCMSMass: 611.0 (M⁺+1).

Step 3:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-(1-phenyl-H-1H,2,3-triazol-4-yl)butyl)benzamidehydrochloride (Compound 1-217)

The title compound (1-217) was prepared from compound 2 (30 mg, 88%)using the procedure for Example 1, Step 2. ¹H NMR (300 MHz, DMSO-d₆): δ8.50-8.63 (m, 5H), 7.80-7.88 (m, 3H), 7.75 (m, 1H), 7.40-7.62 (m, 6H),7.34 (m, 1H), 4.18-4.28 (m, 2H), 3.22-3.38 (m, 2H), 2.70-2.80 (m, 2H),1.55-1.80 (m, 4H); LCMS Mass: 511.0 (M⁺+1).

Example 80:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-hydroxybenzamidehydrochloride (Compound 1-218)

The title compound (1-218) was prepared using the procedure for Example1, using hydroxylamine hydrochloride in Step 1. LCMS Mass: 328.0 (M⁺+1).

Example 81:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-methoxybenzamidehydrochloride (Compound 1-219)

The title compound (1-219) was prepared using the procedure for Example1, using O— methylhydroxylamine in Step 1. LCMS Mass: 342.0 (M⁺+1).

Examples 82 and 83: Methyl(S)-3-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoate(Compound 1-220) and(S)-3-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoicacid (Compound 1-221)

Step 1: Methyl(S)-3-(3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoate(2)

To a stirred solution of Int-A (200 mg, 0.48 mmol) in DMF (8 mL) at RT,were added methyl (S)-3-aminopent-4-ynoate hydrochloride (62 mg, 0.48mmol) (prepared following procedures described in J. A. Zablocki et al,J. Med. Chem. 1995, 38, 2378), HATU (277 mg, 0.73 mmol), and DIEA (0.25mL, 1.46 mmol), and the mixture was stirred at RT for 16 h. The mixturewas quenched with water (20 mL) and extracted with EtOAc (2×20 mL). Thecombined organic extracts were washed with brine (10 mL), dried(Na₂SO₄), filtered and concentrated. The residue was purified (silicagel; eluting 30-35% EtOAc/hexanes) to afford compound 2 (60 mg, 24%) asan off-white sticky solid. ¹H NMR (500 MHz, DMSO-d₆): δ 8.94 (br m, 1H),7.75 (m, 1H), 7.64 (s, 1H), 7.53-7.59 (m, 2H), 7.50 (s, 1H), 7.38 (br m,1H), 7.11 (s, 1H), 5.08 (m, 1H), 4.25 (br m, 2H), 3.59 (s, 3H), 3.25 (m,1H), 2.77-2.88 (m, 2H), 1.37 (s, 9H); LCMS Mass: 544.1 (M⁺+Na).

Step 2: Methyl(S)-3-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoate(Compound 1-220) &(S)-3-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoicacid (Compound 1-221)

To a stirred solution of compound 2 (60 mg, 0.11 mmol) in CH₂Cl₂ (1 mL)at 0° C. under an inert atmosphere, was added 2M HCl in Et₂O (1 mL, 2mmol). The reaction mixture was gradually warmed to RT and stirred for16 h. The volatiles were removed, and the residue was triturated withn-pentane (2×2 mL), then Et₂O (2×2 mL), and dried under vacuum to obtaina solid which was purified (via preparative HPLC) to afford compound1-220 (7 mg, 14%) as a colorless oil, and compound 1-221 (6.5 mg, 14%)as a white solid.

Compound 1-220: ¹H NMR (500 MHz, CD₃OD): δ 7.70 (m, 1H), 7.61 (m, 1H),7.51-7.55 (m, 2H), 7.36 (m, 1H), 7.22 (s, 1H), 5.26 (m, 1H), 3.92 (s,2H), 3.69 (s, 3H), 2.87 (m, 2H), 2.75 (m, 1H); LCMS Mass: 422.0 (M⁺+1).

Compound 1-221: ¹H NMR (500 MHz, CD₃OD): δ 7.74 (m, 1H), 7.63 (s, 1H),7.54-7.58 (m, 2H), 7.39 (m, 1H), 7.30 (s, 1H), 5.11 (m, 1H), 4.16 (s,2H), 2.67 (br m, 2H), 2.62 (m, 1H); LCMS Mass: 408.0 (M⁺+1).

Examples 84 and 85: Methyl(R)-3-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoatehydrochloride (Compound 1-222) and(R)-3-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoicacid hydrochloride (Compound 1-223))

The title compounds (1-222 and 1-223) were prepared using the procedurefor Examples 82 and 83, using methyl (R)-3-aminopent-4-ynoatehydrochloride (prepared following procedures described in J. A. Zablockiet al, J. Med. Chem. 1995, 38, 2378) in Step 1.

Compound 1-222: ¹H NMR (500 MHz, CD₃OD): δ 7.87 (br m, 1H), 7.77-7.79(m, 2H), 7.71 (m, 1H), 7.48-7.55 (m, 2H), 5.41 (m, 1H), 4.45 (s, 2H),3.84 (s, 3H), 3.03 (m, 2H), 2.91 (m, 1H); LCMS Mass: 421.9 (M⁺+1).

Compound 1-223: ¹H NMR (500 MHz, CD₃OD): δ 7.88 (m, 1H), 7.77-7.79 (m,2H), 7.71 (m, 1H), 7.53 (m, 1H), 7.49 (s, 1H), 5.39 (m, 1H), 4.44 (s,2H), 2.99 (m, 2H), 2.89 (m, 1H); LCMS Mass: 407.9 (M⁺+1).

Example 86:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acidhydrochloride (Compound 1-224)

The title compound (1-224) was prepared from Int-A using the procedurefor Example 1, Step 2. LCMS Mass: 313.0 (M⁺+1).

Example 87:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-aminophenyl)benzamidehydrochloride (Compound 1-225)

The title compound (1-225) was prepared using the procedure for Example1, using 5-aminopyrimidine in Step 1. ¹H NMR (300 MHz, DMSO-d₆): δ 10.42(br s, 1H), 8.66 (br s, 3H), 8.00 (m, 1H), 7.84-7.89 (m, 2H), 7.63 (m,1H), 7.56 (m, 1H), 7.41-7.48 (m, 2H), 7.16-7.30 (m, 3H), 4.20-4.24 (m,2H).

Example 88:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(pyrimidin-5-yl)benzamidehydrochloride (Compound 1-226)

The title compound (1-226) was prepared using the procedure for Example1, using 5-aminopyrimidine in Step 1. LCMS Mass: 390.0 (M⁺+1).

Example 89:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(oxazol-2-yl)benzamidehydrochloride (Compound 1-227)

The title compound (1-227) was prepared using the procedure for Example1, using 2-aminooxazole in Step 1. LCMS Mass: 379.0 (M⁺+1).

Example 90:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(1,3,4-oxadiazol-2-yl)benzamidehydrochloride (Compound 1-228)

The title compound (1-228) was prepared using the procedure for Example1, using 1,3,4-oxadiazol-2-amine in Step 1. ¹H NMR (300 MHz, DMSO-d₆): δ8.74 (br s, 3H), 7.88 (m, 1H), 7.53-7.70 (m, 6H), 7.36 (m, 1H),4.20-4.30 (m, 2H).

Example 91:Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-4-hydroxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-229)

To a stirred solution of racemic-trans-tert-butyl((2-(2-(benzyloxy)-5-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(20 mg, 0.04 mmol) (from Example 93, Step 6) in MeOH (10 mL) at RT, wereadded conc. HCl (1 drop) and 10% Pd/C (50% wet, 2 mg). The reactionmixture was stirred at RT under H2 (1 atmosphere) for 1 h. The mixturewas filtered through celite washing with MeOH (8 mL). The filtrate wasconcentrated and the residue was triturated with Et₂O (2×1 mL) to affordcompound 1-229 (15 mg, 91%) as an off-white solid. ¹H NMR (400 MHz,CD₃OD): δ 7.61 (s, 1H), 7.34-7.40 (m, 3H), 7.04 (m, 1H), 4.95 (m, 1H),4.37 (m, 1H), 4.30 (br s, 2H), 3.78-4.05 (m, 2H), 3.73 (m, 1H), 3.60 (m,1H); LCMS Mass: 416.0 (M⁺+1).

Example 92:Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-hydroxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-230)

Step 1: Methyl3-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-hydroxybenzoate (3)

To a stirred solution of methyl 3,5-dihydroxybenzoate 2 (163 mg, 0.97mmol) in DMF (10 mL) at RT, were added K₂CO₃ (161 mg, 1.16 mmol) and2-chloro-6-(trifluoromethyl)isonicotinonitrile 1 (200 mg, 0.97 mmol).The reaction mixture was stirred at RT for 16 h. The mixture wasquenched with water (20 mL) and extracted with EtOAc (2×20 mL), and thecombined organic extracts were washed with brine (10 mL), dried(Na₂SO₄), filtered and concentrated. The residue was purified (silicagel; eluting 20-25% EtOAc/hexanes) to afford compound 3 (110 mg, 34%) asa white solid. ¹H NMR (500 MHz, CDCl₃): δ 7.59 (s, 1H), 7.41-7.44 (m,2H), 7.36 (s, 1H), 6.90 (br s, 1H), 3.91 (s, 3H); LCMS Mass: 339.1(M⁺+1).

Step 2: Methyl3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-hydroxybenzoate(4)

To a stirred solution of compound 3 (500 mg, 1.48 mmol) in THF (5 mL)and MeOH (10 mL) at ° 0 C under an inert atmosphere, were added CoCl₂(572 mg, 4.44 mmol) and NaBH₄ (562 mg, 14.8 mmol) portion wise. Thereaction mixture was gradually warmed to RT and stirred for 1 h. Themixture was quenched with ice cold water (20 mL) and filtered through apad of celite. The filtrate was extracted with EtOAc (2×30 mL). Thecombined organic extracts were washed with brine (20 mL), dried(Na₂SO₄), filtered, and concentrated to afford compound 4 (415 mg) as anoff white solid, which was used without further purification. ¹H NMR(500 MHz, DMSO-d₆): δ 7.67 (s, 1H), 7.29 (s, 1H), 7.24 (m, 1H), 7.12 (m,1H), 6.82 (m, 1H), 3.84 (s, 2H), 3.82 (s, 3H), 2.2 (br s, 2H); LCMSMass: 342.9 (M⁺+1).

Step 3: Methyl3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-hydroxybenzoate(5)

To a stirred solution of compound 4 (410 mg, crude) in THF (10 mL) atRT, were added (Boc)₂O (0.33 mL, 1.44 mmol) and TEA (0.33 mL, 2.4 mmol).The mixture was stirred at RT for 16 h. The mixture was quenched withwater (20 mL) and extracted with EtOAc (2×30 mL). The combined organicextracts were washed with brine (20 mL), dried (Na₂SO₄), filtered andconcentrated. The residue was purified (silica gel; eluting 30-40%EtOAc/hexanes) to afford compound 5 (490 mg, 75% over two steps) as awhite solid. ¹H NMR (500 MHz, CDCl₃): δ 7.40 (m, 1H), 7.33 (m, 1H),6.95-7.07 (m, 2H), 6.89 (m, 1H), 5.04 (br s, 1H), 4.37-4.41 (m, 2H),3.90 (s, 3H), 1.47 (br s, 9H); LCMS Mass: 443.0 (M⁺+1).

Step 4:3-((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-hydroxybenzoicacid (6)

To a stirred solution of compound 5 (245 mg, 0.55 mmol) in MeOH (3 mL)and water (3 mL) at RT, was added LiOH.H₂O (46 mg, 1.1 mmol), and themixture was stirred at RT for 16 h. The MeOH was removed under reducedpressure and the mixture was quenched with water (15 mL), acidified withcitric acid to pH ˜3, and extracted with EtOAc (2×20 mL). The combinedorganic extracts were washed with brine (10 mL), dried (Na₂SO₄),filtered and concentrated to afford compound 6 (200 mg, 84%) as a paleyellow viscous oil. ¹H NMR (500 MHz, DMSO-d₆): δ 12.99 (br s, 1H), 10.10(s, 1H), 7.55 (m, 1H), 7.50 (s, 1H), 7.23 (m, 1H), 7.07 (m, 2H), 6.79(m, 1H), 4.24 (m, 2H), 1.36 (s, 9H); LCMS Mass: 429.0 (M⁺+1).

Step 5: Racemic-trans-tert-butyl((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)-5-hydroxyphenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(7)

To a stirred solution of compound 6 (200 mg, 0.47 mmol) in CH₂Cl₂ (5 mL)at RT, were added EDCI hydrochloride (178 mg, 0.93 mmol), HOBt (32 mg,0.23 mmol), racemic-trans-4-fluoropyrrolidin-3-ol hydrochloride (99 mg,0.7 mmol) and DIEA (0.16 mL, 0.93 mmol). The mixture was stirred at RTfor 16 h. The mixture was quenched with water (20 mL) and extracted withCH₂Cl₂ (2×20 mL). The combined organic extracts were washed with brine(15 mE), dried (Na₂SO₄), filtered and concentrated. The residue waspurified (silica gel; eluting 3-5% MeOH/CH₂Cl₂) to afford compound 7(150 mg, 62%) as an off white solid. LCMS Mass: 538.0 (M⁺+Na).

Step 6:Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-hydroxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-230)

To a stirred solution of compound 7 (125 mg, 0.24 mmol) in CH₂Cl₂ (3 mL)at 0° C., was added 2M HCl in Et₂O (3 mL, 6 mmol). The reaction mixturewas gradually warmed to RT and stirred for 16 h. The volatiles wereremoved in vacuo and the crude was purified (preparative HPLC) to affordcompound 1-230 (45 mg, 41%) as a colorless oil. ¹H NMR (400 MHz, CD₃OD):δ 7.62 (s, 1H), 7.31 (s, 1H), 6.84 (m, 1H), 6.78 (m, 1H), 6.73 (m, 1H),5.06 (m, 1H), 4.95 (m, 1H), 4.39 (m, 1H), 4.29 (s, 3H), 3.69-3.99 (m,4H), 3.63 (m, 1H), 3.50 (m, 1H), as a mixture of rotamers; LCMS Mass:416.0 (M⁺+1).

Example 93:Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-4-(benzyloxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone(Compound 1-231)

Step 1: Methyl 4-(benzyloxy)-3-hydroxybenzoate (2)

To a stirred solution of diisopropyl azodicarboxylate (0.9 mL, 4.46mmol) and PPh₃ (1.17 g, 4.46 mmol) in THF (40 mL) at 0° C., was addedbenzyl alcohol (321 mg, 2.98 mmol) and the mixture stirred for 10 min.Methyl 3,4-dihydroxybenzoate 1 (500 mg, 2.98 mmol) in THF (10 mL) wasadded and the mixture was allowed to warm to RT and stirred for 6 h. Themixture was concentrated and the crude was purified (silica gel; eluting5% EtOAc/hexanes) to afford compound 2 (350 mg, 45%) as an off whitesolid. ¹H NMR (500 MHz, CDCl₃): δ 7.57-7.62 (m, 2H), 7.41-7.43 (m, 4H),7.26 (s, 1H), 6.95 (m, 1H), 5.68 (s, 1H), 5.17 (s, 2H), 3.88 (s, 3H);LCMS Mass: 256.9 (M−H⁺).

Step 2: Methyl4-(benzyloxy)-3-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate(3)

To a stirred solution of compound 2 (350 mg, 1.36 mmol) in DMF (10 mL)at 0° C., were added 2-chloro-6-(trifluoromethyl)isonicotinonitrile (279mg, 1.36 mmol) and K₂CO₃ (281 mg, 2.03 mmol). The mixture was graduallywarmed to RT and stirred for 4 h. The mixture was diluted with water (20mL) and extracted with EtOAc (2×30 mL). The combined organic extractswere washed with brine (20 mL), dried (Na₂SO₄), filtered andconcentrated. The residue was purified (silica gel; eluting 2%EtOAc/hexanes) to afford compound 3 (540 mg, 93%) as an off white solid.¹H NMR (500 MHz, CDCl₃): δ 7.96 (m, 1H), 7.88 (m, 1H), 7.46 (s, 1H),7.33 (s, 1H), 7.26-7.28 (m, 3H), 7.03-7.07 (m, 3H), 5.04 (s, 2H), 3.90(s, 3H); LCMS Mass: 427.1 (M−H⁺).

Step 3: Methyl3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-4-(benzyloxy)benzoate(4)

To a stirred solution of compound 3 (540 mg, 1.26 mmol) in THF (10 mL)and MeOH (20 mL) at 0° C. under an inert atmosphere, was added CoCl₂(488 mg, 3.78 mmol), followed by NaBH₄ (479 mg, 12.62 mmol) portionwise. The mixture was stirred at 0° C. for 10 min. The mixture wasquenched with ice cold water (30 mL) and filtered through celite. Thefiltrate was extracted with EtOAc (2×30 mL), washed with brine (20 mL),dried (Na₂SO₄), filtered and concentrated to afford compound 4 (540 mg)as a green oil. This was used without further purification. LCMS Mass:433.3 (M⁺+1).

Step 4: Methyl4-(benzyloxy)-3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate(5)

To a stirred solution of compound 4 (540 mg, crude) in THF (50 mL) at 0°C., were added (Boc)₂O (0.34 mL, 1.5 mmol) and Et₃N (0.26 mL, 1.87mmol). The reaction mixture was gradually warmed to RT and stirred for 4h. The mixture was diluted with water (20 mL) and extracted with EtOAc(2×30 mL). The combined organic extracts were washed with brine (20 mL),dried (Na₂SO₄), filtered and concentrated. The residue was purified(silica gel; eluting 15% EtOAc/hexanes) to afford compound 5 (350 mg,53% over two steps) as a colorless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.90(m, 1H), 7.86 (m, 1H), 7.23-7.25 (m, 4H), 7.06-7.10 (m, 2H), 6.96-7.02(m, 2H), 5.06 (s, 2H), 4.90 (br s, 1H), 4.34 (m, 2H), 3.89 (s, 3H), 1.53(s, 9H).

Step 5:4-(Benzyloxy)-3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoicacid (6)

To a stirred solution of compound 5 (350 mg, 0.66 mmol) in MeOH (15 mL)and water (5 mL) at 0° C., was added LiOH.H₂O (55 mg, 1.31 mmol). Thereaction mixture was gradually warmed to RT and stirred for 12 h. Themixture was concentrated and the obtained residue was diluted with water(20 mL) and acidified with citric acid to pH ˜4. The precipitated solidwas filtered and dried under vacuum to afford compound 6 (208 mg, 61%)as an off white solid. ¹H NMR (500 MHz, DMSO-d₆): δ 12.86 (br s, 1H),7.86 (m, 1H), 7.72 (m, 1H), 7.60 (m, 1H), 7.47 (s, 1H), 7.32 (m, 1H),7.22-7.26 (m, 3H), 7.12 (s, 1H), 6.98-7.01 (m, 2H), 5.13 (s, 2H), 4.25(m, 2H), 1.38 (s, 9H); LCMS Mass: 519.0 (M⁺+1).

Step 6: Racemic-trans-tert-butyl((2-(2-(benzyloxy)-5-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(7)

To a stirred solution of compound 6 (208 mg, 0.4 mmol) in CH₂Cl₂ (15 mL)at 0° C., were added racemic-trans-4-fluoropyrrolidin-3-ol hydrochloride(73 mg, 0.52 mmol), EDCI hydrochloride (115 mg, 0.6 mmol), HOBt (54 mg,0.4 mmol) and DIEA (0.21 mL, 1.2 mmol). The reaction mixture wasgradually warmed to RT and stirred for 12 h. The mixture was dilutedwith water (15 mL) and extracted with CH₂Cl₂ (2×20 mL). The combinedorganic extracts were washed with brine (10 mL), dried (Na₂SO₄),filtered and concentrated. The residue was purified (silica gel; eluting40% EtOAc/hexanes) to afford compound 7 (113 mg, 46%) as an off whitesolid. ¹H NMR (400 MHz, DMSO-d₆): δ 7.59 (br m, 1H), 7.45-7.52 (m, 3H),7.22-7.29 (m, 4H), 7.13 (s, 1H), 7.01-7.04 (m, 2H), 5.56 (m, 1H), 5.11(s, 2H), 5.00 (m, 1H), 4.25 (m, 2H), 4.20 (m, 1H), 3.38-3.92 (m, 4H),1.39 (s, 9H), as a mixture of rotamers.

Step 7:Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-4-(benzyloxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone(Compound 1-231)

To a stirred solution of compound 7 (110 mg, 0.2 mmol) in CH₂Cl₂ (5 mL)at 0° C., was added 2M HCl in Et₂O (12 mL, 24 mmol) and the mixture waswarmed to RT and stirred for 12 h. The mixture was concentrated and theresidue purified (preparative HPLC) to afford compound 1-231 (40 mg,40%) as a colorless oil. ¹H NMR (400 MHz, CD₃OD): δ 7.56 (s, 1H), 7.50(m, 1H), 7.44 (m, 1H), 7.33 (s, 1H), 7.23-7.28 (m, 4H), 7.12-7.15 (m,2H), 5.10 (s, 2H), 4.96 (m, 1H), 4.36 (m, 1H), 4.25 (s, 2H), 4.02 (m,1H), 3.69-3.94 (m, 3H), 3.60 (n, 1H), as a mixture of rotamers; LCMSMass: 506.3 (M⁺+1).

Example 94:Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-methoxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-232)

Step 1: Racemic-trans-tert-butyl((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)-5-methoxyphenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(2)

To a stirred solution of racemic-trans-tert-butyl((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)-5-hydroxyphenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate1 (24 mg, 0.046 mmol) (from Example 92, Step 5) in THF (3 mL) at 0° C.,were added K₂CO₃ (13 mg, 0.091 mmol) and iodomethane (13 mg, 0.091mmol). The mixture was warmed to RT and stirred for 16 h. The mixturewas cooled to 0° C. and to this were added iodomethane (26 mg, 0.183mmol) and DMF (1.5 mL). The mixture was stirred at RT for 3 h. Themixture was concentrated under reduced pressure and dried under vacuumto afford 2 (45 mg) as a white solid, which was not purified further.LCMS Mass: 530.0 (M⁺+1).

Step 2:Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-methoxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-232)

The title compound (1-232) was prepared from compound 2 (37 mg) usingthe procedure for Example 1, Step 2. ¹H NMR (300 MHz, DMSO-d₆): δ 8.80(br s, 3H), 7.87 (m, 1H), 7.52 (m, 1H), 6.91-6.95 (m, 3H), 5.67 (m, 1H),4.79-5.08 (m, 2H), 4.10-4.30 (m, 3H), 3.79 (s, 3H), 3.40-3.70 (br m,3H); LCMS Mass: 430.0 (M⁺+1).

Example 95:1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)pyridin-2(1H)-one(Compound 1-169)

Step 1: 1-(3-Methoxyphenyl)pyridin-2(1H)-one (2)

To a stirred solution of pyridin-2-ol 1 (500 mg, 5.26 mmol) in CH₂Cl₂(40 mL) at RT, were added (3-methoxyphenyl)boronic acid (1.59 g, 10.53mmol), Cu(OAc)₂ (209 mg, 1.05 mmol), pyridine (0.8 mL, 10.53 mmol) and 4Å MS (cat.). The mixture was stirred at RT under 02 atmosphere for 24 h.The mixture was filtered through celite, washed with EtOAc (50 mL) andthe filtrate was concentrated. The residue was dissolved in water (20mL), diluted with sat. aq. CuSO₄ (20 mL), then extracted with CH₂Cl₂(2×30 mL). The combined organic extracts were washed with brine (20 mL),dried (Na₂SO₄), filtered, and concentrated. The obtained residue waspurified (silica gel; eluting 35% EtOAc/hexanes) to afford compound 2(760 mg, 76%) as an off-white solid. ¹H NMR (500 MHz, DMSO-d₆): δ 7.61(m, 1H), 7.49 (m, 1H), 7.40 (m, 1H), 7.01 (m, 1H), 6.91-6.97 (m, 2H),6.45 (m, 1H), 6.29 (m, 1H), 3.77 (s, 3H); LCMS Mass: 201.9 (M⁺+1).

Step 2: 1-(3-Hydroxyphenyl)pyridin-2(1H)-one (3)

To a stirred solution of compound 2 (170 mg, 0.84 mmol) in CH₂Cl₂ (10mL) at 0° C. under an inert atmosphere, was added BBr₃ (0.16 mL, 1.69mmol). The mixture was warmed to RT and stirred for 2 h. The mixture wasquenched with sat. aq. NaHCO₃(20 mL) and extracted with CH₂Cl₂ (2×20mL). The combined organic extracts were washed with brine (10 mL), driedover Na₂SO₄, filtered and concentrated. The crude was triturated withEt₂O (2×5 mL) to afford compound 3 (65 mg, 41%) as an off white solid.¹H NMR (500 MHz, DMSO-d₆): δ 9.81 (s, 1H), 7.59 (dd, J=6.9, 1.7 Hz, 1H),7.46-7.51 (m, 1H), 7.29 (t, J=8.0 Hz, 1H), 6.83 (dd, J=8.1, 1.4 Hz, 1H),6.74-6.78 (m, 2H), 6.45 (d, J=9.3 Hz, 1H), 6.28 (td, J=6.7, 1.2 Hz, 1H);LCMS Mass: 187.9 (M⁺+1).

Step 3:2-(3-(2-Oxopyridin-1(2H)-yl)phenoxy)-6-(trifluoromethyl)isonicotinonitrile(4)

A mixture of 2-chloro-6-(trifluoromethyl)isonicotinonitrile (200 mg,0.97 mmol), compound 3 (181 mg, 0.97 mmol), K₂CO₃ (268 mg, 1.94 mmol),and DMF (5 mL), was stirred at RT for 12 h. The mixture was diluted withwater (20 mL) and extracted with EtOAc (2×20 mL). The combined organicextracts were washed with brine (15 mL), dried (Na₂SO₄), filtered andconcentrated. The residue was purified (silica gel; eluting 50%EtOAc/hexanes) to afford compound 4 (220 mg, 77%) as an off-white solid.¹H NMR (400 MHz, DMSO-d₆): δ 8.23 (s, 1H), 8.05 (s, 1H), 7.58-7.67 (m,2H), 7.50 (m, 1H), 7.33-7.41 (m, 3H), 6.49 (m, 1H), 6.33 (m, 1H); LCMSMass: 357.9 (M⁺+1).

Step 4:1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)pyridin-2(1H)-one (Compound 1-169)

To a stirred solution of compound 5 (150 mg, 0.42 mmol) in THF/MeOH(1:1, 10 mL) at 0° C. under an inert atmosphere, were added CoCl₂ (136mg, 1.05 mmol) and NaBH₄ (80 mg, 2.11 mmol) portion wise. The mixturewas stirred at 0° C. for 30 min. The mixture was diluted with EtOAc (20mL) and water (20 mL), filtered through a pad of celite and washed withEtOAc (15 mL). The filtrate was washed with water (15 mL), brine (10mL), dried (Na₂SO₄), filtered and concentrated to obtain the desiredamine. To this amine was added 4 M HCl in 1,4-dioxane (5 mL) at 0° C.and stirred at RT for 30 min. Then the mixture was concentrated in vacuoto obtain the crude which was purified (via preparative HPLC) to affordcompound 1-169 (24 mg, 15%) as an off white solid. ¹H NMR (400 MHz,DMSO-d₆): δ 7.64-7.68 (m, 2H), 7.57 (m, 1H), 7.50 (m, 1H), 7.25-7.34 (m,4H), 6.48 (m, 1H), 6.32 (m, 1H), 3.84 (s, 2H), 2.21 (br s, 2H); LCMSMass: 361.9 (M⁺+1).

Example 96:5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1-(2-hydroxyethyl)-3,4-dihydroquinolin-2(1H)-onehydrochloride (Compound 1-60)

Step 1: Ethyl2-(5-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate (1)

To a stirred solution of ethyl2-(5-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate(120 mg, 0.28 mmol) (from Example 97) in CH₂Cl₂ (20 mL) at RT, wereadded (Boc)₂O (0.1 mL, 0.42 mmol) and TEA (0.08 mL, 0.57 mmol). Themixture was stirred at RT for 3 h. The mixture was diluted with water(15 mL) and extracted with CH₂Cl₂ (2×15 mL), washed with brine (10 mL),dried (Na₂SO₄), filtered and concentrated. The residue was purified(silica gel; eluting 20% EtOAc/hexanes) to afford compound 1 (100 mg,67%) as an off white solid. ¹H NMR (500 MHz, DMSO-d₆): δ 7.58 (m, 1H),7.47 (s, 1H), 7.29 (m, 1H), 7.06 (s, 1H), 6.90 (m, 2H), 4.67 (s, 2H),4.24 (m, 2H), 4.13 (m, 2H), 2.61-2.67 (m, 2H), 2.51-2.53 (m, 2H), 1.36(s, 9H), 1.19 (m, 3H); LCMS Mass: 546.1 (M⁺+Na).

Step 2: tert-Butyl((2-((1-(2-hydroxyethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-5-yl)oxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(2)

To a stirred solution of compound 1 (50 mg, 0.009 mmol) in EtOH (2 mL)at RT under an inert atmosphere, was added NaBH₄ (54 mg, 1.43 mmol), andthe mixture was stirred at RT for 20 h. The mixture was diluted withwater (15 mL), acidified with citric acid to pH ˜3 and extracted withEtOAc (2×15 mL), washed with brine (10 mL), dried over Na₂SO₄, filteredand concentrated. The residue was purified (silica gel; eluting 40%EtOAc/hexanes) to afford compound 2 (20 mg, 43%) as a pale brown stickysolid. ¹H NMR (400 MHz, CDCl₃): δ 7.29 (s, 1H), 7.25 (m, 1H), 6.93-7.02(m, 2H), 6.85 (m, 1H), 5.03 (br s, 1H), 4.38 (m, 2H), 4.18 (m, 2H), 3.98(m, 2H), 2.74-2.80 (m, 2H), 2.59-2.64 (m, 2H), 1.46 (s, 9H); LCMS Mass:482.1 (M⁺+1).

Step 3:5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1-(2-hydroxyethyl)-3,4-dihydroquinolin-2(1H)-onehydrochloride (Compound 1-60)

To a stirred solution of compound 2 (20 mg, 0.04 mmol) in Et₂O (5 mL) at0° C., was added 4 M HCl in 1,4-dioxane (2 mL). The mixture wasgradually warmed to RT and stirred for 4 h. The volatiles were removedunder reduced pressure. The residue was triturated with Et₂O (2×1 mL),n-pentane (2×1 mL) and dried under vacuum. The crude was dissolved inwater (2 mL) and concentrated under reduced pressure to afford compound1-60 (10 mg, 58%) as an off white sticky solid. ¹H NMR (400 MHz, CD₃OD):δ 7.62 (s, 1H), 7.31-7.38 (m, 2H), 7.26 (m, 1H), 6.87 (m, 1H), 4.30 (s,2H), 4.13 (m, 2H), 3.80 (m, 2H), 2.73-2.78 (m, 2H), 2.54-2.59 (m, 2H);LCMS Mass: 381.9 (M⁺+1).

Example 97: Ethyl2-(5-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate(Compound 1-235)

Step 1: 5-(Benzyloxy)-3,4-dihydroquinolin-2(1H)-one (2)

To a stirred solution of 5-hydroxy-3,4-dihydroquinolin-2(1H)-one 1 (2 g,12.27 mmol) in acetonitrile (80 mL) at RT, were added Cs₂CO₃ (6 g, 18.4mmol) and benzyl bromide (1.46 mL, 12.27 mmol). The mixture was heatedto reflux for 4 h. After cooling to RT, the mixture was diluted withwater (50 mL) and stirred for 20 min. The precipitated solid wascollected via filtration, washed with water (15 mL) and dried undervacuum to afford compound 2 (2.5 g, 81%) as an off white solid. ¹H NMR(500 MHz, DMSO-d₆): δ 10.05 (s, 1H), 7.44-7.47 (m, 2H), 7.40 (m, 2H),7.33 (m, 1H), 7.08 (m, 1H), 6.70 (m, 1H), 6.49 (m, 1H), 5.10 (s, 2H),2.84 (m, 2H), 2.41 (m, 2H); LCMS Mass: 254.0 (M⁺+1).

Step 2: Ethyl2-(5-(benzyloxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate (3)

To a stirred solution of compound 2 (2.5 g, 9.88 mmol) in THF (80 mL) atRT under an inert atmosphere, was added NaH (60% in mineral oil, 593 mg,14.82 mmol) at RT, and the mixture stirred for 30 min. To this was addedethyl 2-bromoacetate (2.47 g, 14.82 mmol), and the mixture was stirredat RT for 12 h. The mixture was quenched with ice cold water (50 mL) andextracted with EtOAc (2×50 mL). The combined organic extracts werewashed with brine (25 mL), dried (Na₂SO₄), filtered and concentrated.The residue was purified (silica gel; eluting 20% EtOAc/hexanes) toafford compound 3 (2 g, 61%) as an off white solid. ¹H NMR (500 MHz,DMSO-d₆): δ 7.43-7.47 (m, 2H), 7.39 (m, 2H), 7.32 (m, 1H), 7.16 (m, 1H),6.83 (m, 1H), 6.57 (m, 1H), 5.13 (s, 2H), 4.62 (s, 2H), 4.11 (m, 2H),2.86 (m, 2H), 2.53 (m, 2H), 1.18 (t, J=7.2 Hz, 3H); LCMS Mass: 340.0(M⁺+1).

Step 3: Ethyl 2-(5-hydroxy-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate(4)

To a stirred solution of compound 3 (2 g, 5.9 mmol) in EtOAc (50 mL) andMeOH (20 mL) at RT, was added 10% Pd/C (50% wet, ˜800 mg). The mixturewas stirred at RT under H2 (1 atmosphere) for 12 h. The mixture wasfiltered through celite washing with MeOH (30 mL). The filtrate wasconcentrated under reduced pressure and the crude was triturated withn-pentane (2×10 mL) to afford compound 4 (1.4 g, 95%) as an off whitesolid. ¹H NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 7.00 (m, 1H), 6.57 (m,1H), 6.38 (m, 1H), 4.60 (s, 2H), 4.12 (m, 2H), 2.76-2.81 (m, 2H),2.51-2.54 (m, 2H), 1.19 (m, 3H); LCMS Mass: 250.0 (M⁺+1).

Step 4: Ethyl2-(5-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate(5)

To a stirred solution of compound 4 (200 mg, 0.8 mmol) inN-methyl-2-pyrrolidone (5 mL) at RT, were added K₂CO₃ (222 mg, 1.61mmol) and 2-chloro-6-(trifluoromethyl)isonicotinonitrile (182 mg, 0.88mmol) and the mixture was stirred for 12 h. The mixture was diluted withwater (15 mL) and stirred for 20 min. The obtained solid was collectedvia filtration, which was dissolved in CH₂Cl₂ (50 mL), dried (Na₂SO₄),filtered and concentrated. The residue was triturated with n-pentane(2×2 mL) to afford compound 5 (210 mg, 62%) as an off white solid. ¹HNMR (500 MHz, DMSO-d₆): δ 8.21 (s, 1H), 8.04 (s, 1H), 7.32 (m, 1H), 6.94(m, 2H), 4.70 (s, 2H), 4.15 (m, 2H), 2.65-2.70 (m, 2H), 2.50-2.55 (m,2H), 1.20 (m, 3H); LCMS Mass: 420.0 (M⁺+1).

Step 5: Ethyl2-(5-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate(Compound 1-235)

To a stirred solution of compound 5 (158 mg, 0.38 mmol) in ethanol (10mL) at RT, was added PtO₂ (16 mg). The reaction mixture was stirred atRT under H2 (1 atmosphere) for 4 h. The mixture was filtered through apad of celite washing with EtOH (10 mL). The filtrate was concentratedunder reduced pressure and the crude was triturated with n-pentane (2×5mL) to afford compound 1-235 (126 mg, 79%) as a pale brown solid. ¹H NMR(400 MHz, DMSO-d₆): δ 7.62 (s, 1H), 7.26-7.33 (m, 2H), 6.89 (dd, J=8.2,4.0 Hz, 2H), 4.69 (s, 2H), 4.15 (q, J=7.1 Hz, 2H), 3.83 (s, 2H),2.65-2.70 (m, 2H), 2.51-2.55 (m, 2H), 2.03 (br s, 2H), 1.21 (t, J=7.2Hz, 3H); LCMS Mass: 424.3 (M⁺+1).

Example 98:2-(5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)aceticacid hydrochloride (Compound 1-236)

Step 1:2-(5-((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)aceticacid (2)

To a stirred solution of ethyl2-(5-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate 1 (35 mg, 0.07 mmol) (from Example 96, Step 1) in amixture of ethanol/water (1:1, 10 mL) at RT, was added LiOH monohydrate(3 mg, 0.13 mmol), and the mixture was stirred for 3 h. The volatiles(ethanol) were removed under reduced pressure. The residue was dilutedwith water (10 mL), acidified with citric acid to pH ˜4 and extractedwith EtOAc (2×10 mL). The combined organic extracts were washed withbrine (8 mL), dried (Na₂SO₄), filtered, and concentrated under reducedpressure. The residue was purified via trituration with Et₂O (2×3 mL),followed by n-pentane (2×3 mL) and dried under vacuum to afford compound2 (28 mg, 85%) an off white solid. LCMS Mass: 496.1 (M⁺+1).

Step 2:2-(5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)aceticacid hydrochloride (Compound 1-236)

To compound 2 (28 mg, 0.06 mmol) was added HCl (4M solution in1,4-dioxane, 5 mL, 20 mmol). The mixture was stirred at RT for 2 h. Themixture was concentrated under reduced pressure. The residue waspurified via trituration with Et₂O (2×2 mL), followed by n-pentane (2×2mL) and dried under vacuum to afford compound 1-236 (19 mg, 76%) as anoff white solid.

¹H NMR (400 MHz, DMSO-d₆): δ 12.63 (br s, 1H), 8.61 (br s, 3H), 7.83 (s,1H), 7.47 (s, 1H), 7.33 (t, J=8.3 Hz, 1H), 6.90 (dd, J=8.3, 1.8 Hz, 2H),4.60 (s, 2H), 4.21 (s, 2H), 2.64-2.69 (m, 2H), 2.52-2.55 (m, 2H); LCMSMass: 395.9 (M⁺+1).

Example 99:2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-1-(piperazin-1-yl)ethan-1-onedihydrochloride (Compound 1-233)

To a stirred solution of tert-butyl4-(2-(4-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)acetyl)piperazine-1-carboxylate1-57 (100 mg, 0.19) (from Example 52) in 1,4-dioxane (1 mL) at 0° C.,was added 4 M HCl in 1,4-dioxane (5 mL). The mixture was warmed to RTand stirred for 1 h. The mixture was concentrated in vacuo and the crudetriturated with EtOAc (2×3 mL) then purified (preparative HPLC) toafford the title compound (18 mg, 22%) as an off-white solid. ¹H NMR(400 MHz, DMSO-d₆): δ 8.97 (br s, 2H), 8.39 (br s, 3H), 7.77 (s, 1H),7.42 (s, 1H), 7.33 (m, 1H), 7.23 (m, 1H), 7.15 (m, 1H), 6.85 (m, 1H),6.16 (m, 1H), 5.27 (s, 2H), 4.21-4.23 (m, 2H), 3.78-3.80 (m, 2H),3.65-3.67 (m, 2H), 3.25-3.27 (m, 2H), 3.05-3.16 (m, 2H); LCMS Mass:433.9 (M⁺+1).

Example 100:2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-N-carbamimidoylacetamidedihydrochloride (Compound 1-234)

Step 1: Ethyl2-(4-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)acetate(2)

To a stirred solution of2-((1H-indol-4-yl)oxy)-6-(trifluoromethyl)isonicotinonitrile 1 (440 mg,1.46 mmol) (from Example 49, Step 1) in DMF (5 mL) at RT, were addedethyl 2-bromoacetate (487 mg, 2.91 mmol), Cs₂CO₃ (983 mg, 4.37 mmol) andNBu₄I (234 mg, 0.73 mmol). The mixture was stirred at RT for 12 h. Themixture was diluted with water (25 mL) and extracted with EtOAc (2×30mL). The combined organic extracts were washed with brine (15 mL), dried(Na₂SO₄), filtered and concentrated. The residue was purified (silicagel; eluting 10% EtOAc/hexanes) to afford compound 2 (370 mg, 65%) as anoff white solid. ¹H NMR (500 MHz, DMSO-d₆): δ 8.17 (s, 1H), 7.95 (s,1H), 7.30-7.37 (m, 2H), 7.16 (m, 1H), 6.90 (m, 1H), 6.18 (m, 1H), 5.15(s, 2H), 4.13 (m, 2H), 1.19 (m, 3H); LCMS Mass: 390.0 (M⁺+1).

Step 2: Ethyl2-(4-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)acetate(3)

To a stirred solution of compound 2 (310 mg, 0.8 mmol) in THF/MeOH (1:1,20 mL) at 0° C. under an inert atmosphere, were added CoCl₂ (76 mg, 2.0mmol) followed by NaBH₄ (257 mg, 2.0 mmol) portion wise, and the mixturestirred for 10 min. The mixture was filtered through a pad of celite andthe filtrate was concentrated to afford compound 3 (230 mg) as a palebrown semi solid which was used without further purification. LCMS Mass:394.3 (M⁺+1).

Step 3: Ethyl2-(4-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)acetate (4)

To a stirred solution of compound 3 (230 mg, crude) in CH₂Cl₂ (40 mL) atRT, were added TEA (0.24 mL, 1.76 mmol) followed by (Boc)₂O (0.15 mL,0.64 mmol), and the mixture was stirred for 12 h. The mixture wasquenched with water (20 mL) and extracted with EtOAc (2×20 mL). Thecombined organic extracts were washed with brine (15 mL), dried(Na₂SO₄), filtered and concentrated. The crude was purified (silica gel;eluting 10% EtOAc/hexanes) to afford compound 4 (191 mg, 49% over twosteps) as a pale brown solid. ¹H NMR (500 MHz DMSO-d₆): δ 7.56 (m, 1H),7.47 (s, 1H), 7.31-7.35 (m, 2H), 7.16 (m, 1H), 7.02 (s, 1H), 6.85 (m,1H), 6.17 (m, 1H), 5.16 (s, 2H), 4.22 (m, 2H), 4.16 (m, 2H), 1.34 (s,9H), 1.22 (m, 3H); LCMS Mass: 494.1 (M⁺+1).

Step 4:2-(4-((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)aceticacid (5)

To a stirred solution of compound 4 (140 mg, 0.28 mmol) in THF/MeOH(1:1, 10 mL) at RT, was added LiOH.H₂O (60 mg, 1.42 mmol), and themixture stirred for 2 h. The volatiles were removed under reducedpressure. The residue was diluted with water (15 mL) and washed withEtOAc (2×5 mL). The organic layer was separated, and the aqueous layerwas acidified with saturated citric acid solution to pH ˜3 and extractedwith CH₂Cl₂ (2×15 mL). The combined organic extracts were washed withbrine (10 mL), dried (Na₂SO₄), filtered and concentrated in vacuo toafford compound 5 (110 mg, 83%) as an off white solid, which did notrequire further purification. ¹H NMR (400 MHz, DMSO-d₆): δ 7.52 (m, 1H),7.47 (s, 1H), 7.28-7.32 (m, 2H), 7.14 (m, 1H), 6.99 (s, 1H), 6.82 (m,1H), 6.13 (m, 1H), 4.89 (s, 2H), 4.20 (m, 2H), 1.34 (s, 9H).

Step 5:2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-N-Boc-carbamimidoylacetamide(7)

To a stirred solution of compound 5 (31 mg, 0.07 mmol) in DMF (5 mL) andTHF (1 mL) at RT, were added HATU (38 mg, 0.1 mmol) and DIEA (0.03 mL,0.2 mmol), and the mixture stirred for 15 min. To this was addedN-Boc-guanidine 6 (16 mg, 0.1 mmol) and the mixture was stirred at RTstirred for 12 h. The mixture was concentrated, and the residue wasdiluted with water (10 mL) then extracted with EtOAc (2×10 mL). Thecombined organic extracts were washed with brine (8 mL), dried (Na₂SO₄),filtered and concentrated. The residue was purified (silica gel; eluting10% EtOAc/hexanes) to afford compound 7 (35 mg, 62%) as an off whitesolid. ¹H NMR (500 MHz, DMSO-d₆): δ 11.11 (br s, 1H), 8.62 (br s, 1H),7.54 (m, 1H), 7.47 (s, 1H), 7.26-7.34 (m, 2H), 7.15 (m, 1H), 7.01 (s,1H), 6.83 (m, 1H), 6.16 (br s, 1H), 5.01 (br s, 2H), 4.21 (m, 2H), 1.43(s, 9H), 1.34 (s, 9H); LCMS Mass: 629.2 (M⁺+Na).

Step 6:2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-N-carbamimidoylacetamidedihydrochloride (Compound 1-234)

To a stirred solution of compound 7 (30 mg, 0.05 mmol) in MeOH (1 mL) at0° C., was added HCl in MeOH (2 mL). The reaction mixture was graduallywarmed to RT and stirred for 12 h. The volatiles were removed and thecrude was purified (preparative HPLC) to afford compound 1-234 (10 mg,43%) as an off white solid. ¹H NMR (400 MHz, CD₃OD): δ 7.61 (s, 1H),7.33 (m, 1H), 7.21-7.28 (m, 3H), 6.93 (m, 1H), 6.31 (m, 1H), 5.21 (s,2H), 4.25 (s, 2H); LCMS Mass: 407.0 (M⁺+1).

Example 101:1-(2-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-6-azaspiro[3.4]octan-6-yl)ethanonehydrochloride (Compound 1-244)

Step 1: tert-Butyl2-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)-6-azaspiro[3.4]octane-6-carboxylate(3)

A mixture of tert-butyl 2-hydroxy-6-azaspiro[3.4]octane-6-carboxylate 1(950 mg, 4.18 mmol), 2-chloro-6-(trifluoromethyl)isonicotinonitrile 2(1.03 g, 4.99 mmol), Cs₂CO₃ (2.73 g, 8.4 mmol), and DMF (22 mL), wasstirred at RT for 16 h. The mixture was partitioned between water,brine, aq. 1M HCl, and EtOAc. The organic layer was separated and theaq. layer re-extracted with additional EtOAc. The combined organiclayers were dried (MgSO₄), filtered, and concentrated under reducedpressure. The residue was purified (silica gel; eluting 0-40%EtOAc/hexanes) to afford compound 3 (1.04 g, 63%) as a yellow oil. ¹HNMR (300 MHz, DMSO-d₆): δ 8.00 (m, 1H), 7.77 (m, 1H), 5.14 (m, 1H),3.10-3.30 (m, 6H), 2.00-2.20 (m, 2H), 1.80-2.00 (m, 2H), 1.36 (s, 9H);LCMS Mass: 342.0 (M⁺+1−C₄H9).

Step 2:2-(6-Azaspiro[3.4]octan-2-yloxy)-6-(trifluoromethyl)isonicotinonitrilehydrochloride (4)

A mixture of compound 3 (935 mg, 2.35 mmol), HCl (2M in Et₂O, 5 mL, 10mmol), and DCM (5 mL), was stirred at RT for 16 h. The mixture wasconcentrated under reduced pressure and dried, to afford compound 4 (775mg, 99%) as a white solid, which did not require further purification.

¹H NMR (300 MHz, DMSO-d₆): δ 9.11 (br s, 2H), 8.02 (m, 1H), 7.78 (m,1H), 5.15 (m, 1H), 3.00-3.40 (m, 5H), 2.62 (m, 1H), 2.10-2.40 (m, 2H),2.00-2.20 (m, 2H); LCMS Mass: 298.0 (M⁺+1).

Step 3:2-((6-Acetyl-6-azaspiro[3.4]octan-2-yl)oxy)-6-(trifluoromethyl)isonicotinonitrile(5)

To a stirred mixture of compound 4 (100 mg, 0.30 mmol), DIEA (0.116 mg,0.899 mmol), and THF (1.5 mL) at RT, was added acetyl chloride (23 mg,0.30 mmol). The mixture was stirred at RT for 3 h. The mixture wasconcentrated under reduced pressure. The residue was purified directly(silica gel; eluting 0-100% EtOAc/hexanes) to afford compound 5 (38 mg,38%) as a colorless oil. ¹H NMR (300 MHz, DMSO-d₆): δ 8.01 (m, 1H), 7.78(m, 1H), 5.15 (m, 1H), 3.20-3.40 (m, 6H), 2.10-2.30 (m, 2H), 1.80-2.00(m, 5H); LCMS Mass: 340.0 (M⁺+1).

Step 4:1-(2-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-6-azaspiro[3.4]octan-6-yl)ethanonehydrochloride (Compound 1-244)

To a stirred solution of compound 5 (38 mg, 0.112 mmol) in THF/MeOH(1:1, 2 mL) at 0° C. were added CoCl₂ (29 mg, 0.224 mmol) and NaBH₄ (42mg, 1.12 mmol) portion-wise under inert atmosphere. The reaction waswarmed to RT and stirred for 45 min. The reaction mixture wasconcentrated under reduced pressure and the residue obtained wasdissolved in EtOAc. This was filtered through a pad of celite and theresidue was washed with 10% MeOH/CH₂Cl₂. The filtrate was washed withbrine (10 mL), dried (MgSO₄), filtered, and concentrated under reducedpressure to obtain the desired amine.

To this amine in CH₂Cl₂ (2 mL) was added HCl (2M in Et₂O, 2 mL, 4 mmol)and the mixture stirred at RT for 10 min. The obtained solid wasfiltered and dried under vacuum to afford compound 1-244 (25 mg, 59%) asa white solid. LCMS Mass: 344.0 (M⁺+1).

Example 102:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)thio)-N-phenylbenzamidehydrochloride (Compound 1-68)

The title compound (1-68) was prepared using the procedure for Example1, using Int-M in Step 1.

¹H NMR (500 MHz, DMSO-d₆): δ 10.40 (s, 1H), 8.45 (br s, 3H), 8.21 (m,1H), 8.12 (m, 1H), 7.72-7.85 (m, 4H), 7.67 (m, 1H), 7.48 (m, 1H),7.30-7.35 (m, 2H), 7.10 (m, 1H), 4.07-4.17 (m, 2H); LCMS Mass: 404.0(M⁺+1).

Example 103:3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)-N-phenylbenzamidehydrochloride (Compound 1-105)

The title compound (1-105) was prepared using the procedure for Example1, using Int-L in Step 1.

¹H NMR (500 MHz, DMSO-d₆): δ 10.21 (s, 1H), 8.24 (br s, 3H), 7.90-7.96(m, 2H), 7.82 (m, 1H), 7.74 (m, 2H), 7.53 (m, 1H), 7.47 (m, 1H), 7.33(m, 2H), 7.05-7.11 (m, 2H), 6.79 (s, 1H), 4.57 (m, 2H), 3.99 (m, 2H);LCMS Mass: 401.3 (M⁺+1).

Example 104:3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)-N-(2-(methylsulfonyl)ethyl)benzamidehydrochloride (Compound 1-106)

The title compound (1-106) was prepared using the procedure for Example1, using Int-L and 2-(methylsulfonyl)ethan-1-amine hydrochloride inStep 1. ¹H NMR (400 MHz, DMSO-d₆): δ 8.70 (m, 1H), 8.34 (br s, 3H), 7.91(m, 1H), 7.84 (s, 1H), 7.69 (m, 1H), 7.49 (m, 1H), 7.40 (m, 1H), 7.08(s, 1H), 6.80 (s, 1H), 4.53 (m, 2H), 3.98 (m, 2H), 3.61-3.69 (m, 2H),3.32-3.37 (m, 2H), 3.01 (s, 3H); LCMS Mass: 431.3 (M⁺+1).

Example 105:(S)-(3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)phenyl)(3-hydroxypyrrolidin-1-yl)methanonehydrochloride (Compound 1-237

The title compound (1-237) was prepared using the procedure for Example1, using Int-L and (S)-pyrrolidin-3-ol in Step 1. ¹H NMR (500 MHz,DMSO-d₆): δ 8.48 (br s, 3H), 7.93 (br s, 1H), 7.41-7.48 (m, 2H),7.33-7.39 (m, 2H), 7.11 (s, 1H), 6.83 (s, 1H), 4.53 (s, 2H), 4.31 (m,1H), 4.20 (m, 1H), 3.96-3.99 (m, 2H), 3.45-3.59 (m, 2H), 3.34 (m, 1H),3.14 (m, 1H), 1.70-1.97 (m, 2H); LCMS Mass: 395.1 (M⁺+1).

Example 106:N′-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-N³-phenylisophthalamidetrifluoroacetate (Compound 1-240)

Step 1: 2-Chloro-6-(trifluoromethyl)isonicotinamide (1)

To a stirred solution of 2-chloro-4-iodo-6-(trifluoromethyl)pyridine (5g, 16.29 mmol) in N-methyl-2-pyrrolidone (20 mL) at RT under an inertatmosphere, was added CuCN (5.84 g, 65.15 mmol). The reaction mixturewas heated at 120° C. for 3 h. The mixture was cooled to RT, dilutedwith EtOAc (25 mL), and filtered through a pad of celite and washed withEtOAc (20 mL). The filtrate was diluted with water (60 mL), extractedwith EtOAc (2×50 mL), washed with brine (40 mL), dried (Na₂SO₄),filtered and concentrated under reduced pressure. The residue waspurified (silica gel; eluting 2-4% EtOAc/hexanes followed by 30%EtOAc/hexanes) to afford compound 1 (500 mg, 7%) as pale brown solid. ¹HNMR (400 MHz, CDCl₃): δ 7.96 (m, 1H), 7.89 (s, 1H), 6.03-6.32 (m, 2H);LCMS Mass: 222.9 (M−H⁺).

Step 2: (2-Chloro-6-(trifluoromethyl)pyridin-4-yl)methanamine (2)

To a stirred solution of compound 1 (5 g, 22.32 mmol) in THF (60 mL) at0° C. under an inert atmosphere, was added BH₃. DMS (5 M sol. in Et₂O,22.3 mL, 111.61 mmol) drop-wise. The reaction mixture was heated toreflux and stirred for 16 h. The mixture was poured into ice cold water(80 mL) and extracted with EtOAc (2×80 mL). The combined organicextracts were washed with brine (40 mL), dried (Na₂SO₄), filtered andconcentrated to afford compound 2 (5.3 g) as a pale yellow oil, whichwas used without further purification.

Step 3: tert-Butyl((2-chloro-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate (3)

To a stirred solution of compound 2 (5.3 g, crude) in CH₂Cl₂ (60 mL) atRT, were added (Boc)₂O (6.95 mL, 30.28 mmol) and TEA (7.03 mL, 50.48mmol), and the mixture was stirred for 16 h. The mixture was quenchedwith water (80 mL) and extracted with CH₂Cl₂ (2×80 mL). The combinedorganic extracts were washed with brine (40 mL), dried (Na₂SO₄),filtered and concentrated. The residue was purified (silica gel; eluting15% EtOAc/hexanes) to afford compound 3 (2 g, 29% over two steps) aspale yellow crystals. ¹H NMR (500 MHz, CDCl₃): δ 7.51 (s, 1H), 7.43 (s,1H), 5.03 (br s, 1H), 4.39 (m, 2H), 1.47 (br s, 9H); LCMS Mass: 310.9(M⁺+1).

Step 4: tert-Butyl(E)-((2-hydrazono-6-(trifluoromethyl)-1,2-dihydropyridin-4-yl)methyl)carbamate(4)

To compound 3 (2 g, 6.45 mmol) was added hydrazine hydrate (35 mL) atRT. The reaction mixture was heated to 100° C. and stirred for 16 h.After cooling to RT, the mixture was concentrated under reducedpressure. To the residue was added Et₂O (10 mL) and MeOH (5 mL) and wasstirred for 30 min. The mixture was filtered, and the filtrate wasconcentrated under reduced pressure to afford compound 4 (2 g) as a palebrown viscous liquid, which did not require further purification.

¹H NMR (500 MHz, CD₃OD): δ 6.90 (s, 1H), 6.85 (s, 1H), 4.20 (s, 2H),1.46 (s, 9H); LCMS Mass: 307.2 (M⁺+1).

Step 5: tert-Butyl((2-amino-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate (5)

To a stirred solution of compound 4 (50 mg, crude) in EtOH (5 mL) at RTunder an inert atmosphere, was added Raney Ni (5 mg). The reactionmixture was stirred at RT under H2 (1 atmosphere) for 16 h. The mixturewas filtered through a pad of celite and washed with MeOH (10 mL). Thefiltrate was concentrated under reduced pressure to afford compound 5(35 mg) as an off white solid, which was used without furtherpurification. ¹H NMR (500 MHz, DMSO-d₆): δ 7.44 (m, 1H), 6.99-7.25 (m,2H), 6.75 (s, 1H), 6.51 (m, 1H), 4.03 (m, 2H), 1.38 (s, 9H).

Step 6: tert-Butyl((2-(3-(phenylcarbamoyl)benzamido)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate (7)

To a stirred solution of 3-(phenylcarbamoyl)benzoic acid (124 mg, 0.51mmol) in pyridine (4 mL) at 0° C., were added compound 5 (150 mg, 0.51mmol) followed by POCl₃ (0.47 mL, 5.15 mmol). The mixture was stirred at0° C. for 1 h. The mixture was poured into ice cold water (20 mL) andextracted with CH₂Cl₂ (2×20 mL). The organic layer was separated, washedwith aq. CuSO₄ (20 mL), brine (15 mL), dried (Na₂SO₄), filtered andconcentrated. The residue was purified (silica gel; eluting 30-35%EtOAc/hexanes) to afford compound 7 (90 mg, 34%) as a pale blue solid.¹H NMR (500 MHz, DMSO-d₆): δ 11.27 (s, 1H), 10.35 (s, 1H), 8.57 (s, 1H),8.40 (s, 1H), 8.16 (m, 2H), 7.77 (m, 2H), 7.67 (m, 1H), 7.62 (m, 1H),7.51 (s, 1H), 7.36 (m, 2H), 7.11 (m, 1H), 4.28 (m, 2H), 1.40 (s, 9H);LCMS Mass: 513.2 (M−H⁺).

Step 7:N′-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-N³-phenylisophthalamidetrifluoroacetate (Compound 1-240)

To a stirred solution of compound 7 (20 mg, 0.04 mmol) in CH₂Cl₂ (2 mL)at 0° C., was added TFA (0.1 mL). The reaction mixture was graduallywarmed to RT and stirred for 16 h. The mixture was concentrated and theresidue was purified via trituration with Et₂O (2×1 mL), then n-pentane(2×2 mL), and dried under vacuum to afford compound 1-240 (12 mg, 75%)as an off white solid.

¹H NMR (500 MHz, DMSO-d₆): δ 11.44 (s, 1H), 10.36 (s, 1H), 8.60 (m, 2H),8.34 (br s, 3H), 8.19 (m, 2H), 7.75-7.81 (m, 3H), 7.69 (m, 1H), 7.37 (m,2H), 7.12 (m, 1H), 4.26 (s, 2H); LCMS Mass: 415.0 (M+H⁺).

Example 107:(S)—N-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-3-(3-hydroxypyrrolidine-1-carbonyl)benzamidetrifluoroacetate (Compound 1-241)

Step 1: Methyl3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)carbamoyl)benzoate(3)

To a stirred solution of 3-(methoxycarbonyl)benzoic acid 2 (100 mg, 0.55mmol) in pyridine (3 mL) at 0° C., were added tert-butyl((2-amino-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate 1 (162 mg,0.55 mmol) (from Example 106, Step 5) followed by POCl₃ (0.51 mL, 5.55mmol) drop-wise. The mixture was stirred at 0° C. for 2 h. The mixturewas quenched with ice cold water (20 mL), washed with CuSO₄ solution (20mL) and extracted with EtOAc (2×20 mL). The combined organic extractswere washed with brine (10 mL), dried (Na₂SO₄), filtered andconcentrated. The residue was purified (silica gel; eluting 25-30%EtOAc/hexanes) to afford compound 3 (50 mg, 20%) as a pale yellow stickysolid. ¹H NMR (500 MHz, CDCl₃): δ 8.71 (br s, 1H), 8.51-8.57 (m, 2H),8.27 (m, 1H), 8.16 (m, 1H), 7.63 (m, 1H), 7.41 (s, 1H), 5.08 (br s, 1H),4.38-4.49 (m, 2H), 3.99 (s, 3H), 1.49 (s, 9H); LCMS Mass: 476.1 (M⁺+Na).

Step 2:3-((4-(((tert-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)carbamoyl)benzoicacid (4)

To a stirred solution of compound 3 (175 mg, 0.39 mmol) in MeOH:H₂O(1:1, 4 mL) was added LiOH.H₂O (18 mg, 0.77 mmol), and the mixture wasstirred at RT for 3 h. The MeOH was removed under reduced pressure andthe mixture then diluted with water (15 mL), acidified with citric acidto pH ˜3, and extracted with EtOAc (2×20 mL). The combined organicextracts were washed with brine (10 mL), dried (Na₂SO₄), filtered andconcentrated in vacuo afford compound 4 (200 mg) as an off white solid,which was used without further purification. LCMS Mass: 438.1 (M−H⁺).

Step 3: tert-Butyl(S)-((2-(3-(3-hydroxypyrrolidine-1-carbonyl)benzamido)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(5)

To a stirred solution of compound 4 (220 mg, crude) in CH₂Cl₂ (6 mL) atRT, were added EDCI hydrochloride (191 mg, 1.0 mmol), HOBt (34 mg, 0.25mmol), (S)-pyrrolidin-3-ol (65 mg, 0.75 mmol) and DIEA (0.17 mL, 1.0mmol). The mixture was stirred at RT for 48 h. The mixture was quenchedwith water (20 mL) and extracted with CH₂Cl₂ (2×20 mL). The combinedorganic extracts were washed with brine (10 mL), dried (Na₂SO₄),filtered and concentrated. The residue was purified (silica gel; eluting90-95% EtOAc/hexanes) to afford compound 5 (50 mg, 25% over two steps)as an off-white solid. ¹H NMR (500 MHz, DMSO-d₆): δ 11.30 (m, 1H), 8.38(s, 1H), 8.14 (m, 1H), 8.09 (m, 1H), 7.73 (m, 1H), 7.56-7.64 (m, 2H),7.50 (s, 1H), 5.00 (m, 1H), 4.23-4.37 (m, 3H), 3.52-3.64 (m, 2H), 3.41(m, 1H), 3.20 (m, 1H), 1.76-1.97 (m, 2H), 1.42 (s, 9H); LCMS Mass: 507.2(M−H⁺).

Step 4:(S)—N-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-3-(3-hydroxypyrrolidine-1-carbonyl)benzamidetrifluoroacetate (Compound 1-241)

To a stirred solution of compound 5 (20 mg, 0.04 mmol) in CH₂Cl₂ (2 mL)at 0° C., was added TFA (0.03 mL, 0.39 mmol). The reaction mixture wasgradually warmed to RT and stirred for 7 h. The mixture was concentratedunder reduced pressure, and the residue was triturated with Et₂O (2×1mL), n-pentane (2×1 mL), then dried under vacuum to afford compound1-241 (10 mg, 62%) as an off white solid. ¹H NMR (500 MHz, CD₃OD): δ8.69 (s, 1H), 8.15 (m, 1H), 8.11 (m, 1H), 7.80 (m, 1H), 7.62-7.69 (m,2H), 4.53 (br s, 1H), 4.41 (br s, 1H), 4.33 (s, 2H), 3.62-3.85 (m, 3H),3.50 (m, 1H), 1.92-2.20 (m, 2H), 1.35 (m, 1H); LCMS Mass: 409.0 (M+H⁺).

Example 108:N′-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-N³-(2-(methylsulfonyl)ethyl)isophthalamidetrifluoroacetate (Compound 1-242)

Step 1: Methyl 3-((2-(methylsulfonyl)ethyl)carbamoyl)benzoate (2)

To a stirred solution of 3-(methoxycarbonyl)benzoic acid 1 (500 mg, 2.78mmol) in DMF (5 mL) at 0° C., were added 2-(methylsulfonyl)ethan-1-aminehydrochloride (443 mg, 2.78 mmol), HATU (1.58 g, 4.17 mmol), and DIEA(1.45 mL, 8.33 mmol). The reaction mixture was gradually warmed to RTand stirred for 16 h. The mixture was diluted with water (30 mL) andextracted with EtOAc (2×30 mL). The combined organic extracts werewashed with brine (20 mL), dried (Na₂SO₄), filtered and concentrated.The residue was purified (silica gel; eluting 3% MeOH/CH₂Cl₂) to affordcompound 2 (450 mg, 57%) as an off white solid. ¹H NMR (500 MHz,DMSO-d₆): δ 8.93 (m, 1H), 8.42 (s, 1H), 8.06-8.11 (m, 2H), 7.63 (m, 1H),3.88 (s, 3H), 3.68 (m, 2H), 3.38 (m, 2H), 3.02 (s, 3H); LCMS Mass: 285.9(M+H⁺).

Step 2: 3-((2-(Methylsulfonyl)ethyl)carbamoyl)benzoic acid (3)

To a stirred solution of compound 2 (450 mg, 1.58 mmol) in a mixture ofTHF:H2O (2:1, 8 mL) at 0° C., was added LiOH.H₂O (133 mg, 3.16 mmol).The reaction mixture was gradually warmed to RT and stirred for 16 h.The volatiles were removed under reduced pressure, and the residue wasdiluted with water (30 mL) then acidified with citric acid to pH ˜4. Theprecipitated solid was collected via filtration, and dried under vacuumto afford compound 3 (400 mg, 94%) as white solid. LCMS Mass: 271.8(M+H⁺).

Step 3: tert-Butyl((2-(3-((2-(methylsulfonyl)ethyl)carbamoyl)benzamido)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(5)

To a stirred solution of tert-butyl((2-amino-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate 4 (50 mg,0.17 mmol) (from Example 106, Step 5) and compound 3 (46 mg, 0.17 mmol)in pyridine (3 mL) at 0° C., was added POCl₃ (0.16 mL, 1.72 mmol)drop-wise. The mixture was stirred at 0° C. for 1 h, then poured intoice cold water (15 mL) and extracted with EtOAc (2×15 mL). The combinedorganic extracts were washed with brine (10 mL), dried (Na₂SO₄),filtered and concentrated. The residue was purified (silica gel; eluting1-5% MeOH/CH₂Cl₂; followed by trituration with Et₂O (2×2 mL)) to affordcompound 5 (15 mg, 16%) as a pale yellow solid. LCMS Mass: 543.1 (M−H⁺).

Step 4:N′-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-N³-(2-(methylsulfonyl)ethyl)isophthalamidetrifluoroacetate (Compound 1-242)

To a stirred solution of compound 5 (15 mg, 0.03 mmol) in CH₂Cl₂ (3 mL)at 0° C., was added TFA (0.004 mL, 0.05 mmol). The reaction mixture wasgradually warmed to RT and stirred for 16 h. The volatiles were removedand the crude was triturated with Et₂O (2×1 mL) to afford compound 1-242(10 mg, 67%) as a pale yellow solid. ¹H NMR (400 MHz, CD₃OD): δ 8.69 (s,1H), 8.46 (m, 1H), 8.16 (m, 1H), 8.07 (m, 1H), 7.63-7.68 (m, 2H), 4.33(s, 2H), 3.88-3.93 (m, 2H), 3.45-3.50 (m, 2H), 3.06 (s, 3H); LCMS Mass:444.9 (M+H⁺).

Example 109: Methyl3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)carbamoyl)benzoatetrifluoroacetate (Compound 1-238)

To a stirred solution of methyl3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)carbamoyl)benzoate1 (50 mg, 0.11 mmol) (from Example 107, Step 1) in CH₂Cl₂ (3 mL) at 0°C., was added TFA (0.08 mL, 1.1 mmol). The reaction mixture wasgradually warmed to RT and stirred for 16 h. The mixture wasconcentrated under reduced pressure and the crude was triturated withEt₂O (2×2 mL) and dried under vacuum to afford compound 1-238 (25 mg,65%) as a white solid. ¹H NMR (500 MHz, CD₃OD): δ 8.67 (s, 1H), 8.62 (t,J=1.6 Hz, 1H), 8.19-8.27 (m, 2H), 7.63-7.68 (m, 2H), 4.32 (s, 2H), 3.96(s, 3H); LCMS Mass: 353.8 (M⁺+1).

Example 110:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)carbamoyl)benzoicacid trifluoroacetate (Compound 1-239)

The title compound (1-239) was prepared from3-((4-(((tert-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)carbamoyl)benzoicacid (from Example 107, Step 2) using the procedure for Example 109. ¹HNMR (500 MHz, CD₃OD): δ 8.70 (s, 1H), 8.65 (s, 1H), 8.28 (m, 1H), 8.22(m, 1H), 7.65-7.70 (m, 2H), 4.34 (s, 2H); LCMS Mass: 339.9 (M⁺+1).

Example 111:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-1-benzyl-6-methylpyrimidine-2,4(1H,3H)-dionehydrochloride (Compound 1-134)

Step 1: 1-Benzyl-6-methylpyrimidine-2,4(1H,3H)-dione (2)

To 5-acetyl-4-hydroxy-2H-1,3-thiazine-2,6(3H)-dione 1 (1 g, 5.35 mmol)was added benzyl amine (15 mL) at RT under inert atmosphere. Thereaction mixture was stirred and heated to reflux for 1 h. The excess ofbenzyl amine was distilled off under reduced pressure. The residue wasdiluted with 0.5 N aq. NaOH solution (30 mL) and stirred at RT for 30min. The mixture was filtered (to remove solid), and the filtrate wasacidified with 2 N aq. HCl solution (20 mL). The precipitated solid wascollected via filtration and dried under vacuum to afford compound 2(250 mg, 28%) as pale yellow solid. ¹H NMR (500 MHz, DMSO-d₆): δ 11.32(br s, 1H), 7.32-7.37 (m, 2H), 7.26 (m, 1H), 7.16 (d, J=7.5 Hz, 2H),5.54 (s, 1H), 5.03 (s, 2H), 2.10 (s, 3H); LCMS Mass: 216.9 (M⁺+1).

Step 2: tert-Butyl((2-((3-benzyl-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(4)

To a stirred solution of compound 2 (40 mg, 0.18 mmol) in anhydrous THF(10 mL) at 0° C. under an inert atmosphere, were added tert-butyl((2-(hydroxymethyl)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate N-4(62 mg, 0.2 mmol) (from Int-N, Step 3), PPh₃ (73 mg, 0.28 mmol),followed by diisopropyl azodicarboxylate (0.05 mL, 0.28 mmol). Thereaction mixture was warmed to RT and stirred for 24 h. The reactionmixture was diluted with water (10 mL) and extracted with EtOAc (2×10mL). The combined organic extracts were washed with brine (7 mL), dried(Na₂SO₄), filtered, and concentrated under reduced pressure. The residuewas purified by preparative HPLC to afford compound 4 (8 mg, 9%) ascolorless viscous syrup. ¹H NMR (400 MHz, CDCl₃): δ 7.51 (m, 1H), 7.44(s, 1H), 7.36 (m, 1H), 7.30 (m, 1H), 7.18 (d, J=7.0 Hz, 2H), 5.69 (d,J=0.7 Hz, 1H), 5.37 (s, 2H), 5.15 (s, 2H), 4.34-4.43 (m, 2H), 2.20 (s,3H), 1.58 (br s, 9H), 1.47 (br s, 3H); LCMS Mass: 527.2 (M⁺+Na).

Step 3:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-1-benzyl-6-methylpyrimidine-2,4(1H,3H)-dionehydrochloride (Compound 1-134)

To compound 4 (8 mg, 0.01) at 0° C., was added HCl (4 M in 1,4-dioxane,0.5 mL, 2 mmol). The reaction mixture was warmed to RT and stirred for 2h. The mixture was concentrated under reduced pressure. The residue waspurified via trituration with Et₂O (2×1 mL) and dried under vacuum toafford compound 1-134 (6 mg, 86%) as colorless viscous syrup. ¹H NMR(400 MHz, CD₃OD): δ 7.91 (m, 1H), 7.80 (s, 1H), 7.69 (s, 1H), 7.25-7.37(m, 2H), 7.21 (br d, J=7.2 Hz, 2H), 5.79 (s, 1H), 5.39 (s, 2H), 5.23 (s,2H), 4.27-4.35 (m, 2H), 2.25 (s, 3H); LCMS Mass: 405.3 (M⁺+1).

Example 112:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-1-(2-hydroxyethyl)-6-methylpyrimidine-2,4(1H,3H)-dionehydrochloride (Compound 1-135)

Step 1: 1-(2-Hydroxyethyl)-6-methylpyrimidine-2,4(1H,3H)-dione (2)

The title compound (2) (300 mg, 33%) was prepared using the procedurefor Example 111, Step 1, using 2-aminoethan-1-ol in Step 1. ¹H NMR (500MHz, DMSO-d₆): δ 11.11 (br s, 1H), 5.45 (s, 1H), 4.93 (br s, 1H), 3.77(t, J=5.6 Hz, 2H), 3.56 (br t, J=5.5 Hz, 2H), 2.26 (s, 3H); LCMS Mass:171.3 (M⁺+1).

Step 2: tert-Butyl((2-((3-(2-hydroxyethyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(3)

To a stirred solution of compound 2 (40 mg, 0.23 mmol) in DMF (6 mL) at0° C., were added compound Int-N (84 mg, 0.26 mmol), K₂CO₃ (97 mg, 0.7mmol) and tetrabutylammonium iodide (cat.). The reaction mixture washeated at 50° C. for 3 h. The reaction mixture was diluted with water(10 mL) and extracted with EtOAc (2×15 mL). The combined organicextracts were washed with brine (8 mL), dried (Na₂SO₄), filtered, andconcentrated under reduced pressure. The residue was purified (silicagel; eluting 2% MeOH/CH₂Cl₂; followed by preparative HPLC) to affordcompound 3 (13 mg, 12%) as colorless viscous syrup. ¹H NMR (400 MHz,DMSO-d₆): δ 7.59 (s, 1H), 7.55 (br t, J=5.9 Hz, 1H), 7.28 (s, 1H), 5.71(s, 1H), 5.13 (s, 2H), 4.96 (t, J=5.6 Hz, 1H), 4.22 (br d, J=6.1 Hz,2H), 3.86 (t, J=5.6 Hz, 2H), 3.57 (q, J=5.6 Hz, 2H), 2.35 (s, 3H), 1.38(s, 9H); LCMS Mass: 459.2 (M⁺+1).

Step 3:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-1-(2-hydroxyethyl)-6-methylpyrimidine-2,4(1H,3H)-dionehydrochloride (Compound 1-135)

To a stirred solution of compound 3 (16 mg, 0.03) in CH₂Cl₂ (1 mL) at 0°C., was added HCl (4 M solution in 1,4-dioxane, 1 mL, 4 mmol). Thereaction mixture was warmed to RT and stirred for 2 h. Then the reactionmixture was concentrated under reduced pressure. The residue wastriturated with Et₂O (2×2 mL) and dried under vacuum to afford compound1-135 (11 mg, 78%) as an off white solid. ¹H NMR (400 MHz, DMSO-d₆): δ8.43 (br s, 3H), 7.93 (s, 1H), 7.59 (s, 1H), 5.73 (s, 1H), 5.16 (s, 2H),5.01 (br s, 1H), 4.19 (br s, 2H), 3.87 (br t, J=5.6 Hz, 2H), 3.57-3.61(m, 2H), 2.37 (s, 3H); LCMS Mass: 359.3 (M⁺+1).

Example 113:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-6-methyl-1-(pyrimidin-4-ylmethyl)pyrimidine-2,4(1H,3H)-dionehydrochloride (Compound 1-243)

The title compound (1-243) was prepared using the procedure for Example112, using pyrimidin-4-ylmethanamine in Step 1. ¹H NMR (400 MHz,DMSO-d₆): δ 9.12 (d, J=1.3 Hz, 1H), 8.75 (d, J=5.2 Hz, 1H), 8.52 (br s,3H), 7.94 (s, 1H), 7.63 (s, 1H), 7.47 (dd, J=5.2, 1.1 Hz, 1H), 5.86 (s,1H), 5.20 (s, 2H), 5.16 (s, 2H), 4.18 (q, J=5.6 Hz, 2H), 2.26 (s, 3H);LCMS Mass: 407.3 (M⁺+1).

Example 114:4′-(Aminomethyl)-6′-(trifluoromethyl)-2H-[1,2′-bipyridin]-2-one

Step 1: 2-Oxo-6′-(trifluoromethyl)-2H-[1,2′-bipyridine]-4′-carbonitrile(2)

To a stirred solution of 2-chloro-6-(trifluoromethyl)isonicotinonitrile1 (500 mg, 2.43 mmol) in N-methyl-2-pyrrolidone (10 mL) at RT, wereadded pyridin-2-ol (461 mg, 4.85 mmol) followed by K₂CO₃ (1 g, 7.28mmol). The mixture was stirred at RT for 12 h. Water (30 mL) was addedand extracted with Et₂O (2×30 mL). The combined organic extracts werewashed with brine (15 mL), dried (Na₂SO₄), filtered and concentrated.The residue was purified (silica gel; eluting 10% EtOAc/hexanes) toafford compound 2 (520 mg, 81%) as a pale yellow solid. ¹H NMR (500 MHz,DMSO-d₆): δ 8.71 (s, 1H), 8.62 (s, 1H), 7.90 (m, 1H), 7.61 (m, 1H), 6.59(m, 1H), 6.47 (m, 1H); LCMS Mass: 265.9 (M⁺+1).

Step 2: 4′-(Aminomethyl)-6′-(trifluoromethyl)-2H-[1,2′-bipyridin]-2-onehydrochloride (Compound 1-161)

To a stirred solution of compound 2 (500 mg, 1.89 mmol) in THF/MeOH(1:1, 20 mL) at 0° C. under an inert atmosphere, were added CoCl₂ (487mg, 3.77 mmol) and NaBH₄ (179 mg, 4.72 mmol) portion wise. The mixturewas stirred at 0° C. for 10 min. The mixture was filtered through a padof celite washed with EtOAc (10 mL) and the filtrate concentrated invacuo to obtain the desired amine.

To a stirred solution of the amine in CH₂Cl₂ (20 mL) at RT, were addedEt₃N (0.79 mL, 5.66 mmol) and (Boc)₂O (0.65 mL, 2.83 mmol). The mixturewas stirred at RT for 12 h. The mixture was quenched with water (15 mL)and extracted with CH₂Cl₂ (2×15 mL), washed with brine (15 mL), driedover Na₂SO₄, filtered and concentrated. The residue was purified (viapreparative HPLC) to afford the Boc-protected amine. To thisBoc-protected amine was added 4 M HCl in 1,4-dioxane (4 mL) at 0° C.under inert atmosphere and stirred at RT for 2 h. The volatiles wereremoved in vacuo, the crude was triturated with Et₂O (2×2 mL) and driedunder vacuum to afford compound 1-161 (18 mg, 3%) as a white solid. ¹HNMR (400 MHz, CD₃OD): δ 8.20 (s, 1H), 8.02 (s, 1H), 7.96 (m, 1H), 7.67(m, 1H), 6.69 (m, 1H), 6.56 (m, 1H), 4.38 (s, 2H); LCMS Mass: 269.9(M⁺+1).

Example 115:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(3-ethylphenyl)benzamidehydrochloride (Compound 1-245)

The title compound (1-245) was prepared using the procedure for Example1, using 3-ethylaniline in Step 1. LCMS Mass: 416.0 (M⁺+1).

Example 116:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-ethylphenyl)benzamidehydrochloride (Compound 1-246)

The title compound (1-246) was prepared using the procedure for Example1, using 4-ethylaniline in Step 1. LCMS Mass: 416.0 (M⁺+1).

Example 117:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(3-ethynylphenyl)benzamidehydrochloride (Compound 1-247)

The title compound (1-247) was prepared using the procedure for Example1, using 3-ethynylaniline in Step 1. LCMS Mass: 412.0 (M⁺+1).

Example 118:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(prop-2-yn-1-yl)benzamidehydrochloride (Compound 1-248)

The title compound (1-248) was prepared using the procedure for Example1, using propargylamine in Step 1. LCMS Mass: 350.0 (M⁺+1).

Example 119:3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-methyl-2-oxo-2H-chromen-7-yl)benzamidehydrochloride (Compound 1-249)

The title compound (1-249) was prepared using the procedure for Example1, using 7-amino-4-methylcoumarin in Step 1. LCMS Mass: 470.0 (M⁺+1).

Example 120: (R,S) or(S,R)-cis-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Enantiomer 1) (Compound 1-250)

Step 1: Single enantiomers of cis-tert-butyl((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate(2) and (3)

Compound 2 (35 mg) and compound 3 (35 mg) were both obtained fromcompound 1 (160 mg, 0.32 mmol) (from Example 73, Step 2) via chiral HPLCseparation (Chiral Pak ADH, 250×20 mm, 5 μm column, elutingisocratically with 10% MeOH:EtOH (1:1) and 90% hexanes (containing 0.1%DEA), flow rate 18 mL/min), wherein compound 2 was the first to eluteand compound 3 was the second to elute.

Compound 2: ¹H NMR (500 MHz, DMSO-d₆): δ 7.59 (m, 1H), 7.49-7.55 (m,2H), 7.29-7.43 (m, 3H), 7.15 (s, 1H), 5.48 (m, 1H), 4.87 (m, 1H),4.15-4.34 (m, 3H), 3.46-3.82 (m, 3H), 3.26 (m, 1H), 1.39 (s, 9H). ChiralHPLC analysis: R_(t)=14.21 min (Chiral Pak ADH, 250×4.6 mm, 5 μm column,eluting isocratically with 10% MeOH:EtOH (1:1) and 90% hexanes(containing 0.1% DEA) over 25 mins; flow rate 1.0 mL/min).

Compound 3: ¹H NMR (500 MHz, DMSO-d₆): δ 7.59 (m, 1H), 7.49-7.55 (m,2H), 7.29-7.43 (m, 3H), 7.15 (s, 1H), 5.48 (m, 1H), 4.87 (m, 1H),4.15-4.34 (m, 3H), 3.46-3.82 (m, 3H), 3.26 (m, 1H), 1.39 (s, 9H). ChiralHPLC analysis: R_(t)=15.31 min (Chiral Pak ADH, 250×4.6 mm, 5 μm column,eluting isocratically with 10% MeOH:EtOH (1:1) and 90% hexanes(containing 0.1% DEA) over 25 mins; flow rate 1.0 mL/min).

Step 2: (R,S) or(S,R)-cis-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Enantiomer 1) (Compound 1-250)

The title compound (1-250) (26 mg, 97%) was prepared from singleenantiomer 2 (35 mg, 0.07 mmol) using the procedure for Example 1, Step2. ¹H NMR (400 MHz, CD₃OD): δ 7.64 (s, 1H), 7.58 (m, 1H), 7.45 (m, 1H),7.30-7.38 (m, 3H), 5.09 (m, 1H), 4.26-4.48 (m, 3H), 3.63-3.95 (m, 3H),3.46 (n, 1H); LCMS Mass: 400.0 (M⁺+1); Chiral HPLC analysis: R_(t)=14.86min (Chiralpak-IA, 250×4.6 mm, 5 μm column, eluting isocratically with20% MeOH:DCM (1:1) and 80% hexanes (containing 0.1% DEA); flow rate 1.0mL/min).

Example 121: (R,S) or(S,R)-cis-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanonehydrochloride (Enantiomer 2) (Compound 1-251)

The title compound (1-251) (23 mg, 85%) was prepared from singleenantiomer 3 (35 mg, 0.07 mmol) (from Example 120, Step 1) using theprocedure for Example 1, Step 2. ¹H NMR (400 MHz, CD₃OD): δ 7.65 (s,1H), 7.58 (m, 1H), 7.45 (m, 1H), 7.32-7.40 (m, 3H), 5.09 (m, 1H),4.26-4.50 (m, 3H), 3.63-3.96 (m, 3H), 3.46 (m, 1H); LCMS Mass: 400.0(M⁺+1); Chiral HPLC analysis: R_(t)=17.53 min (Chiralpak-IA, 250×4.6 mm,5 m column, eluting isocratically with 20% MeOH:DCM (1:1) and 80%hexanes (containing 0.1% DEA); flow rate 1.0 mL/min).

Example 122:4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpicolinamidehydrochloride (Compound 1-252)

The title compound (1-252) was prepared using the procedure for Example1, using Int-O in Step 1. LCMS Mass: 389.0 (M⁺+1).

Example A-1: Parenteral Pharmaceutical Composition

To prepare a parenteral pharmaceutical composition suitable foradministration by injection (subcutaneous, intravenous), 1-1000 mg of acompound described herein, or a pharmaceutically acceptable salt orsolvate thereof, is dissolved in sterile water and then mixed with 10 mLof 0.9% sterile saline. A suitable buffer is optionally added as well asoptional acid or base to adjust the pH. The mixture is incorporated intoa dosage unit form suitable for administration by injection

Example A-2: Oral Solution

To prepare a pharmaceutical composition for oral delivery, a sufficientamount of a compound described herein, or a pharmaceutically acceptablesalt thereof, is added to water (with optional solubilizer(s), optionalbuffer(s) and taste masking excipients) to provide a 20 mg/mL solution.

Example A-3: Oral Tablet

A tablet is prepared by mixing 20-50% by weight of a compound describedherein, or a pharmaceutically acceptable salt thereof, 20-50% by weightof microcrystalline cellulose, 1-10% by weight of low-substitutedhydroxypropyl cellulose, and 1-10% by weight of magnesium stearate orother appropriate excipients. Tablets are prepared by directcompression. The total weight of the compressed tablets is maintained at100-500 mg.

Example A-4: Oral Capsule

To prepare a pharmaceutical composition for oral delivery, 10-500 mg ofa compound described herein, or a pharmaceutically acceptable saltthereof, is mixed with starch or other suitable powder blend. Themixture is incorporated into an oral dosage unit such as a hard gelatincapsule, which is suitable for oral administration.

In another embodiment, 10-500 mg of a compound described herein, or apharmaceutically acceptable salt thereof, is placed into Size 4 capsule,or size 1 capsule (hypromellose or hard gelatin) and the capsule isclosed.

Example A-5: Topical Gel Composition

To prepare a pharmaceutical topical gel composition, a compounddescribed herein, or a pharmaceutically acceptable salt thereof, ismixed with hydroxypropyl celluose, propylene glycol, isopropyl myristateand purified alcohol USP. The resulting gel mixture is then incorporatedinto containers, such as tubes, which are suitable for topicaladministration.

Example B-1: Human LOXL2 Amine Oxidase Activity Assay

LOXL2 amine oxidase activity is evaluated by measuring Amplex Redfluorescence using 10-20× concentrated conditioned media from CHO cellsstably expressing human LOXL2. To assay for amine oxidase activity, 10μL of the concentrated conditioned media is incubated with 2 μL of testcompound in DMSO and 73 μL Assay Buffer (50 mM Borate Buffer, pH8) for 2h at 37° C. After the 2 h incubation, 5 ul of 10 mM 1,5-Diaminopentane(DAP) diluted in Assay Buffer and 10 μl of Amplex Red Mix (8.5 μl AssayBuffer+0.5 μl of 10 mM Amplex Red+1 μl of 500 U/ml HorseradishPeroxidase) are added and the plate mixed and immediately placed on theFlexStaion for fluorescence measurements. Fluorescence is read inkinetic mode every 2 min for 1 hour at excitation=544 and emission=590.The amine oxidase activity is calculated from the slope of the linearportion of the curve.

TABLE 2 Example Compound IC₅₀ 1 1-7  A 2 1-9  A 3 1-10  A 4 1-11  A 51-12  A 6 1-13  A 7 1-14  A 8 1-15  A 9 1-16  A 10 1-17  A 11 1-18  A 121-19  A 13 1-20  A 14 1-21  A 15 1-22  A 16 1-23  A 17 1-24  C 18 1-25 B 19 1-26  A 20 1-27  A 21 1-28  A 22 1-29  A 23 1-30  A 24 1-31  A 251-32  A 26 1-33  A 27 1-34  A 28 1-35  A 29 1-36  A 30 1-8  A 31 1-39  A32 1-40  A 33 1-43  B 34 1-44  A 35 1-46  A 36 1-47  A 37 1-48  A 381-49  A 39 1-50  A 40 1-51  B 41 1-52  A 42 1-45  B 43 1-41  B 44 1-42 A 45 1-53  A 46 1-54  A 47 1-55  A 48 1-58  A 49 1-37  A 50 1-38  A 511-56  B 52 1-57  A 53 1-59  A 54 1-1  A 55 1-2  A 56 1-3  A 57 1-4  A 581-5  A 59 1-6  A 60 1-198 A 61 1-199 A 62 1-200 A 63 1-201 A 64 1-202 A65 1-203 A 66 1-204 A 67 1-205 A 68 1-206 A 69 1-207 A 70 1-208 A 711-209 A 72 1-210 A 73 1-211 A 74 1-212 A 75 1-213 A 76 1-214 A 77 1-215A 78 1-216 A 79 1-217 A 80 1-218 B 81 1-219 A 82 1-220 A 83 1-221 B 841-222 A 85 1-223 B 86 1-224 B 87 1-225 A 88 1-226 A 89 1-227 A 90 1-228A 91 1-229 B 92 1-230 A 93 1-231 A 94 1-232 B 95 1-169 A 96 1-60  B 971-235 B 98 1-236 C 99 1-233 B 100 1-234 C 101 1-244 B 102 1-68  A 1031-105 A 104 1-106 A 105 1-237 B 106 1-240 A 107 1-241 A 108 1-242 A 1091-238 A 110 1-239 A 111 1-134 A 112 1-135 C 113 1-243 B 114 1-161 C 1151-245 A 116 1-246 A 117 1-247 A 118 1-248 A 119 1-249 A 120 1-250 A 1211-251 A 122 1-252 A A is <300 nM; B is 300 nM to 1000 nM; C is >1000 nM

Example B-2: LOXL2 Human Blood Amine Oxidase Activity Assay

The amine oxidase activity of human LOXL2 in the context of human wholeblood is measured using an Amplex Red assay. Since Human, recombinanthuman LOXL2 (purchased from Sino Biologicals, Beijing, China) is addedto human blood collected in heparin vacutainer tubes. Briefly, 0.5-2 μgrecombinant, human LOXL2 (reconstituted in water) and 2 μl test compoundin DMSO is added to 192 l blood, mixed and incubated at 37° C. for 2 h.After the 2 h incubation, the blood is centrifuged at 2000×g for 15 minat room temperature to isolate the plasma. 50 μl of plasma is removedand mixed with 25 μl of 40 mM DAP (diluted in water) and 25 μl AmplexRed Mix (23.5 μl 50 mM Borate Buffer, pH8+0.5 μl 10 mM Amplex Red+1 μl500 U/ml Horseradish Peroxidase). Samples are mixed and immediatelyplaced on the FlexStaion for fluorescence measurements. Fluorescence isread in kinetic mode every 2 min for 1 hour at excitation=544 andemission=590. The amine oxidase activity is calculated from the slope ofthe linear portion of the curve.

Example B-3: Mouse Oropharyngeal Bleomycin Model of Lung Fibrosis

Lung fibrosis is induced in C57Bl/6 male mice by administering bleomycin(0.1-4 U/kg) via oropharyngeal instillation. Mice are either pretreatedwith vehicle or test compound (1 day to 1 hour) orally,intraperitoneally, intravenously or subcutaneously before bleomycininstallation (prophylactic dosing) or 7-14 days post bleomycininstillation (therapeutic dosing). The route and frequency of dosing arebased on previously determined pharmacokinetic properties for the LOXL2inhibitor in mouse. After bleomycin instillation animals are monitoreddaily for weight loss and clinical signs for 14-28 days prior tosacrifice. Animals are euthanized at study termination and weighed andblood (for isolation of plasma) and bronchoalveolar lavage are collectedand frozen for subsequent analyses. Lungs are removed, weighed, theneither inflated and fixed by instillation of 10% formalin and preparedfor histological examination or homogenized in 1 ml PBS for collagendetermination using a hydroxyproline assay. For histologicalexamination, lung slices are stained with Masson's trichrome orPicro-Sirius red to measure cross-linked collagen as an indicator offibrosis and an Ashcroft score of lung fibrotic and inflammatory damagedetermined. In addition, immunohistochemistry of fibrotic proteins suchas a-smooth muscle actin can be recorded. For lung hydroxyprolinecontent, 0.5 ml of the lung homogenate is removed and added to 0.5 ml 12N HCl and the samples heated at 120° C. overnight. After the acidhydrolysis, 25-100 μl of the supernatant is dried down, resuspended in25 μl water and the hydroxyproline content determined by the addition of0.5 ml Chloramine T solution (140 mg Chloramine T in 6.5 ml ddH₂0+1 mln-propanol+2.5 ml 1M sodium acetate) and incubation at room temperaturefor 20 min. After the incubation, 0.5 ml Erlich's solution (1.48 g of4-(dimethylamino(benzaldehyde) in 7 ml n-propanol+2.88 ml 60% perchloricacid and 0.12 ml ddH₂O) is added and incubated at 65° C. for 15 minbefore reading the absorbance at 550 nm. The concentration ofhydroxyproline in each skin biopsy is determined from a hydroxyproline(purchased from Sigma) standard curve.

Compounds 1-7, 1-15, 1-19, 1-20, 1-21 1-30 and 1-59 (dosedprophylactically at 60 mg/kg p.o.) were efficacious in this model.Compounds 1-19, 1-20 and 1-21 (dosed therapeutically at 60 mg/kg p.o.)were efficacious in this model.

Example B-4: Mouse Subcutaneous Bleomycin Model of Skin and LungFibrosis

Skin and lung fibrosis is induced in female C57Bl/6 mice byadministering bleomycin via subsutaneous injection to two sites (50 μgbleo/site) on the backs of mice. Animals are anesthetized withisoflurane and bleomycin (100 μl, or PBS control) is injected at thesame site daily for 28 days to induce skin and lung fibrosis. Mice areeither pretreated with vehicle or test compound (1 day to 1 hour)orally, intraperitoneally, intravenously or subcutaneously beforebleomycin injection (prophylactic dosing) or 7-14 days post bleomycininjection (therapeutic dosing). Animals are euthanized at studytermination and weighed and blood (for isolation of plasma) andbronchoalveolar lavage are collected and frozen for subsequent analyses.Lungs are either removed, weighed, then homogenized in PBS fordetermination of collagen content using a hydroxyproline assay orinflated and fixed by instillation of 10% formalin and prepared forhistological examination by trichrome staining or Picrosirius redstaining. Skin biopsies are taken from each injection site using a 6 mmdermal punch biopsy (Acuderm). One punch biopsy is sandwiched in acassette with a sponge, placed in formalin and prepared for histologicalexamination by H&E staining, trichrome staining and/or Picrosirius redstaining. The other punch biopsy is placed in 0.5 ml PBS and mincedusing fine scissors. 500 μl 12 N HCl is then added and the samplesheated at 120° C. overnight. After the acid hydrolysis, 25-100 μl of thesupernatant is dried down, resuspended in 25 μl water and thehydroxyproline content determined by the addition of 0.5 ml Chloramine Tsolution (140 mg Chloramine T in 6.5 ml ddH₂0+1 ml n-propanol+2.5 ml 1Msodium acetate) and incubation at room temperature for 20 min. After theincubation, 0.5 ml Erlich's solution (1.48 g of4-(dimethylamino(benzaldehyde) in 7 ml n-propanol+2.88 ml 60% perchloricacid and 0.12 ml ddH₂O) is added and incubated at 65° C. for 15 minbefore reading the absorbance at 550 nm. The concentration ofhydroxyproline in each skin biopsy is determined from a hydroxyproline(purchased from Sigma) standard curve.

Example B-5: Rat/Mouse CCl₄ Model of Liver Fibrosis

Liver fibrosis is induced in mice (Balb/c or C57Bl/6) by intraperitonealadministration of CCl₄ (0.5-2 ml/kg body weight) diluted in corn oiltwice weekly for 4-8 weeks or by oral administration two-three timesweekly using an escalating dose protocol (Popov et al. 2011Gastroenetrology; 140(5): 1642-1652.). Liver fibrosis is induced in ratsby either intraperitoneal administration (1-2.5 ml/kg) or by oraladministration in oil (mineral, olive or corn) twice weekly for 6-12weeks. LOXL2 inhibitors are delivered orally, intraperitoneally,intravenously or subcutaneously 1 day to 1 hour prior to the initialCCl₄ dosing (prophylactic dosing) or 1-4 weeks after the initial CCl₄dosing (therapeutic dosing). At the end of the study, mice aresacrificed by opening the chest cavity under isoflurane, blood is drawnvia cardiac puncture into EDTA vacutainer tubes and the liver isharvested. Part of the liver is fixed in 10% neutral buffered formalinfor subsequent histopathological analysis of inflammation and fibrosisby H&E staining and Picrosirius red staining. The remaining tissue issnap frozen at −80° C. for subsequent hydroxyproline analysis of totalcollagen content.

Example B-6: Mouse Mdr2 Knockout Model of Biliary Fibrosis

Liver disease develops in the BALB/cMdr2−/− mouse model with bridgingfibrosis/early cirrhosis between 8 and 12 weeks of age (Ikenaga et al.2015 Am J Pathology, 185: 325-334). LOXL2 inhibitors are deliveredorally, intraperitoneally, intravenously or subcutaneously intoBALB/c.Mdr2−/− mice once daily for 6 weeks beginning at week 6 afterbirth. At the end of the study, mice are anesthetized with isoflurane(1.5% v/v) via precise vaporizer. After laparotomy, portal pressure ismeasured directly by inserting a high-fidelity pressure catheter intothe portal vein and measuring pressure signals for 5 minutes. Serum iscollected for analysis of liver (ALT, AST, ALP, and bilirubin) andkidney (creatinine) biochemistries. Part of the liver is fixed in 10%neutral buffered formalin for histopathological analysis ofinflammation, necrosis and fibrosis by H&E staining and Picrosirius redstaining.

Collagen content is determined from a portion of the liver tissue usinghydroxyproline analysis.

Example B-7: Mouse Alport Model of Kidney Fibrosis

Mice with mutations in one of the genes of glomerular basement membranecollagen, Collagen IV-a3/a4/a5, have defects in glomerular function withdevelopment of kidney fibrosis These mice develop renal dysfunction anddie prematurely of renal failure with specific timing dependent on thestrain background upon which the mutation is present. LOXL2 inhibitorsare administered orally to Col4A3 deficient mice on a SV129 backgroundeither prophylactically (ca. weeks 2-3 of age) or therapeutically (ca.weeks 4-6 wks of age). Mice are either sacrificed at a predefined time(7-9 wks of age) or continually dosed until they lose >15% of their bodyweight which preceeds death by 1-3 days. If specifically terminated,mice are perfused transcardially with PBS, and one kidney clamped at therenal artery and the other perfused with Dynabeads for magneticisolation of glomeruli. The other kidney is halved and a small sample ofrenal cortex fixed for transmission electron microscopic (TEM) analysisand a second sample of renal cortex used for RNA isolation. The otherhalf of the bisected kidney is embedded in OCT for immunohistochemicalanalysis. RNA from glomeruli and renal cortex is analyzed by real timeRT-PCR for genes of interest including MMP-10, MMP-12, IL6, MCP-1,TGF-b1, CTGF, MMP-2, and MMP-9. Immunohistochemical analysis willinclude staining for collagen 1, CD45, fibronectin, smooth muscle actin,WT-1, and integrin alpha 8/laminin a5. Collagen 1 staining is blindlyanalyzed for fibrosis scoring, and fibronectin staining is blindlyanalyzed for glomerulosclerosis scoring. For all studies albuminuria isassessed weekly and BUN at the time of tissue harvest.

Compound 1-21 (dosed prophylactically at 30 mg/kg p.o.) was efficaciousin this model.

The examples and embodiments described herein are for illustrativepurposes only and various modifications or changes suggested to personsskilled in the art are to be included within the spirit and purview ofthis application and scope of the appended claims.

What is claimed is:
 1. A compound of Formula (I), or a pharmaceuticallyacceptable salt thereof:

wherein, each R¹ is independently H, D, or F; L¹ is absent, X¹,X¹—C₁-C₆alkylene, or C₁-C₆alkylene; X¹ is —O—, —S—, —S(═O)—, —S(═O)₂—,—C(═O)—, —C(═O)O—, —C(═O)NR²—, —NR²C(═O)—, or —NR²—; R² is H,substituted or unsubstituted C₁-C₆alkyl, C₁-C₆fluoroalkyl, orC₁-C₆deuteroalkyl; each R³ is independently H, D, halogen, —CN, —OR⁵,—SR⁵, —S(═O)R⁴, —S(═O)₂R⁴, —S(═O)₂N(R⁵)₂, —NR²S(═O)₂R⁴, —C(═O)R⁴,—OC(═O)R⁴, —CO₂R⁵, —OCO₂R⁴, —N(R⁵)₂, —OC(═O)N(R⁵)₂, —NR²C(═O)R⁴,—NR²C(═O)OR⁴, C₁-C₆alkyl, C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl,C₁-C₆heteroalkyl, substituted or unsubstituted C₃-C₁₀cycloalkyl,substituted or unsubstituted C₂-C₁₀heterocycloalkyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl; m is 0,1, or 2; each R⁴ is independently selected from C₁-C₆alkyl,C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl, C₁-C₆heteroalkyl, substituted orunsubstituted C₃-C₁₀cycloalkyl, substituted or unsubstitutedC₂-C₁₀heterocycloalkyl, substituted or unsubstituted aryl, andsubstituted or unsubstituted heteroaryl; each R⁵ is independentlyselected from H, C₁-C₆alkyl, C₁-C₆fluoroalkyl, C₁-C₆deuteroalkyl,C₁-C₆heteroalkyl, substituted or unsubstituted C₃-C₁₀cycloalkyl,substituted or unsubstituted C₂-C₁₀heterocycloalkyl, substituted orunsubstituted aryl, and substituted or unsubstituted heteroaryl; or twoR⁵ on the same N atom are taken together with the N atom to which theyare attached to a substituted or unsubstituted N-containing heterocycle;Ring A is monocyclic carbocycle, bicyclic carbocycle, monocyclicheterocycle, or bicyclic heterocycle; L² is absent, —X²—, or—C₁-C₆alkylene-X²—; X² is —O—, —S—, —S(═O)—, —S(═O)₂—, —S(═O)₂NR⁶—,—C(═O)—, —C(═O)O—, —C(═O)NR⁶—, —C(═O)NR⁶—, —NR⁶C(═O)—, —NR⁶S(═O)₂—, or—NR⁶—; R⁶ is H, C₁-C₆alkyl, C₁-C₆fluoroalkyl, or C₁-C₆deuteroalkyl; Q isH, substituted or unsubstituted C₁-C₆alkyl, substituted or unsubstitutedC₁-C₆fluoroalkyl, substituted or unsubstituted C₁-C₆heteroalkyl,substituted or unsubstituted C₃-C₈cycloalkyl,—C₁-C₄alkylene-(substituted or unsubstituted C₃-C₈cycloalkyl),substituted or unsubstituted C₂-C₈heterocycloalkyl,—C₁-C₄alkylene-(substituted or unsubstituted C₂-C₈heterocycloalkyl),substituted or unsubstituted aryl, —C₁-C₄alkylene-(substituted orunsubstituted aryl), substituted or unsubstituted heteroaryl, or—C₁-C₄alkylene-(substituted or unsubstituted heteroaryl); wherein if Qis substituted then Q is substituted with one or more R⁸; or Q and R⁶are taken together with the N atom to which they are attached to formring B, wherein ring B is a substituted or unsubstituted N-containingheterocycle, wherein if ring B is substituted then ring B is substitutedwith 1-3 R⁸; each R⁸ is independently D, halogen, CN, —OR⁵, —SR⁵,—S(═O)R⁴, —S(═O)₂R⁴, —OS(═O)₂R⁴, —S(═O)₂N(R⁵)₂, —NR⁵S(═O)₂R⁴, —C(═O)R⁴,OC(═O)R⁴, —CO₂R⁵, —OCO₂R⁴, —N(R⁴)₂, —OC(═O)N(R⁵)₂, —NHC(═O)R⁴,—NHC(═O)OR⁴, C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkynyl, C₁-C₆fluoroalkyl,C₁-C₆deuteroalkyl, C₁-C₆heteroalkyl, substituted or unsubstitutedC₃-C₁₀cycloalkyl, substituted or unsubstituted C₂-C₁₀heterocycloalkyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl; or two R⁸ groups attached to the same carbon atom are takentogether with carbon atom to which they are attached to form either asubstituted or unsubstituted carbocycle or substituted or unsubstitutedheterocycle.
 2. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein: each R¹ is H; L¹ is absent, X¹, orX¹—C₁-C₆alkylene.
 3. The compound of claim 1 or claim 2, or apharmaceutically acceptable salt thereof, wherein: X¹ is —O—.
 4. Thecompound of any one of claims 1-3, or a pharmaceutically acceptable saltthereof, wherein: L¹ is absent, —O—, or —O—CH₂—.
 5. The compound of anyone of claims 1-4, or a pharmaceutically acceptable salt thereof,wherein the compound has the structure of Formula (II), or apharmaceutically acceptable salt thereof:


6. The compound of any one of claims 1-3, or a pharmaceuticallyacceptable salt thereof, wherein: L¹ is —O—, or —O—CH₂—.
 7. The compoundof claim 4, or a pharmaceutically acceptable salt thereof, wherein thecompound has the structure of Formula (III), or a pharmaceuticallyacceptable salt thereof:


8. The compound of any one of claims 1-7, or a pharmaceuticallyacceptable salt thereof, wherein: Ring A is monocyclic C₃-C₆carbocycle,bicyclic C₅-C₁₂carbocycle, monocyclic C₁-C₅heterocycle, bicyclicC₅-C₁₀heterocycle.
 9. The compound of any one of claims 1-8, or apharmaceutically acceptable salt thereof, wherein: Ring A is monocyclicC₃-C₆carbocycle.
 10. The compound of any one of claims 1-9, or apharmaceutically acceptable salt thereof, wherein: Ring A is phenyl,cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
 11. The compound ofany one of claims 1-10, or a pharmaceutically acceptable salt thereof,wherein: Ring A is phenyl.
 12. The compound of any one of claims 1-10,or a pharmaceutically acceptable salt thereof, wherein: Ring A is


13. The compound of any one of claims 1-11, or a pharmaceuticallyacceptable salt thereof, wherein: Ring A is


14. The compound of any one of claims 1-7, or a pharmaceuticallyacceptable salt thereof, wherein: Ring A is a bicyclic C₅-C₁₂carbocyclethat is a fused C₅-C₁₂carbocycle, bridged C₅-C₁₂carbocycle, orspirocyclic C₅-C₁₂carbocycle.
 15. The compound of any one of claims 1-7,or a pharmaceutically acceptable salt thereof, wherein: Ring A isbicyclic C₉-C₁₀carbocycle.
 16. The compound of claim 15, or apharmaceutically acceptable salt thereof, wherein: Ring A is naphthyl,indanyl, indenyl, or tetrahyodronaphthyl.
 17. The compound of any one ofclaims 1-7, or a pharmaceutically acceptable salt thereof, wherein: RingA is a monocyclic heterocycle containing 1-4 N atoms and 0 or 1 O or Satom, monocyclic heterocycle containing 0-4 N atoms and 1 O or S atoms,bicyclic heterocycle containing 1-4 N atoms and 0 or 1 O or S atoms, orbicyclic heterocycle containing 0-4 N atoms and 1 O or S atoms.
 18. Thecompound of claim 17, or a pharmaceutically acceptable salt thereof,wherein: Ring A is pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl,tetrahydrofuranonyl, dihydrofuranonyl, dihydrofuranyl,tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl,tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl,piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl,homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl,thiazepinyl, 1,2,3,6-tetrahydropyridinyl, indolinyl, indolinonyl,1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl,3,4-dihydro-2(1H)-quinolinonyl, furanyl, pyrrolyl, oxazolyl, thiazolyl,imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl,oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinazolinyl,quinoxalinyl, naphthyridinyl, indolyl, indazolyl, benzoxazolyl,benzisoxazolyl, benzofuranyl, benzothienyl, benzothiazolyl,benzimidazolyl, purinyl, cinnolinyl, phthalazinyl, pteridinyl,pyridopyrimidinyl, pyrazolopyrimidinyl, or azaindolyl.
 19. The compoundof any one of claims 1-7, or a pharmaceutically acceptable salt thereof,wherein: Ring A is pyrrolidinyl, pyrrolidinonyl, piperidinyl,piperazinyl, indolinyl, indolinonyl, 1,2,3,4-tetrahydroquinolinyl,1,2,3,4-tetrahydroisoquinolinyl, 3,4-dihydro-2(1H)-quinolinonyl,pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl,pyridazinyl, indolyl, indazolyl, or benzimidazolyl.
 20. The compound ofany one of claims 1-7, or a pharmaceutically acceptable salt thereof,wherein: Ring A is


21. The compound of any one of claims 1-7, or a pharmaceuticallyacceptable salt thereof, wherein: Ring A is a bicyclic C₅-C₁₀heterocyclecontaining 1-4 N atoms and 0 or 1 O or S atoms, or bicyclic heterocyclecontaining 0-4 N atoms and 1 O or S atoms that is a fused bicyclicC₅-C₁₀heterocycle, bridged bicyclic C₅-C₁₀ heterocycle, or spirobicyclic C₅-C₁₀heterocycle.
 22. The compound of any one of claims 1-7 orclaim 21 or a pharmaceutically acceptable salt thereof, wherein: Ring Ais


23. The compound of any one of claims 1-7 or claim 21, or apharmaceutically acceptable salt thereof, wherein: Ring A is a bridgedbicyclic C₅-C₁₀heterocycloalkyl that is


24. The compound of any one of claims 1-7 or claim 21, or apharmaceutically acceptable salt thereof, wherein: Ring A is spirobicyclic C₅-C₁₀heterocycloalkyl that is


25. The compound of any one of claims 1-24, or a pharmaceuticallyacceptable salt thereof, wherein: L² is absent, —O—, —CH₂—O—, —C(═O)—,—C(═O)NR⁶—, —NR⁶C(═O)—, —NR⁶—, or —CH₂—C(═O)NR⁶—.
 26. The compound ofany one of claims 1-25, or a pharmaceutically acceptable salt thereof,wherein: Q is H, substituted or unsubstituted C₁-C₆alkyl, substituted orunsubstituted C₁-C₆fluoroalkyl, substituted or unsubstitutedC₁-C₆heteroalkyl, substituted or unsubstituted C₃-C₆cycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₃-C₆cycloalkyl),substituted or unsubstituted C₂-C₈heterocycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₂-C₈heterocycloalkyl),substituted or unsubstituted phenyl, —C₁-C₂alkylene-(substituted orunsubstituted phenyl), substituted or unsubstituted heteroaryl, or—C₁-C₂alkylene-(substituted or unsubstituted heteroaryl); wherein if Qis substituted then Q is substituted with one or more R⁸; or Q and R⁶are taken together with the N atom to which they are attached to formring B, wherein ring B is a substituted or unsubstituted monocyclicN-containing heterocycle, or a substituted or unsubstituted bicyclicN-containing heterocycle, wherein if ring B is substituted then ring Bis substituted with 1-3 R⁸.
 27. The compound of any one of claims 1-26,or a pharmaceutically acceptable salt thereof, wherein: Q is substitutedor unsubstituted C₃-C₆cycloalkyl, —C₁-C₂alkylene-(substituted orunsubstituted C₃-C₆cycloalkyl), substituted or unsubstitutedC₂-C₈heterocycloalkyl, —C₁-C₂alkylene-(substituted or unsubstitutedC₂-C₈heterocycloalkyl), substituted or unsubstituted phenyl,—C₁-C₂alkylene-(substituted or unsubstituted phenyl), substituted orunsubstituted heteroaryl, or —C₁-C₂alkylene-(substituted orunsubstituted heteroaryl); wherein if Q is substituted then Q issubstituted with one or more R⁸; or Q and R⁶ are taken together with theN atom to which they are attached to form ring B, wherein ring B is asubstituted or unsubstituted monocyclic N-containing heterocycle, or asubstituted or unsubstituted bicyclic N-containing heterocycle, whereinif ring B is substituted then ring B is substituted with 1-3 R⁸.
 28. Thecompound of any one of claims 1-25, or a pharmaceutically acceptablesalt thereof, wherein: L² is —C(═O)NR⁶—, or —CH₂—C(═O)NR⁶—; Q is H,substituted or unsubstituted C₁-C₆alkyl, substituted or unsubstitutedC₁-C₆fluoroalkyl, substituted or unsubstituted C₁-C₆heteroalkyl,substituted or unsubstituted C₃-C₆cycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₃-C₆cycloalkyl),substituted or unsubstituted C₂-C₈heterocycloalkyl,—C₁-C₂alkylene-(substituted or unsubstituted C₂-C₈heterocycloalkyl),substituted or unsubstituted phenyl, —C₁-C₂alkylene-(substituted orunsubstituted phenyl), substituted or unsubstituted heteroaryl, or—C₁-C₂alkylene-(substituted or unsubstituted heteroaryl); wherein if Qis substituted then Q is substituted with one or more R⁸; or Q and R⁶are taken together with the N atom to which they are attached to formring B, wherein ring B is a substituted or unsubstituted monocyclicN-containing heterocycle, or a substituted or unsubstituted bicyclicN-containing heterocycle, wherein if ring B is substituted then ring Bis substituted with 1-3 R⁸.
 29. The compound of claim 28, or apharmaceutically acceptable salt thereof, wherein the compound has thestructure of Formula (IV), or a pharmaceutically acceptable saltthereof:


30. The compound of any one of claims 1-29, or a pharmaceuticallyacceptable salt thereof, wherein: -L²-Q is —C(═O)NR⁶-Q; Q and R⁶ aretaken together with the N atom to which they are attached to form a ringB, wherein ring B is a substituted or unsubstituted monocyclicN-containing heterocycle, or a substituted or unsubstituted bicyclicN-containing heterocycle, wherein if ring B is substituted then ring Bis substituted with 1-3 R⁸.
 31. The compound of any one of claims 1-30,or a pharmaceutically acceptable salt thereof, wherein: Q and R⁶ aretaken together with the N atom to which they are attached to form a ringB, wherein ring B is a substituted or unsubstituted aziridinyl,substituted or unsubstituted azetidinyl, substituted or unsubstitutedpyrrolidinyl, substituted or unsubstituted pyrrolidinonyl, substitutedor unsubstituted piperidinyl, substituted or unsubstitutedpiperidinonyl, substituted or unsubstituted morpholinyl, substituted orunsubstituted thiomorpholinyl, substituted or unsubstituted piperazinyl,substituted or unsubstituted piperazinonyl, substituted or unsubstitutedindolinyl, substituted or unsubstituted indolinonyl, substituted orunsubstituted 1,2,3,4-tetrahydroquinolinyl, substituted or unsubstituted1,2,3,4-tetrahydroisoquinolinyl, substituted or unsubstituted3,4-dihydro-2(1H)-quinolinonyl, wherein if ring B is substituted thenring B is substituted with 1-3 R⁸.
 32. The compound of any one of claims1-29, or a pharmaceutically acceptable salt thereof, wherein thecompound has the structure of Formula (V), or a pharmaceuticallyacceptable salt thereof:

wherein, ring B is a monocyclic N-containing heterocycle or a bicyclicN-containing heterocycle; n is 0, 1, 2, or
 3. 33. The compound of claim32, or a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1, or
 2. 34. The compound of claim 32, or a pharmaceuticallyacceptable salt thereof, wherein


35. The compound of claim 32, or a pharmaceutically acceptable saltthereof, wherein


36. The compound of claim 1, wherein the compound has the structure ofFormula (VI), or a pharmaceutically acceptable salt thereof:

wherein, L₁ is absent, —O— or —O—CH₂—; L² is absent, —O—, —CH₂—O—,—C(═O)—, —C(═O)NR⁶—, —NR⁶—, or —CH₂—C(═O)NR⁶—.
 37. The compound of claim36, wherein the compound has the structure of Formula (VII), or apharmaceutically acceptable salt thereof:


38. The compound of claim 37, or a pharmaceutically acceptable saltthereof, wherein: L² is absent, —O—, —C(═O)NR⁶—, or —CH₂—C(═O)NR⁶—. 39.The compound of claim 38, wherein the compound has the structure ofFormula (VIII), or a pharmaceutically acceptable salt thereof:


40. The compound of claim 36, wherein the compound has the structure ofFormula (IX), or a pharmaceutically acceptable salt thereof:


41. The compound of claim 40, or a pharmaceutically acceptable saltthereof, wherein: L² is absent, —O—, —C(═O)NR⁶—, or —CH₂—C(═O)NR⁶—. 42.The compound of claim 41, wherein the compound has the structure ofFormula (X), or a pharmaceutically acceptable salt thereof:


43. The compound of claim 42, or a pharmaceutically acceptable saltthereof, wherein: Q and R⁶ are taken together with the N atom to whichthey are attached to form a ring B, wherein ring B is a substituted orunsubstituted monocyclic N-containing heterocycle having one of thefollowing structures:

each R⁸ is independently D, F, Cl, CN, —OH, —OCH₃, —OCH₂CH₃, —NH₂,—N(CH₃)₂, —CH₃, —CH₂CH₃, —CF₃, —CH₂CF₃, or —OCH₂OH.
 44. The compound ofclaim 1, wherein the compound is:(6-(Trifluoromethyl)-[2,3′-bipyridin]-4-yl)methanamine;(2-([1,1′-Biphenyl]-3-yloxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine;(2-(3-Phenoxyphenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine;(2-(3-(Phenoxymethyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylaniline;(2-(3-(1H-Pyrazol-4-yl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylbenzamide;3-((4-(Aminomethyl-d₂)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylbenzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-fluorobenzyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(benzo[b]thiophen-2-ylmethyl)benzamide;(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3,4-dihydroisoquinolin-2(1H)-yl)methanone;(3-(1H-Pyrazol-1-yl)azetidin-1-yl)(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)methanone;N-((2H-Tetrazol-5-yl)methyl)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamide;N-(2-(1H-1,2,4-Triazol-1-yl)ethyl)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamide;N-(2-(1H-Tetrazol-1-yl)ethyl)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-hydroxyethyl)benzamide;(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-hydroxypyrrolidin-1-yl)methanone;(R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-hydroxypyrrolidin-1-yl)methanone;Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;(S,S)-trans-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;(R,R)-trans-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;(R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-aminopyrrolidin-1-yl)methanone;Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(-3-(dimethylamino)-4-hydroxypyrrolidin-1-yl)methanone;(S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)pyrrolidine-2-carboxylicacid;(R)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)pyrrolidine-2-carboxylicacid;(R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-(hydroxymethyl)pyrrolidin-1-yl)methanone;8-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(2-oxooxazolidin-3-yl)ethyl)benzamide;Racemic-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((5-oxopyrrolidin-2-yl)methyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(methylsulfonyl)ethyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(1-(hydroxymethyl)cyclopropyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-hydroxy-2-methylpropyl)benzamide;(R)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2,3-dihydroxypropyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-sulfamoylethyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(dimethylamino)ethyl)benzamide;Racemic-trans-(3-(((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;(2-((1-(1-Methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)oxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine;2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-N-methyl-N-phenylacetamide;(R)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpyrrolidine-1-carboxamide;(S)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpyrrolidine-1-carboxamide;4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpiperidine-1-carboxamide;4-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)-N-phenylpiperidine-1-carboxamide;(R)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpiperidine-1-carboxamide;(S)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpiperidine-1-carboxamide;(S)-3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)methyl)-N-phenylpiperidine-1-carboxamide;(S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-phenylethanone;(S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-(3,4-dichlorophenyl)ethanone;(S)-2-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidine-1-carbonyl)-4H-chromen-4-one;(5)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)(pyridin-3-yl)methanone;(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)(pyrimidin-5-yl)methanone;(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)(5-methyl-1,3,4-oxadiazol-2-yl)methanone;(S)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)piperidin-1-yl)-2-methylpropan-1-one;5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-(methylsulfonyl)ethyl)nicotinamide;(R)-(5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)pyridin-3-yl)(3-aminopyrrolidin-1-yl)methanone;Racemic-trans-(5-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)pyridin-3-yl)(-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-1-(piperidin-1-yl)ethanone;1 tert-Butyl4-(2-(4-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)acetyl)piperazine-1-carboxylate;(2-((1H-Indol-4-yl)oxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine;5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-3,4-dihydroquinolin-2(1H)-one;5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1-(2-hydroxyethyl)-3,4-dihydroquinolin-2(1H)-one;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)thio)-N-phenylbenzamide;3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)-N-phenylbenzamide;3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)-N-(2-(methylsulfonyl)ethyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-1-benzyl-6-methylpyrimidine-2,4(1H,3H)-dione;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-1-(2-hydroxyethyl)-6-methylpyrimidine-2,4(1H,3H)-dione;4′-(Aminomethyl)-6′-(trifluoromethyl)-2H-[1,2′-bipyridin]-2-one;1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)pyridin-2(1H)-one;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-cyanoethyl)benzamide;1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)azetidine-3-carbonitrile;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(oxetan-3-yl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((1-hydroxycyclobutyl)methyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-hydroxyethyl)-N-methylbenzamide;(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-(hydroxymethyl)piperidin-1-yl)methanone;(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(4-(hydroxymethyl)piperidin-1-yl)methanone;(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(4-hydroxy-4-methylpiperidin-1-yl)methanone;(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-(methoxymethyl)azetidin-1-yl)methanone;(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(7-oxa-2-azaspiro[3.5]nonan-2-yl)methanone;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((1R,2S)-2-hydroxycyclopentyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-((1S,2R)-2-hydroxycyclopentyl)benzamide;Racemic-cis-(3-((4-(aminomethyl)-6-(trifluoromethyl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;(R)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoropyrrolidin-1-yl)methanone;(S)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoropyrrolidin-1-yl)methanone;(3R,4R)-1-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoyl)-4-fluoropyrrolidin-3-ylmethanesulfonate;(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(2,5-dihydro-1H-pyrrol-1-yl)methanone;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(hex-5-yn-1-yl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-(1-phenyl-1H-1,2,3-triazol-4-yl)butyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-hydroxybenzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-methoxybenzamide;Methyl(S)-3-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoate;(S)-3-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoicacid; Methyl(R)-3-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoate;(R)-3-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamido)pent-4-ynoicacid; 3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoicacid;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(2-aminophenyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(pyrimidin-5-yl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(oxazol-2-yl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(1,3,4-oxadiazol-2-yl)benzamide;Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-4-hydroxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-hydroxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-4-(benzyloxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;Racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-5-methoxyphenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-1-(piperazin-1-yl)ethan-1-one;2-(4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indol-1-yl)-N-carbamimidoylacetamide;Ethyl2-(5-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetate;2-(5-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)aceticacid;(S)-(3-(((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)amino)methyl)phenyl)(3-hydroxypyrrolidin-1-yl)methanone;Methyl3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)carbamoyl)benzoate;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)carbamoyl)benzoicacid;N¹-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-N³-phenylisophthalamide;(S)—N-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-3-(3-hydroxypyrrolidine-1-carbonyl)benzamide;N¹-(4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-N³-(2-(methylsulfonyl)ethyl)isophthalamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)methyl)-6-methyl-1-(pyrimidin-4-ylmethyl)pyrimidine-2,4(1H,3H)-dione;1-(2-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-6-azaspiro[3.4]octan-6-yl)ethanone;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(3-ethylphenyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-ethylphenyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(3-ethynylphenyl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(prop-2-yn-1-yl)benzamide;3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-(4-methyl-2-oxo-2H-chromen-7-yl)benzamide;(R,S) or(S,R)-cis-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;(R,S) or(S,R)-cis-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone;4-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-N-phenylpicolinamide;or a pharmaceutically acceptable salt thereof.
 45. A pharmaceuticalcomposition comprising a compound, or a pharmaceutically acceptablesalt, or solvate thereof, of any one of claims 1-44, and at least onepharmaceutically acceptable excipient.
 46. The pharmaceuticalcomposition of claim 45, wherein the pharmaceutical composition isformulated for administration to a mammal by intravenous administration,subcutaneous administration, oral administration, inhalation, nasaladministration, dermal administration, or ophthalmic administration. 47.The pharmaceutical composition of claim 45, wherein the pharmaceuticalcomposition is in the form of a tablet, a pill, a capsule, a liquid, asuspension, a gel, a dispersion, a solution, an emulsion, an ointment,or a lotion.
 48. A method of treating a disease or condition in a mammalthat would benefit from the inhibition of the activity of Lysyl oxidaselike-2 (LOXL2) comprising administering to the mammal a compound, orpharmaceutically acceptable salt or solvate thereof, of any one ofclaims 1-44.
 49. The method of claim 48, wherein the disease orcondition is fibrosis.
 50. A method of treating fibrosis in a mammalcomprising administering to the mammal a compound, or pharmaceuticallyacceptable salt or solvate thereof, of any one of claims 1 to
 44. 51.The method of claim 50, wherein the fibrosis is myelofibrosis.
 52. Themethod of claim 50, wherein the fibrosis comprises lung fibrosis, liverfibrosis, kidney fibrosis, cardiac fibrosis, peritoneal fibrosis orcutaneous fibrosis.